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ABBREVIATIONS 
3D-CRT Three-dimensional conformal radiotherapy
ABC (or TD-
ABC)
Activity-based costing (or Time driven activity-based costing)
AJCC American Joint Committee on Cancer
ALND Axillary lymph node dissection
AMT Anterior myocardial territory
APBI Accelerated partial breast irradiation
ASTRO American Society for Radiation Oncology
BCS Breast conserving surgery
BCSM Breast cancer specific mortality
BCSS Breast cancer speficic survival
BCT Breast conserving therapy (includes radiotherapy)
bid. bis in diem (twice per day)
BMI Body mass index (kg/m2)
CA Cost analysis
CALGB Cancer and leukemia group B
CBA Cost benefit analysis
CC Cost comparison
CEA Cost effectiveness analysis
CHEERS Consolidated health economic evaluation reporting standards
CLBC Contralateral breast cancer
CMA Cost minimization analysis
CT Computed tomography
CTV Clinical Target Volume
CUA Cost utility analysis
D50/D95/D98 Dose received by 50%/95%/98% of  the volume
DCIS Ductal carcinoma in situ
DFS Disease free survival
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DNA Deoxyribonucleic acid
EBCTCG Early breast cancer trialists’ collaborative group
EBRT External beam radiotherapy
EIC Extensive intraductal component
EORTC European organisation for Research and Treatment of  Cancer
EQD2 Equivalent dose in 2Gy fractions
ER Oestrogen receptor
ESBC Early stage breast cancer
ESTRO European society for radiotherapy & oncology
GEC-ESTRO Groupe Europeen de curietherapie-European society for radiotherapy & oncology
GTV Gross Target Volume
GUH Ghent university hospital
Gy Gray
HAI-5 Highly accelerated irradiation in 5 fractions
HEE Health economic evaluation
HER2 or ErbB2 Herceptin receptor
HR Hazard ratio, also ratio of  hazards rates
IBTR In-breast true recurrence
ICER Incremental cost-effectiveness ratio
IDC Invasive ductal cancer
IGRT Image-guided radiotherapy
IMNI Internal mammary node irradiation
IMRT Intensity modulated radiotherapy
IOERT Intraoperative electron radiotherapy
IORT Intraoperative radiotherapy
ISPOR International society for pharmaco-economic and outcomes research
kV Kilovolt
LABC Locally advanced stage breast cancer
LAD Anterior interventricular branch of  left coronary artery
LNI Lymph node irradiation
LQ Linear quadratic model
LR Local recurrence
LRR Loco-regional recurrence
LVSI Lympho-vascular space invasion
LYG Life years gained
ME Mastectomy
MHD/MLD Mean Heart Dose/Mean Lung Dose
MV Megavolt
NS Not significant
NSABP National Surgical Adjuvant breast and Bowel Project
NST Non-special type
NTCP Normal tissue complication probability
OAR Organ at risk
OECD Organisation for Economic Co-operation and Development
OS Overall survival
PBI Partial breast irradiation
PMRT Post-mastectomy radiotherapy
PR Progesterone receptor
PRV Planning volume for organs at risk
PTV Planning Target Volume
QALY Quality adjusted life years (gained)
QHES Quality in health economic studies
R0 Resection margins not involved with tumour
R1/2 Resection margins involved with tumour, microscopically/macroscopically
RAPID-trial Randomized trial of  accelerated partial breast irradiation using three-dimensional 
conformal external beam radiotherapy
RIBP Radiation induced brachial plexopathy
RR Relative risk
RT Radiotherapy
RTOG Radiation therapy oncology group
SBRT Stereotactic body radiotherapy
SEER Surveillance, Epidemiology, and End Results Program
SIB Simultaneously integrated boost
SIR Standard incidence ratio
SLND Sentinel lymph node dissection
SN Sentinel node
START UK Standardisation of  Breast Radiotherapy
TN Triple negative (hormone and Herceptin receptor negative)
UICC Union for International Cancer Control
UK United Kingdom
US United States
VMAT Volumetric modulated arc radiotherapy
WBI Whole breast irradiation
WTP Willingness-to-pay 
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INTRODUCTION
Breast cancer ranks second in cancer incidence worldwide (baso-cellular skin cancer ex-
cluded) and is the most frequent cancer type in women: with an incidence of  1,671,000 
cases diagnosed per year it represents 25% of  all cancers diagnosed in women[1]. 
In Belgium, it is even the most common cancer: in 2014, the Belgian Cancer Registry re-
corded 10,466 new diagnoses of  invasive breast cancer, of  which 6021 new cases in Flan-
ders, with a medium age of  62.5 years[2]. The majority of  diagnoses comes at an early 
stage - 43% were stage I and 33.9% stage II in 2014 – with a small minority of  patients 
(5.9% of  cases) presenting with metastasized disease at diagnosis. These figures suggest 
that each year over 9000 Belgian women present with an indication for curative intent 
breast cancer treatment, including a local treatment – surgery most frequently combined 
with radiotherapy - and systemic therapy, i.e. chemotherapy, targeted therapy, hormonal 
therapy, alone or combined.
The incidence rates of  new cancer diagnoses typically increase with age. This also holds 
true for breast cancer. In Belgium, in 2014, 417 and 419 new invasive breast cancer di-
agnoses were recorded per 100,000 women between 60 and 69 years and older than 
70 years, respectively, compared to respectively 23.5, 202 and 306 per 100,000 for the 
age groups below 40 years, 40-49 years and 50-59 years. Contrarily to yearly declining 
incidences in the other age groups, in women over 70, incidence has been rising since 
2005. Possible explanations for this continuing increase may be an improved awareness 
for breast cancer in older women or the increasing life expectancy in women (average life 
expectancy of  83.9 years in 2014, compared to 76.7 years in 1980[3]).
Adjuvant radiotherapy is an evidence-based part of  breast cancer treatment, improving 
local control and overall survival [4, 5]. Excellent results however come at the cost of  
radiation toxicity and burdensome treatment courses, which may hamper optimal radi-
otherapy utilization, especially in the older patient population. Following evidence-based 
recommendations, radiotherapy is indicated in 86% of  all newly diagnosed Belgian breast 
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cancer patients[6]. However, despite the known negative impact on loco-regional control 
and disease-specific survival of  omitting radiotherapy, even in elderly patients, this specif-
ic population often foregoes irradiation in Belgium[7, 8]. A recent conjoint study of  the 
Belgian College for Physicians in Radiotherapy and Oncology and the Belgian Cancer 
Registry, linking reimbursement data to individual cancer patients, demonstrated that the 
overall high utilization of  radiotherapy in breast cancer did not as such apply for elderly 
patients. A difference in uptake was observed between patients younger versus older than 
65 years (86% vs. 63%), with an even more pronounced difference when the cut off was 
placed at 80 years (83% vs. 36%)[6].  
In answer to these obstacles, accelerated and partial breast radiotherapy approaches have 
been introduced for early stage breast cancer (ESBC), with acceleration aiming to address 
the problem of  protracted schedules and reduced target volumes to avoid the potential 
toxicity of  high fraction doses. Acceleration using treatment schedules of  5 fractions only 
may lower the threshold for adequate radiotherapy utilization. Two large randomized 
trials have been performed in the UK to evaluate the safety and efficacy of  this fractiona-
tion schedule, mainly focusing on whole breast irradiation (WBI) in the context of  breast 
conserving treatment[9, 10].  The question of  accelerated partial breast irradiation, on 
the other hand, has been addressed in a multitude of  studies, evaluating the safety, clinical 
outcome and toxicity of  various technical approaches[11-16].
These new techniques and fractionation schedules are bound to have an economic 
impact: in acceleration, costs may be lower due to reduced resource needs; the in-
troduction of  more complex techniques, on the other hand, may translate into high-
er costs. Because of  the large patient population to which these new treatment ap-
proaches apply, the impact on the health care budget may be substantial. Yet, a simple 
answer to the question of  the economic consequences is not readily available, due the 
multitude in fractionation schemes, technical approaches and health care contexts, 
and calls for an in-depth analysis of  how the different parameters impact on the cost 
and cost-effectiveness. This is the domain of  health economics, a science that explores 
the changes in costs of  new strategies in relation to its incremental clinical effective-
ness and thus provides an answer to the question if  new interventions are worthwhile 
from a societal perspective.
Staging and prognosis of  breast cancer
Breast cancer treatment options, including surgery, radiotherapy and systemic treatment, 
depend on staging and prognostic features. In the non-metastasized disease, where cura-
tion is the goal, a more aggressive approach will be chosen for more advanced tumour 
stages, whereas early stages justify a more gentile approach. The most commonly used 
staging systems are the UICC and the AJCC, which take into account tumour size, lymph 
node status and distant metastasis. Based on these anatomic features, breast cancer can 
roughly be divided into an early stage (ESBC), a locally advanced stage (LABC) and me-
tastasized breast cancer. Although no real consensus exists on these categories, stage I and 
II breast cancer are commonly referred to as ESBC (T1-2 N0-1 and T3N0 disease), stage 
III as LABC (including T0-2 N2-3, T3 N1-3, T4 any N disease), and any M1 disease as 
metastasized breast cancer.
Prognostic factors in breast cancer predict the likelihood of  tumour recurrence after sur-
gery if  no adjuvant therapy is given. Some of  these prognostic factors have also a pre-
dictive value, identifying which systemic therapy the tumour may best respond to[17]. A 
recent update advises to complement the prognostic information from actual anatomic 
staging with other prognostic characteristics, including hormonal status, Her2 status, in-
dex of  mitotic activity (Ki67)[18], molecular profiling… Additional prognostic factors in 
breast cancer are age[19, 20], grade[21] and lymphovascular invasion[22, 23]. Hormonal 
status [24, 25] and Her2/neu combine a prognostic with a predictive value. 
‘Favourable’ breast cancer is usually reserved for the combination of  ESBC with hor-
mone sensitive breast cancer. In search for radiotherapy schedules and techniques that are 
gentler and less cumbersome for the patient (see section 6), guidelines from two scientif-
ic bodies, the Groupe Européen de Curiethérapie-European society for radiotherapy & 
oncology (GEC-ESTRO) and the American Society of  Radiation Oncologists (ASTRO) 
are available. Both define risk groups for APBI, giving guidance as to which prognostic 
groups are suitable for APBI, or on the contrary, need caution or are even contra-indi-
cated[26-28]. Groups are based on prognostic factors including age, tumour stage and 
microscopic characteristics. Molecular profiling is not yet retained.
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Role of  radiotherapy in breast cancer
Long-term follow-up of  large randomized trials comparing breast conserving therapy 
(BCT) with mastectomy has embedded the role of  radiotherapy after breast conserving 
surgery (BCS) in achieving similar overall survival[29-31]. In the NSABP-06 trial, BCS 
for stage I-II disease with tumours ≤ 4cm was compared to BCS with adjuvant radiother-
apy or total mastectomy. The combined treatment was found a safe alternative to total 
mastectomy, with no significant difference in survival between the three arms. However, 
adding radiotherapy after tumourectomy led to a significant reduction in ipsilateral recur-
rences. In the group with tumour-free resection margins, radiotherapy after tumourec-
tomy reduced the incidence of  breast-cancer-specific mortality (BCSM). The result was 
partially offset by death from other causes, but this may be due to older radiotherapy 
techniques[29]. The most recent update of  the EORTC 10801 trial in 2012 showed a 20-
year overall survival of  44.5% after ME and 39.1% after BCT (not significantly different) 
with young age (< 50 years) or pathologically positive lymph nodes as risk factors[31]. Dif-
ferentiation between breast-cancer specific mortality or mortality due to other malignant 
disease was not possible. However, death from malignant disease was similar in the first 
five years and showed a non-significant difference at 20 years (37.4% for ME and 43.3% 
for BCT, p = 0.13).
The primary effect of  radiotherapy after BCS relies in avoiding loco-regional relapses. 
Robust data come from a meta-analysis by the Early Breast Cancer Trialists’ Collabora-
tive Group (EBCTCG), summarizing the results of  17 randomized studies that compare 
BCS only with BCS and radiotherapy for ESBC. Adding radiotherapy reduces the 10-
year loco-regional recurrence from 35.0% to 19.3%, a 15.7% absolute risk reduction. 
This loco-regional control translates into a 15-year risk absolute reduction for BCSM of  
3.3%. The benefit observed is greatest in lymph node positive breast cancer, with an 8.5% 
absolute BCSM risk reduction. Loco-regional relapses influence overall survival, with one 
breast cancer death avoided by year 15 for every 4 recurrences by year 10[4].
Radiotherapy does however come with adverse effects. In search of  an acceptable bal-
ance between toxicity and benefit of  adjuvant radiotherapy for ESBC, it was questioned 
if  radiotherapy could safely be omitted in very early stages. A trial by Wickberg et al. on 
381 women with stage pT1N0 R0 breast cancer compared overall survival and cumula-
tive incidence of  first breast cancer-related events after 20 years after BCS with or with-
out radiotherapy[32]. They confirmed the added value of  radiotherapy in this selected 
group (30.9% if  radiotherapy was added versus 45.1% if  not, HR 0.58; OS 49.6% versus 
46%) and even in an anticipated low-risk group (>55 years, non-lobular or comedo-type 
breast cancer), adding radiotherapy improved outcome (any recurrence of  24.8% with 
and 36.1% without radiotherapy). The difference was obtained within the first five years 
after treatment and maintained in the following years. This last finding may indicate that 
radiotherapy is mainly responsible for eradicating undetected cancer foci present at sur-
gery. Beyond 5 years, both groups presented with similar rates of  local recurrence, most 
likely to be new primary tumours. Fyles et al. confirmed the additive effect of  radiothera-
py on local control in favourable ESBC in a trial with 769 patients, randomized between 
tamoxifen only (LR 7.7%) or tamoxifen with radiotherapy (LR 0.6%). Overall survival 
and distant metastases rates were similar in both arms[33]. The results of  two more recent 
trials on this subject in elderly patients with favourable ESBC (CALGB 9343 and PRIME 
trial) will be discussed latier (chapter 6.1). These two trials reported respectively increased 
10-year loco-regional and 5-year local relapse rates, however without impacting breast 
cancer specific or overall survival. 
Although breast conserving surgery is usually aimed for, mastectomy is advised when a 
breast tumour is multifocal, exceeds 4cm, if  no negative surgical margins can be obtained 
without severely compromising the aesthetic outcome of  the breast or if  a patient wishes 
to avoid radiotherapy[34]. An EBCTCG meta-analysis pooled studies between ’64 and 
’86 on the effect of  post-mastectomy radiotherapy (PMRT). In case of  negative lymph 
nodes, PMRT does not result in a significant benefit for LRR (1.6 vs. 3.0%), overall recur-
rence risk (21.1 vs. 22.4%) or BCSM (26.6 vs. 28.8%). However, in regionally advanced 
breast cancer, with invaded lymph nodes, radiotherapy improves LRR as well as BCSM, 
with a larger benefit in more advanced lymph node stages (absolute reduction of  LRR 
16.5% in pN1 vs. 22.1% in pN2, or BCRM 7.9% in pN1 vs. 10.1% in pN2)[5].
LNI in lymph node positive breast cancer results in a benefit in BCSM[35], even though 
mean heart and lungs doses increase, especially in case of  internal mammary chain irra-
diation (IMNI)[36]. Such higher doses come however with toxicity[37]. The French trial 
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could not demonstrate a benefit in overall survival for IMNI after ME[38]. In contrast, 
the Danish trial did find a small but significant improvement in OS (HR 0,82), at least for 
right-sided lymph-node positive breast cancer[39]. This finding cannot be extrapolated to 
left-sided breast cancer, as heart doses are most influenced by IMNI in the left-sided situa-
tion. Whereas the AMAROS trial has demonstrated that lymphadenectomy can safely be 
replaced by LNI in ESBC[40], the publication of  the Z0011 trial has put into question the 
need for lymphadenectomy and LNI in clinically node-negative breast cancer with patho-
logic tumour invasion of  maximally two sentinel nodes [41, 42]. As a result, guidelines 
diverge from omission of  lymphadenectomy and LNI in cN0 but sentinel positive breast 
cancer, to LNI including axillary level I if  a positive sentinel is not followed by axillary 
lymphadenectomy or even to LNI including IMNI in node negative breast cancers, when 
the tumour is located medially or centrally in the breast.
The highest risk of  tumour recurrence after BCS, is situated in the region around the 
primary tumour[43-45]. A logical consequence is the adding of  a boost to reach a higher 
total and biological effective dose in this region. Bartelink et al. evaluated the effect of  a 
boost in stage I and II breast cancer patients, treated with BCS and whole breast irradia-
tion (WBI) to a dose of  50Gy in 25 fractions[46]. In case of  negative resection margins, an 
electron-boost of  16Gy in 8 fractions was delivered (2661 women), whereas 1657 women 
were given no boost. Intermediate reporting of  5 and 10-year follow-up showed a ben-
efit in LC of  respectively 3% and 4%. Highest benefit was always observed in younger 
women (< 40 years) with an absolute difference in LR of  9.3% after 5 years and 10.4% 
after 10 years. The recent 20-year follow-up data of  this trial confirm the improvement 
in local control with a boost (LR of  9% versus 13% if  no boost)[47]. However, this does 
not translate in a statistically significant difference in overall survival (respectively 61.1% 
and 59.7%). Improved local control comes at the cost of  a higher incidence of  fibrosis (re-
spectively 5.2% versus 1.8%). The largest benefit of  a boost is observed in young patients, 
combining better local control with less occurrence of  fibrosis, whereas the opposite is 
observed in older age groups.
In 1985 Solin suggested to introduce clips in the tumourectomy cavity, to help define the depth 
of  the tumourectomy cavity in the breast for subsequent electron boost[48]. This technique is 
still used, and strongly recommended, especially if  partial breast irradiation is intended[49].
Toxicity of  radiotherapy
An overview of  RCTs and meta-analysis reporting on radiotherapy-related toxicity in 
breast cancer is listed in table 1. The concept toxicity covers morbidity and mortality due 
to dose to surrounding organs at risk, but also aesthetic and functional impairment of  the 
irradiated breast. 
Cardiac morbidity has been found to be linearly related to heart dose (7.4%/Gy), without a 
threshold and coming apparent within the first years after radiotherapy[50]. Although dose 
increased cardiac mortality for cohorts before 1980, thus compromising the benefit of  radio-
therapy, this relation cannot any longer be withheld with more advanced radiotherapy tech-
niques[51-57]. However, increased rates of  cardiac morbidity, including myocardial infarction, 
ischemic disease and valvular disease after adjuvant breast radiotherapy, justify further efforts 
to reduce cardiac dose. Pre-existing cardiac disease and smoking habits increase the deleteri-
ous effect of  radiotherapy on the heart[50, 55, 58]. Mean heart doses are highest in left-sided 
breast cancer (5.4Gy vs 3.3Gy for right-sided breast cancer) and in case the lymph node region 
is irradiated, most notably when the mammary chain is included (8.8Gy)[36].
The risk of  radiation-induced lung cancer increases with lung-dose (8.5%/Gy), with an 
even higher impact in patient with smoking habits (17.3%/Gy). The effect is almost neg-
ligible in never smokers (0.6%/Gy) [59]. The relative risk of  secondary lung cancer after 
breast radiotherapy increases with younger age and time after radiotherapy [60]. 
Cardiac and lung-cancer related toxicity may compromise the absolute gain in breast cancer 
specific survival (BCSS), which is especially relevant in case of  a limited gain, as in ESBC. The 
impact of  radiation toxicity to heart and lungs may be deducted from an analysis by Taylor et 
al.[61] They estimated the impact of  mean lungs and heart dose on excess cumulative lung can-
cer death and cardiac mortality for different risk factors (eg. smoking habits). With the following 
formula, these excess risks per Gy are related to the absolute BCSS gain of  radiotherapy :
1– (improvement in BCSS if  RT )=1– (1 – PL ) (1 – PC )
with PL = excess risk of  lung cancer mortality per Gy * mean lungs dose (MLD) 
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and PC = excess risk of  cardiac mortality per Gy * mean heart dose (MHD)
The formula can be transformed to the relation between MLD and MHD for a specific 
gain in BCSS:
MLD = (1– ––––––––––––––––––––––––––––– )  /risk lung cancer mortality per Gy
 
Based on BCSS as documented by the EBCTCG meta-analysis (left side of  figure 1) and 
the excess cardiac and lung cancer mortality if  risk factors are present (Taylor, right above 
graph), the relation between MLD and MHD for different breast cancer stages can be 
plotted in a graph[4]. If  mean heart and lung dose remain below the lines, the benefit of  
adjuvant radiotherapy on BCSS exceeds loss due to its toxicity. If  mean heart and lungs 
doses are located above the respective lines, benefit is compromised by cardiac and lung 
cancer mortality risk. Or also, the lower the potential BCSS benefit, the less tolerant we 
may be for mean heart and lungs dose. 
Fig 1 – The relation between MLD and MHD for different gains in BCSS of  adjuvant radiotherapy after BCS is illustrated in the graph right 
below. Data come from the EBCTCG meta-analysis on the 15-year gain in BCSS after BCS (left side) and from Taylor et al., who estimated the 
risks of  breast cancer radiotherapy from recent randomized trials (right above)[4, 61]. The yellow line is based on a gain in BCSS of  3.8% (all 
ESBC included), blue on 3.3% (pN0 only) and orange on: 8.5% (pN+ only) (with courteousy to Prof. W. De Neve, the architect of  this formula).
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  0.88%/Gy
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  and	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  0.075%/Gy
EBCTCG.  Lancet.  2011;;  378:  1707-­16.  
The development of  contralateral breast cancer is strongly age related, with turn point 
at age 40-45 [62, 63]. In patients with a strong family history of  breast cancer, the joint 
effect was found higher than the sum of  both risks (HR 3.52)[62]. Angiosarcoma is the 
most prevalent secondary sarcoma after breast RT, occurring mostly in or adjacent to the 
radiated fields. However, the absolute risk remains very small (0.09% increase in cumula-
tive incidence at 15 years)[64].
Ipsilateral toxicity of  breast radiotherapy is mainly related to aesthetic problems with col-
our changes, fibrosis, breast retraction, as well as pain and oedema (figure 2). 
Fig 2 - Radiation-induced breast changes
An association between breast fibrosis and patient age was observed in the boost versus no 
boost trial[47]. Improved local control was maintained with a boost of  16Gy, even after 20 
years, but at the cost of  a higher incidence of  severe fibrosis (1.8% vs. 5.2%). Sub-analysis 
per age category demonstrated an inverse association between age and local recurrence 
risk, whereas the opposite was observed for severe fibrosis, which was more present in the 
older age categories.
Most robust insight in the relation between fractionation, total dose and aesthetic outcome 
of  the breast came with the UK trials on hypofractionation. The data of  the START A 
trial confirmed the hypothesized α/β for impact on aesthetic outcomes, with an α/β of  
3.6Gy for any changes in breast appearance and 2.9Gy for marked change. The esti-
mated α/β for breast induration, breast shrinkage and telangiectasia were estimated re-
spectively 3.1Gy, 4.7Gy and 5.1Gy. Based on these data, the authors calculated a linear 
relation between breast changes and total dose, with a 5% increase in total dose causing 
Telangiectasia Edema Retraction
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a 9% increase in the proportion of  patients with marked breast change[65]. These results 
were confirmed after 10-year follow-up and including the results of  the START B trial. 
Cosmesis was similar when comparing 50Gy/25 fractions or 41.6Gy/13 fractions, but 
improved with hypofractionation applying 39Gy/13 fractions and 40.05Gy/15 fractions, 
and this as well for breast induration, telangiectasia as for breast oedema[66]. Patient re-
ported outcomes also favoured hypofractionation (15x2,67Gy), with lower hazard ratios 
for breast hardness, oversensitivity and change in breast or skin appearance[67].
Author, year Title Comparison Results
General
Clarke, 2005 Effects of  radiotherapy and 
of  differences in the extent 
of  surgery for early breast 
cancer on local recurrence 
and 15-year survival: an 





Excess in (older) radiotherapy 
regimens of  
- contralateral breast cancer: HR 
1.18 
- non-breast cancer mortality HR 
1.12 
- due to heart disease HR 1.27 
- due to lung cancer HR 1.78
Cardiac disease
Rutqvist, 1992 Cardiovascular mortality in 
a randomized trial of  adju-
vant radiation therapy versus 




Excess of  death due to ischemic 
cardiac disease in patients with 
highest cardiac dose (left-sided, 
cobalt-60 tangential fields): rel-
ative hazard 3.2 (7.1% vs 2.3%) 
but no difference in overall mor-
tality
Cuzick, 1994 Cause-specific mortality in 
long-term survivors of  breast 
cancer who participated in 
trials of  radiotherapy
Radiotherapy vs 
no radiotherapy
In breast cancer survivors, no in-
crease in 10y all-cause mortality. 
Excess of  cardiac deaths apparent 
in both early and more recent 
trials (p < 0.001) but offset by a 
reduced number of  deaths due to 
breast cancer.  
Darby, 2005 Long-term mortality from 
heart disease and lung 
cancer after radiotherapy 
for early breast cancer: 
prospective cohort study of  





Comparison of  women, diag-
nosed with breast cancer between 
1971-2001 (SEER) for ESBC: 
- 1973-82: cardiac mortality ratio 
1.2 <10 years, 1.42 10-14 years 
and 1. 58 15 years after radio-
therapy; 
- 1983-92: cardiac mortality ratio 
no difference <10 years and 1.27 
10-14 years after radiotherapy 
- 1993-2001: cardiac mortality 





mortality more than fifteen 
years after radiotherapy for 





Comparision of  women, irradi-
ated between 1971-88 with car-
diovascular mortality at 15y: IHD 
HR 1.27; all CVD HR 1.59 
Comparison of  women with left 
vs right-sided radiotherapy: Car-
diovascular mortality at 15y: IHD 
HR 1.23 and all CVD 1.25
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Hooning, 2007 Long-term risk of  cardio-
vascular disease in 10-year 
survivors of  breast cancer
Breast radiother-
apy vs general 
population rates
Comparison of  women treated 
for breast cancer between 1970-
1986: 
- SIR of  1.3 for cardiovascular 
events 
- if  radiotherapy and chemother-
apy: SIR more congestive heart 
failure (HR 1.85) 
- smoking and radiotherapy: HR 
3.04 (more than additive effect) 
- for patients with IMNI: treated 
between 1970-1979: HR 2.55 for 
AMI and HR 1.72 for congestive 
heart failure; patients treated after 
1979: lower risk for AMI but risk 
for congestive heart failure and 
valvular dysfunction remained 
increased.
Mc Gale, 2011 Incidence of  heart disease in 
35,000 women treated with 
radiotherapy for breast can-




Comparison of  women, diag-
nosed with breast cancer between 
1976-2006 
- mean heart dose 6.3Gy left-sid-
ed RT vs 2.7Gy right-sided RT 
- Mortality similar in both groups 
- Incidence ratio AMI 1.22; angi-
na 1.25; pericarditis 1.61; valvular 
heart disease 1.54 
- Incidence ratios for all heart 
disease as high for women irra-
diated after 1990 as for women 
irradiated between 1976-1989: 
1.09 vs 1.08 
- Incidence ratios for all heart dis-
ease higher in women with IHD 
diagnosed prior to breast cancer: 
1.58 vs 1.08
Henson, 2013 Radiation-related mortality 
from heart disease and lung 
cancer more than 20 years 





SEER-based analysis of  women 
diagnosed with breast cancer 
between 1973-2008: 
- Women irradiated between 
1973-1982: cardiac mortality 
ratio 1.19 <10y, 1.35 10-14y, 1.64 
15-19y and 1.9 20+ years after 
diagnosis 
- Women irradiated between 
1983-92: cardiac mortality ratio: 
no evidence for radiation-related 
cardiac mortality
Darby, 2013 Risk of  ischemic heart dis-
ease in women after radio-
therapy for breast cancer
Population-based 
case-control study
Population-based case control 
study in 2168 patients with radio-
therapy for breast cancer between 
1958-2001 and of  which 963 
with major coronary event (AMI, 
coronary revascularization, death 
from IHD) 
- mean heart dose 4.9Gy (6.6Gy 
in left-sided and 2.9Gy in 
right-sided breast cancer) 
- increase in rate of  MCE linear-
ly 7.4%/Gy with no apparent 
threshold 
- absolute increase risk greater in 
women with preexisting cardiac 
risk factors
Taylor, 2015 Exposure of  the heart in 
breast cancer radiation ther-
apy: A systematic review of  
heart doses published during 
2003 to 2013
Mean heart doses Systematic review of  cardiac dos-
es reported from studies published 
between 2003-2013 
- Mean heart dose in left-sided 
breast cancer 5.4Gy, 3.3Gy in 
right-sided breast cancer 
- Mean heart dose if  no IMNI 
4.2Gy 
- Mean heart dose with tangen-
tial fields and breathing control 
1.3Gy or lateral decubitus 1.2Gy 
- Mean heart dose with proton 
therapy 0.5Gy 
- Mean heart dose with IMRT 
5.6Gy 
- Mean heart dose with IMNI 
8Gy and 9.6Gy (highest dose) if  
delivered with tangential fields
Chan, 2015 Long-term mortality from 
cardiac causes after adjuvant 
hypofractionated vs. conven-
tional radiotherapy for local-





Comparison of  women, irradi-
ated for breast cancer between 
1990 and 1998: 
- for left-sided radiotherapy no 
difference in 15y cardiac mor-
tality (4.8% hypofractionation vs 
4.2% normofractionation)
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Merzenich, 
2017
3D conformal radiotherapy 
is not associated with the 
long-term cardiac mortality 
in breast cancer patients: a 






Comparison of  women treated 
for breast cancer between 1998-
2008:  
- no evidence of  tumour laterality 
on overall mortality in irradiated 
patients 
- For cardiac mortality a HR of  
0.94 for left- versus right-sided 
tumours 
- Diagnosis of  cardiac illness prior 
to breast cancer increased cardiac 
mortality risk and overall mortal-
ity risk
Secondary lung cancer
Prochazka, 2002 Lung cancer risks in women with previous breast 
cancer
Comparison of  women, diag-
nosed with breast cancer between 
1958-1997: 
- 5y after radiotherapy increased 
standardized incidence ratio (SIR) 
1.32 with maximum risk after 20 
years (SIR 2.53) 
- higher risk if  smoking
Darby, 2005 Long-term mortality from 
heart disease and lung 
cancer after radiotherapy 
for early breast cancer: 
prospective cohort study of  





Comparison of  women, irradi-
ated between 1971-2001 (SEER) 
for ESBC who developed lung 
cancer: 
- 1973-82: lung cancer mortality 
ratio ipsi- vs contralateral lung 
cancer 1.17 <10 years; 2 10-14 




Proportion of  second can-
cers attributable to radio-
therapy treatment in adults: 





SEER-based analysis evaluating 
secondary cancers attributable to 
radiotherapy for 15 cancer sites 
- Highest relative risk for develop-
ing lung cancer 15y after radio-
therapy: RR 1.62 and in younger 
age groups (<45y: RR 1.42, 45-
59y: RR 1.29, 60-74y: RR 1.20 
and > 75y: 1.14)
Henson, 2013 Radiation-related mortality 
from heart disease and lung 
cancer more than 20 years 





SEER-based analysis of  women 
diagnosed with breast cancer 
between 1973-2008: 
- Women irradiated between 
1973-1982: lung cancer mortality 
ratio: 1.05 <10y, 2.04 10-19y, 
3.87 20+ years after diagnoses 
- Women irradiated between 
1983-92: 1.17 <10y and 1.48 10-
19y after diagnosis
Grantzau, 2014 Risk of  second primary lung 
cancer in women after radio-
therapy for breast cancer
Lung cancer after 
radiotherapy vs 
no lung cancer 
after radiother-
apy
Women with ESBC treated with 
radiotherapy between 1982-2007 
of  which 151 developed lung 
cancer (443 controls): risk related 
to dose in centreS of  secondary 
lung tumour  
- mean age of  developing lung 
cancer 54y 
- median time between radiother-
apy and developing lung cancer 
12y 
- 90% of  patients with lung can-
cer after radiotherapy were ‘ever 
smokers’ versus 40% of  controls 
- in patients with lung cancer, risk 
increased with 8.5%/Gy with 
17.3% for ever smokers and with 
0.6%/Gy for never smokers (but 
this group was too small for firm 
conclusions)
Contralateral breast
Yap, 2002 Sarcoma as a second ma-




Comparison of  patients with sar-
coma after breast cancer, compar-
ing 87 patients with radiotherapy 
and 176 without radiotherapy 
- low 15y cumulative incidence 
for sarcoma (0,0032% if  radio-
therapy vs 0.0023% if  no radio-
therapy) and for angiosarcoma 
(0.0009% if  radiotherapy vs 
0.0001 if  no radiotherapy)  
-  if  sarcoma within radiation 
field: 56.8% angiosarcoma vs 
5.7% if  no radiotherapy 
- Angiosarcoma is the most prev-
alent secondary sarcoma after 
breast RT, occurring mostly in or 
adjacent to the radiated fields
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Hooning, 2008 Roles of  radiotherapy and 
chemotherapy in the de-
velopment of  contralateral 
breast cancer
Radiotherapy-associated risk for 
contralateral breast cancer: HR 
of  1.78 in women younger then 
35y and 1.09 in women over 45 
years 
- in patients with radiotherapy 
and strong family history, the joint 
effect was greater than the sum of  
both risks (HR 3.52)
Stovall, 2008 Dose to the contralateral 
breast from radiotherapy 
and risk of  second primary 
breast cancer in the WE-
CARE study
Absorbed dose in 
bilateral vs unilat-
eral breast cancer
Comparison of  708 patients with 
asynchronous bilateral breast 
cancer versus 1399 controls (uni-
lateral breast cancer) 
- Dose on the controlateral breast: 
Dmean of  1.1Gy  
- If  the mean dose to the con-
tralateral breast exceeded 1Gy, 
women younger than 40 years 
had a 2.5-fold higher risk for 
CLBC than unexposed women, 
with and excess risk of  1% per 
Gy 
- No such risk was observed in 
women over 40 years
Berrington De 
Gonzalez, 2011
Proportion of  second can-
cers attributable to radio-
therapy treatment in adults: 




SEER-based analysis evaluating 
secondary cancers attributable to 
radiotherapy for 15 cancer sites 
- increase in contralateral breast 
cancer (CLBC) of  0.5% at 10 
years, 1.3% at 15 years and 1.6% 
at 20 years after radiotherapy
Ipsilateral breast toxicity
Yarnold, 2005 Fractionation sensitivity and 
dose response of  late adverse 
effects in the breast after 
radiotherapy for early breast 






Any change in breast appearance 
occurred in 39.6% (50Gy/25 
fractions), 30.3% (39Gy/13 frac-
tions) and 45.7% (41.6Gy/13 
fractions) resulted in an α/β 
3.6Gy for any breast change 
For palpable breast induration, 
an α/β of  3.1Gy was calculat-
ed - results were in line with trial 
predictions.
Hopwood, 2010 Comparison of  patient-re-
ported breast, arm, and 
shoulder symptoms and 
body image after radiother-
apy for early breast cancer: 
5-year follow-up in the ran-
domised Standardisation 







tionation (50Gy/25 fractions) and 
39Gy/13 fractions or 41.6Gy/13 
fractions (START A trial) or with 
40Gy/15 fractions (START B 
trial) 
- Overall moderate to marked 
breast changes in 40% of  patients 
and 1/3 of  patients had arm and 
shoulder pain. Breast symptoms 
and body image concerns reduced 
over time. Rates of  adverse effect 
were similar in START A trial 
(50Gy vs. 41.6Gy) and improved 
with hypofractionation (39Gy in 
START A and 40Gy in START B 
trial) compared to 50Gy.  
- Adverse skin change for 39Gy 
vs 50Gy: HR 0.63 - for 40Gy vs 
50Gy: HR 0.83 
- Patient self-rated breast symp-
toms discriminated 10% difference 
in randomised dose intensity 
- No difference in arm/shoulder 
subscale scores between different 
regimens, but 1/3 had overall 
moderate to marked pain in arm 
and shoulder and 10% experi-
enced moderate to marked arm/
hand swelling 
- Many baseline arm/shoulder 
symptoms were associated with 
prior surgery
Haviland, 2013 The UK Standardisation 
of  Breast Radiotherapy 
(START) trials of  radiother-
apy hypofractionation for 
treatment of  early breast 
cancer: 10-year follow-up 






START A trial: moderate or 
marked breast induration, telan-
giectasia, and breast oedema were 
significantly less common normal 
tissue effects in the 39 Gy group 
than in the 50 Gy group. Normal 
tissue effects did not differ signifi-
cantly between 41.6 Gy and 50 
Gy groups.  
START B trial: breast shrinkage, 
telangiectasia, and breast oedema 
were significantly less common 
normal tissue effects in the 40 Gy 
group than in the 50 Gy group.
table 1 - evidence on toxicity from breast cancer radiotherapy
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Factors that influence toxicity
Toxicity in radiotherapy results from the combination of  the physical aspects of  the irradi-
ation, defined by the volume irradiated (including target as well as off-target tissue) and the 
related dose distribution/homogeneity, with the radio-biologic aspects, including radio-sen-
sitivity of  the irradiated tissue (represented by its α/β ratio), dose per fraction and total dose 
delivered. These aspects are explored more in detail, as they constitute the theoretical basis 
for accelerated and partial breast irradiation.
Association between irradiated volume and toxicity
Smaller volumes typically reduce dose to OARs. A dosimetric study on APBI delivered with 
3D-CRT indicated an increase of  15% for the mean ipsi-lateral breast dose with every 5mm 
CTV-PTV increase, a doubling of  the mean heart dose and a tripling of  the lung dose with 
10mm increase in CTV-PTV margins[68].
Regarding ipsilateral breast toxicity, the assumption of  an association between toxicity and 
the volume treated was until recently based on indirect evidence from trials combining dif-
ferent volumes with different treatment schedules or techniques [47, 69]. In the START 
A trial, a 3.3% increased risk for breast induration was calculated per extra Gy in WBI, in 
contrast to only 1.05% per extra Gy for the (smaller) boost volume[66]. 
Direct evidence on the association between dose-volume and aesthetic outcome comes from 
two recent studies: The IMPORT LOW trial and the Danish Breast Cancer Cooperative 
Group (DBCG) trial, both comparing partial breast irradiation to WBI with irradiated 
breast volume as solitary variable. Five-year outcome of  the IMPORT LOW trial for a low 
risk population (age 50 years or older, BCS for unifocal IDC of  grade 1-3, pT1-2 ≤ 3cm, 
pN0-1, R0 ≥ 2 mm) was recently published[70]. Results are promising, with non-inferior 
local control and superior aesthetic outcomes regarding ‘breast appearance’ and ‘firmness 
of  breast’. The Danish’ inclusion criteria were even more stringent and outcomes, presented 
at ESTRO 36, were as reassuring as for the UK trial[71]. Although both trials seem to pave 
the way for EB-APBI, volumes were large, up to approaching half-breast irradiation, as in-
vestigators chose for an easy implementable supine tangential field set-up with field-in-field 
IMRT. Alongside robust evidence on the efficacy of  PBI, both trials deliver direct proof  of  
the relation between irradiated volume and aesthetic outcome.
Tumourbed delineation
Before shrinking the treated volume, it is important to accurately define the breast tissue at 
risk. The target volume for APBI can be deducted from recurrence patterns of  local failure, 
predominately located around the primary tumour[45, 46, 72-74], and from microscopic 
analysis of  mastectomized breasts, evaluating the spread of  micro-satellites. Holland et al. 
found tumour satellites in mastectomy specimen beyond 2cm in 14% of  cases (figure 3)[43]. 
At 1cm beyond the tumour margins, micro-satellites where still present in 20% of  patients. 
Vicini et al. support these data: they examined re-resection specimen and found residual dis-
ease beyond 15mm of  the tumourbed in 9% of  cases. In the group with negative resection 
margins (re-resection because of  suspected radiography of  specimen), tumour cells were 
limited up to 10mm from the cavity wall in 90% of  cases[44]. 
As breast is a homogeneous structure, with little anatomic landmarks, guidelines come at 
help to delineate the tumourbed[75]. Instructions are based on general information (pre-
operative imaging, surgical and histo-pathological reports) and on CT-based information: 
seroma if  present, tissue distortion in comparison to the contralateral breast and clips. 
Although the scar location may bring some information, with the increasing use of  onco-
plastic surgery and closure distant from the lumpectomy cavity, this landmark can be mis-
leading. In case of  full-thickness closure, little if  any seroma is left visible on planning-CT.
 
Fig 3 - Subclinical spread of  invasive cancer in pathological specimen, A cumulative 34%, 20%, 14% and 7% of  the patients had 
invasive microscopic tumour deposits at distances of  respectively 0, 1, 2 and 4 cm from the pathologically estimated resection specimen 
(modified from Holland[43])
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Tissue distortion needs comparison with the contralateral breast, because on CT, post-
operative changes cannot be distinguished from glandular tissue. But in case of  bilateral 
surgery or prone positioning, comparison is impossible. The use of  clips is informative[48, 
49]: these are typically placed in the radial, anterior and posterior cavity walls. However, 
when clips are placed deeply unto the fascia or when (axillary) haemostatic clips are in-
serted, clips may lead to large, protracted volumes, away from the initial tumour location 
and compromising inter-observer delineation conformity. Possible solutions to overcome 
these obstacles and improve target volume delineation after full thickness closure and with 
the patient in prone position, are described in publication 1.
Tumourbed margins
In terms of  radiotherapy, the target volume consists of  the tumourbed, expanded to the 
clinical target volume (CTV) with a reasonable margin to cover for microscopic tumour 
cells, as described by Holland et al[43]. Vicini et al. advocate a symmetrical expansion of  
15mm[44]. A more precise technique may be to expand the tumourbed with 30mm minus 
the excision margins[43]. Recommendations on expansion from tumour bed to CTV vary 
from 0.5-2cm in the literature [76-78]. Bartelink et al suggest an asymmetric expansion, 
based on pathological margins, to reduce CTV volumes. However, in view of  the problem 
of  orientation uncertainty, symmetric expansion of  2cm minus the minimal pathological 
margin may be a safer option[79].
The impact of  fractionation
Sensitivity of  cells to fraction dose is described as the ratio of  α over β (D=α/β). In this 
equation, α represents the linear component, and is assumed to result from a single event 
(DNA double-strand break): the damage is lethal for the cell – the probability to pro-
duce lethal damage is proportional to dose. The linear quadratic component β represents 
sub-lethal damage, with two such events needed to produce cell kill (DNA single-strand 
break). One sub-lethal damage is proportional to the square of  dose. The linear quadratic 
model (LQ model) assumes that cell-kill consists of  these two components α and β, based 
on the formula αD=βD2[80], with the biological effective dose (BED):
The model is applicable for both tumour cells and normal tissue cells. A different α/β is 
translated into a different sensitivity for radiation dose. The therapeutic window for ra-
diotherapy balances between the impact of  a specific dose and fractionation schedule on 
tumour cell kill and damage to surrounding normal tissue cells (figure 4). When the α/β 
of  a tumour is higher (the α/β of  breast cancer cells was previously assumed to be in the 
range of  10Gy) than the surrounding tissue, low fractions in combination with a high 
dose are likely to be more effective. In contrast, when the α/β of  the tumour and the 
surrounding tissue are close or similar, hypofractonation with increased dose per fraction 
but lowered total dose may be more effective and less toxic than normofractionation. An 
example for breast cancer is given in table 2, comparing the effect on BED and EQD2 








Radio-sensitivity (α/β) in Gy
10 2.8 4.6









25 2 60.0 50 85.7 50 71.7 50
15 2.67 50.7 42.3 78.2 45.6 63.3 44.1
5 5.7 44.7 37.3 86.5 50.5 63.8 44.5
Table 2 – This table illustrates the impact of  radio-sensitivity on biologic effective dose (BED) and on equivalent dose compared in 
2Gy fractions (EQD2). For breast tumour cells, an α/β of  10Gy has long been assumed. This is compared to the range of  α/β  
between 2.8Gy and 4.6Gy, the range of  breast cancer radio-sensitivity, as deducted from the START trials.
The mechanisms of  re-distribution, re-oxygenation, repair and repopulation of  cells all 
contribute to the different reactions of  tissue to irradiation. Repair of  sub-lethal dam-
age in between fractions reduces the effect of  a dose, thus requiring a higher total dose 
for the same effect if  radiation is fractionated. In case of  sub-lethal damage (the most 
important component of  tissue with a low α/β), this can be repaired within hours, with 
completion within 24 hours. However, if  sub-lethal damage is added within this period, 
this can interact to produce lethal damage.
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Fig 4 - Therapeutic window of  radiotherapy, balancing between tumour kill and sparing of  normal tissue. The therapeutic window is 
defined as the difference between impact of  dose and fractionation on the tumour versus normal tissue.
At doses over 5Gy per fraction, the linear quadratic model is less reliable because other systems 
interfere. In a review of  Park et al., the effect of  high doses on vascular structures is described. 
In human tumours, treated with normofractionation, the functional status of  the vessels is pre-
served during the early phase of  treatment and only decreases towards the end. Experiments 
on rodents indicate that doses between 5-10Gy induce mild vascular changes, with severe vas-
cular damage once above 10Gy[81]. Immunologic response and different behaviour of  cells 
in a mixed population may further explain why tumour and normal tissue respond differently 
than would be expected by the LQ model only. In the high-dose range, the LQ model predicts 
a bending curve, whereas experiments show a linear relationship between dose and log of  
surviving cells. As a result, the LQ model overestimates the cell-kill effect of  radiation. Such 
different behaviour may be captured in modified radiobiologic models, better predicting cell-
kill effect in the higher dose-ranges. As an example, the Universal Survival Curve, based on 
the LQ model and a multi-target model, explains how, for higher fraction doses, the equivalent 
dose depends on the total dose delivered, rather than on the number of  fractions (figure 5)[82]
The results of  breast hypofractionation are compatible with these theoretic hypotheses. 
The long-term results of  the Canadian and the START trials deliver clinical proof  that 
hypofractionation may be at least equivalent in terms of  tumour control, with breast can-
cer being more sensitive to fraction size than previously assumed[66, 83].
 
Fig 5 – Relation between biologically equivalent dose for stereotactic body radiotherapy in 1, 3 and 5 fractions, and dose for conven-
tionally fractionated radiotherapy. Adapted from Park et al.[82]
 
Higher fraction dose with lower total dose combines this advantage with reduced damage to the 
surrounding tissues, including breast tissue, heart and the brachial plexus. Although premature, 
the first results of  acceleration to five fractions seem to confirm this, with toxicity predominately 
related to the total dose[84]. These findings are not contradicted by the adverse outcomes report-
ed in the RAPID trial on twice-daily accelerated partial breast irradiation, where insufficient time 
in-between fractions may have compromised classical repair of  sub-lethal damage[85].
Technical solutions to overcome toxicity
As suggested above, toxicity may be reduced by improving dose distribution within the 
target volume, by avoiding organs at risk or through adaptation of  fractionation and 
total dose delivered. Several techniques to achieve these goals have already been imple-
mented in daily routine. 
 
Intensity modulated radiation therapy (IMRT)
Clinical application of  IMRT started in 1995, initially for brain and prostate cancer, fol-
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lowed by head and neck tumours. Implementation of  this technique for breast irradiation 
only started by the end of  the nineties[86]. 
IMRT enables the delivery of  concave and inhomogeneous treatment volumes, thus re-
ducing the ratio of  normal tissue dose to tumour dose, improves dose homogeneity within 
the target volume and reduces hot spots. But IMRT tends to be more laborious and thus 
more expensive than standard radiotherapy, such as a wedged tangential field-technique. 
The evidence behind the use of  IMRT has been described in a review by Veldeman et al., 
who showed reduced toxicity for various tumour sites[87]. 
For breast irradiation, two randomized studies using standard fractionation demonstrated that 
IMRT reduced acute moist desquamation[88] as well as late fibrosis[89]. A 10-year update 
of  the study by Pignol et al. could not demonstrate an impact on chronic pain and aesthetic 
outcome, but this may be due to the limited sample size. Multivariate analysis however found 
an association between acute moist desquamation and long-term fibrosis and between acute 
and chronic pain. Pain significantly impacted patient-reported aesthetic results[90].
In 2013, Mukesh et al. published the results of  a RCT, comparing the 5-year results of  
1145 patients treated with hypofractionation. If  dose constraints were not met (>2cc re-
ceiving over 107% of  the prescribed dose) patients were randomized between wedged 
tangential field and IMRT. They found that IMRT resulted in superior cosmetic outcome 
(OR 0.65) and that worse outcome was further associated with breast volume, baseline 
surgical results and addition of  a boost. Skin telangiectasia occurred significantly less with 
IMRT (OR 0.57) and was also related to older age, postoperative breast infection, higher 
breast volume and addition of  a boost[91].
IMRT also comes at help in sparing organs at risk. A dosimetric study by Hurkmans et 
al. compared tangential fields with three-dimensional conformal radiotherapy (3D-CRT) 
and IMRT and found an absolute reduction of  the normal tissue complication probability 
(NTCP) for the heart of  respectively 5.9% to 4% and 2%[92]. Beckham et al. reported 
improved conformity and dose homogeneity with IMRT versus 3D-CRT in breast radi-
otherapy including the internal mammary nodes (IMN). Although IMRT reduced the 
heart and lung volumes receiving high doses, the low dose volume increased with IMRT 
[93]. A similar observation was made by Lohr et al. finding lower doses to the left ventricle 
but an increased mean heart dose with IMRT [94]. Coon et al. reported a benefit with 
IMRT for cardiac dose in case of  unfavourable anatomy [95].
For left-sided breast cancer, the most important volumes exposed to ionizing energy are 
the left ventricle and the LAD, whereas mean heart dose probably underestimates expo-
sition [96]. Tan et al. suggested relating cardiac dose reporting to the anterior myocardial 
territory (AMT), which is located close to the left breast. Mean cardiac dose did not dif-
fer between tangential field technique and IMRT, but the dose to the AMT and the left 
ventricle were significantly reduced[97]. Another dosimetric study on the application of  
multi-leaf  collimation for cardiac shielding confirmed lower heart doses, including mean 
heart dose, but found a compromised CTV coverage in one out of  three WBI patients and 
in one out of  ten APBI patients[98]. 
Breathing techniques and WBI in supine position
It has been demonstrated that breath-hold may significantly reduce heart doses[99]. Sev-
eral techniques exist, including free breathing gating and voluntary or forced breath-hold. 
Korreman et al. tested the impact of  free breathing, end-inspiratory and end-expiratory 
gating, deep inspiratory breath-hold (DiBH) and end-expiratory breath-hold on heart and 
lung dose in 17 patients[100]. Both end-inspiratory gating and DiBH achieved better 
sparing of  heart and lungs, but in left-sided breast cancer, lowest left coronary artery dose 
came with DiBH. Where the dose to the breast is found relatively insensitive to the effects 
of  breast motion during normal breathing, the internal mammary nodes are not, with a 
considerable portion receiving dose during normal inhalation [101].
The UK HeartSpare study did not find a difference in dose to normal tissue when ac-
tive breathing control was compared to voluntary DiBH. Whereas both techniques were 
found comparable in terms of  reproducibility and normal tissue sparing, scanning as well 
as treatment times were shorter with voluntary breath-hold. Moreover, patients as well as 
radio-technologists strongly preferred the voluntary technique[102]. Recently, the results 
of  a multicentre study were published: voluntary DiBH was compared to free-breathing 
3D-CRT for 93 patients with the heart within the 50% isodose. Breath-hold reduced 
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mean heart dose from 1.8Gy to 1.1Gy, mean LAD dose from 12.1 to 5.4Gy and Dmax 
from 35.4 to 24.1Gy. Lung dose also improved[103]. The authors concluded that volun-
tary breath-hold is effective in sparing the heart and feasible in a multicentre setting.
Breathing techniques and loco-regional irradiation in supine position
Remouchamps et al. performed a dosimetric study on the effect of  DiBH, obtained by 
active breathing control, in women undergoing loco-regional radiotherapy, including the 
internal mammary chain. Compared to free breathing, DiBH significantly reduced heart 
and lung doses. They also reported that the combination of  IMRT with DiBH resulted 
in the most optimal combination of  dose homogeneity, reduced heart dose and MU’s 
required for dose delivery[104]. This positive effect of  active breathing control on heart 
dose was confirmed by Mast et al. [105] and Swanson et al. [106]. 
More recently, Pham et al. tested DiBH and free-breathing in volumetric modulated 
arc therapy (VMAT) versus tangential IMRT for loco-regional radiotherapy[107]. They 
found no difference in mean heart dose when DiBH was applied, except in those patients 
where mean heart dose exceeded 6.3Gy. 
Prone position
Changing the position of  the patient from supine to prone holds several dosimetrical 
advantages. Prone position can be performed on a flat, horizontal breast-board or on a 
wedged breast-board, thus maximally exposing the ipsilateral breast to the beams. Grav-
ity induces the breast to fall forward, away from the thoracic wall, lungs and heart. This 
results in lower doses to the organs at risk[108, 109]. The impact on heart dose however 
can be attenuated by the systematic displacement of  the heart towards the ipsilateral 
chest wall, shifting the heart into the high-dose region, an effect especially observed in 
small-breasted patients[110]. As the skin unfolds, build-up of  dose in this radio-sensitive 
region decreases. Prone position also facilitates perpendicular beam entrance which re-
sults in a shorter beam travelling distance and helps to improve the ratio of  non-irradiated 
off-target breast tissue over target volume[111]. This comes with improved dose homoge-
neity and less hot spots.
A UK HeartSpare study compared supine voluntary breath-hold with prone free-breath-
ing on 34 large-breasted patients. Breath-hold resulted in lower mean heart dose (0.4 
vs. 0.7Gy) and mean LAD dose (2.9Gy vs 7.8Gy) compared to prone irradiation. They 
concluded that in large-breasted women, supine voluntary DiBH was superior to prone 
position without breath-hold[112]. 
In a publication by Fan et al., prone position for WBI in average sized breasts was compared 
to supine position. They found lower doses (Dmean, V25 and V20) for the LAD-PRV, the 
left ventricle, the mean heart dose and for the left lung, all favouring prone position[113]. 
Prone position in combination with deep inspiratory breath-hold (DiBH)
Applying prone position with DiBH may combine the best of  two worlds and has been 
explored extensively by Mulliez et al (figure 6). End-inspiratory breath-hold was found 
superior to end-expiratory breath-hold in prone position[114]. 
Fig 6 - Combination of  prone positioning with end-expiratory versus end-inspiratory breath-hold [114] – by courtesy of  T. Mulliez
A dosimetric study compared heart dose in prone with supine position, applying for both 
voluntary DiBH and shallow breathing. DiBH reduced heart dose in both positions, but 
the combination with prone position resulted in the lowest dose, while maintaining the 
advantage of  lung sparing. DiBH in prone position is reproducible[115], but requires 
either larger margins or daily CBCT setup verification to compensate for a higher uncer-
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tainty in longitudinal and lateral direction, especially in patients with a higher BMI[116]. 
Anatomically, prone DiBH was shown to decrease the heart volume by 4.3% and to cause 
a medial, posterior and caudal heart shift, thus retracting the heart away from the higher 
isodose-volumes. In comparison to supine DiBH, prone position holds the advantage of  
minimal to no excursion of  the anterior chest wall and breast[117].
CHANGING  
FRACTIONATION  
IN ADJUVANT BREAST  
RADIOTHERAPY 
First attempts on hypofractionation in the early 1960s led to increased toxicity compared 
to normofractionation, as higher fraction doses were not yet compensated for by lowering 
the total dose. However, together with knowledge on the linear-quadratic model came a 
better understanding of  the radiobiology of  fractionation[118]. In combination with an 
increasing pressure of  resource constraints and growing waiting-lists in the 1980s, this led 
to new trials on hypofractionated breast irradiation in the UK as well as in Canada. First 
robust evidence came from the large randomized trials of  the Ontario Clinical Oncology 
Group (OCOG) applying 42.5Gy/16fractions and from the UK trial comparing nor-
mofractionation with 39Gy/13 fractions and 42.9Gy/13 fractions[65, 119]. Both groups 
reported excellent tumour control and toxicity profiles. Based on the results from the UK 
trial, the α/β ratio for change in breast appearance was set at 3.6Gy (CI 1.8-5.4Gy) and 
the α/β ratio for tumour control at 4Gy (CI 1.0-7.8Gy). 
In a next step, the START A trial was initiated to further evaluate the α/β ratio for 
breast cancer, comparing normofractionation with 41.6Gy or 39Gy in 13 fractions over 
5 weeks[120]. To evaluate the Canadian schedule, the START B trial applied 40Gy over 
15 fractions in 3 weeks in the experimental arm[121]. Long-term results have been pub-
lished, and confirmed equivalence for tumour control with less breast change, as well for 
40Gy/15 fractions as for 42.5/16 fractions[66, 83]. As a result, both the Canadian and 
UK schedule are now progressively replacing normofractionation world-wide. 
These positive results have paved to way to further increase fraction doses. To overcome the 
reluctance for radiotherapy in older women, several trials have evaluated the delivery of  treat-
ment in 5 weekly fractions and reported excellent toxicity profiles[122-124]. Evidence from a 
large RCT came from the UK FAST trial, comparing normofractionation with the delivery 
of  28.5Gy or 30Gy in 5 weekly fractions[9]. At 3 years’ median follow-up, 28.5Gy was found 
milder than 30Gy and comparable to 50Gy. The FAST Trialists’ group has taken acceleration 
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one step further now, and compares delivery of  26 or 27Gy in 5 consecutive days with stand-
ard hypofractionation (40Gy/15 fractions). First results on acute toxicity were reported in 2016 
and show mild to no acute breast skin toxicity[10] and these findings have been confirmed at 
three years’ follow-up during the recent ESTRO 37 congress (abstract book OC-0595).
Towards accelerated partial breast irradiation
Accelerated partial breast irradiation (APBI) is an intriguing solution to overcome both 
the obstacles of  protracted treatment courses and radiation-induced toxicity to the organs 
at risk, including heart, lungs, contralateral breast and axilla. By definition, partial breast 
irradiation shrinks the target to the region deemed most at risk for local recurrence[43, 
44, 72]. In combination with evolving evidence on hypofractionation and evidence on the 
association between irradiated volume and breast-toxicity, this led to the assumption that 
in ESBC, lower volumes permit higher fraction doses with shorter treatment courses and 
result in better aesthetic outcomes, without compromising local control or overall survival.
What is the evidence on APBI? 
Although APBI has already been implemented in many hospitals, also outside of  clinical trials, 
evidence on the outcome and toxicity of  APBI is so far based on short follow-up. Especially 
for favourable ESBC, difference in tumour control may only become apparent after 5 years. 
In the past 15 years, multiple trials on accelerated partial breast radiotherapy have 
been conducted, with the RAPID, NSABP B39/RTOG 0413, GEC-ESTRO, ELIOT, 
TARGIT as some of  the larger ones [11, 12, 14, 125, 126]. For ESBC with good prognos-
tic characteristics [28, 127], some of  these trials reported good to excellent local control 
[13, 126]. However, in other trials an increase in local recurrences was observed [11, 12], 
even though these relapses did not impact overall survival. Moreover, in the very favoura-
ble subsets of  these patient groups, trials on omission of  radiotherapy have also reported 
acceptable LRR[128] and LR[129] with equivalent OS.
An overview of  the partial breast irradiation RCTs with five-year median follow-up or 
longer is listed in table 3. 
Some remarks need to be made. The superior results on aesthetic outcome from intersti-
tial brachytherapy APBI compared to the control arm, may be explained at least partially 
by a less representative comparator, applying normofractionation with boost. 
Trials on external APBI report overall good results[13, 130], except for acceleration to a 
twice daily schedule, as in the RAPID trial, where some authors warn for worse aesthetic 
outcome after three years[85]. 
Both the IMPORT LOW trial [70] and the Danish Breast Cancer Group (ESTRO 36) 
apply hypofractionation for partial breast irradiation and the WBI-group. No difference 
in local control was reported; difference in aesthetic outcome is small and for the IM-
PORT LOW trial in favour of  volume reduction.
The American Society of  Breast Surgeons Mammosite Registry on intraluminal 
brachytherapy reports relatively good results, but this is an observational study. Two large 
population-based registries on brachytherapy in the US reported a higher incidence of  
subsequent mastectomy and complications after brachytherapy[131, 132]. 
The most paradigm changing evolution could be a shift to a single intra-operative dose 
delivery for adjuvant breast radiotherapy. However, these techniques, applying intra-op-
erative delivery of  either electrons (IOERT) as in the ELIOT trial, or low-energy photons 
(IORT) as in the TARGIT trial, observe an increase in IBTR rates[11, 12]. In the ELIOT 
trial, a five-year IBTR of  4.4% was found, compared to 0.4% for WBI, which may to 
some extent be explained by the impossibility to safely add WBI in case of  adverse patho-
logical findings (involved margins or lymph nodes). This illustrates the risks of  pre-surgery 
treatment decisions[133]. IOERT also came with a higher occurrence of  fat necrosis. The 
TARGIT-trial is subject to controversy: 5-year follow up is based on a median follow-up 
of  2.4years, statistical methodology is contested and the non-inferiority claimed in the 
pre-pathology-stratum is comparable to IBTR when no radiotherapy is given, at least for 
the studied very favourable risk group. As WBI has demonstrated to improve the relative 
relapse risk with two-thirds[4], regardless of  risk characteristics, IBTR in case of  omission 
of  radiotherapy in this group can be estimated at 3.9% (5-year IBTR was 1.3% in the 
WBI-arm), which comes close to the 3.3% reported.




Number of  patients Median follow-up  
(Range) 
(months)

















WBI EBRT 25x2Gy 
PBI: Interstitial  
brachytherapy 7x5.2Gy  
or electron beam  
PBI 25x2Gy
Tumour bed delineation: clip 
based with 2cm expansion 
 
WBI EBRT: Cobalt 6-9MV 
wedged tangential fields 25x2Gy 
with boost 8x2Gy (electrons) in 1 
patient only. 
PBI: Interstitial brachytherapy: 
HDR (Ir192 stepping source) 
7x5.2Gy b.i.d. or EB-PBI  with 
25x2Gy 6-15MeV en face (2cm 
margin)
pT1 pN0-1mi grade 1-2 non-lob-
ular ESBC, no EIC, R0
5y LR 
- PBI 4% 
- WBI 3.3% 
10y LR
- PBI 5.9% 
- WBI 5.1% 
10y regional relapse 











WBI EBRT 25x2Gy  
with boost 5x2Gy 
PBI: multi-catheter  
brachytherapy,  
HDR 8x4Gy or 7x4, 
3Gy bid or PDR 50Gy  
at 0.6-0.8Gy/h
WBI: Tangential field 4-10MV 
in 25-28x1.8-2Gy, followed by 
electron boost in 5x2Gy, no dose 
reductions allowed. Target de-
fined on fluoroscopic or CT sim-
ulator (not further explained) 
APBI: Tumourbed delineation: 
tumourbed of  at least 2cm, indi-
vidually defined. 100% of  dose 
to 90% of  target volume.  Maxi-
mum skin dose restricted to 70% 
of  prescribed dose.
Age ≥40y, lumpectomy for uni-
focal pTis or pT1-2 (≤3cm) IDC, 
ILC or DCIS, pN0-1mi, no EIC, 
≥2mm uninvolved margin (5mm 
if  ILC or DCIS), no LVSI, if  




- PBI 1.44% 
5y regional recurrence 
- WBI 0.18% 
- PBI 0.48% 
Non-inferiority (increase of  LR 








Lower dose to surrounding organs




Full knowledge of histology, resection margins
Dose to surrounding organs




Specializ d expertise  needed
Low  dose to surroundingorgans







1449 63 No comparator –  
observational study




External beam  
APBI
SPANISH trial 








WBI 24x2Gy +/-  
boost 5x2Gy 
APBI 10x3,75Gy bid
PTV = same quadrant as prima-
ry tumour site 
Both WBI and APBI by 3D-CRT
Age ≥60y, grade 1-2 unifocal 
IDC, pT1-2 (≤3cm), pN0. No 
DCIS, no lobular carcinoma, no 
EIC, margins >3mm, no postsur-
gical hematoma >2cm or seroma 
requiring multiple aspirations.










WBI 16x2.66Gy or  
25x2Gy supine tangential  
fields with 10Gy boost if   
indicated. 
APBI: 10x3,85Gy bid  
(min. 6h in between  
fractions) - no boost. 
Tumourbed delineation: tu-
mourbed or seroma on CT, 
including surgical clips, with 1cm 
margin inside breast tissue (5mm 
from skin). Addition of  1cm 
CTV to PTV expansion.
IDC or DCIS treated with 
lumpectomy, R0, pN0 (cN0 if  
DCIS), ≥40y, combined tumour 
size (DCIS + IDC) ≤3cm, uni-
focal
No publication on tumour con-
trol yet
Elektrons 3-9MeV – 21Gy ! 90% isodose at 13-24mm
Depth < 4cm
Delivery time low (+30’ operation time)
Mobilisation of breast tissue to insert protective disc
! Mobetron: mobile self shielded mobile linear accelerator,
US, since 1997
• Novac/Liac: mobile unshielded linear accelerator, Italy
Low Energy X-ray 50kV over 20-45’
Depth low, RBE high, 20Gy ! at 1cm 5-7Gy
Conventional walls shield enough
Thungsten impregnated sheet
• Intrabeam: mobile X-ray source, max. 50kV
delivery Germany, since 1999
Intra-operative techniques
Catheter based Mammosite, Contura, Savi, Clearpath
   ! HDR afterloader – 10x/5 days (<29 days)
 
Axxent    ! electronic brachy: 50kV




Elektrons 3-9MeV – 21Gy ! 90% isodose at 13-24mm
Depth < 4cm
Delivery time low (+30’ operation time)
Mobilisation of breast tissue to insert protective disc
! Mobetron: mobile self shielded mobile linear accelerator,
US, since 1997
• Novac/Liac: mobile unshielded linear accelerator, Italy
Low Energy X-ray 50kV over 20-45’
Depth low, RBE high, 20Gy ! at 1cm 5-7Gy
Conventional walls shield enough
Thungsten impregnated sheet
• Intrabeam: mobile X-ray source, max. 50kV
delivery Germany, since 1999
Intra-operative techniques
Catheter based Mammosite, Contura, Savi, Clearpath
   ! HDR afterloader – 10x/5 days (<29 days)
 
Axxent    ! electronic brachy: 50kV










-­ electronic brachytherapy 50kV
-­ Conventional walls shield enough








Lower dose to surrounding organs




Full knowledge of histology, resection margins






Full  knowledge of  histology,  resection
margin
Dose to surrounding organs









(IQR 41 - 84 
- APBI: 32-84 
- WBI: 46-84)
WBI 25x2Gy with boost 5x2Gy 
APBI 5x6Gy IMRT
Tumourbed based on clips, with 
1cm expansion to CTV with 
3mm from skin. Addition of  1cm 
for CTV to PTV. 
  
WBI: Tangential field EBRT 
25x2Gy followed by electron 
beam boost 5x2Gy 
APBI: IMRT with 4 or 5 co-
planar fields 5x6Gy 6MV (step 
and shoot technique) in supine 
position.
Age >40y, unifocal ESBC pT1-2 
≤ 2.5cm, including DCIS, LVSI, 
pN0-1. No EIC, R0≥5mm
5y IBTR (LR =true recurrence 
in index quadrant) 
-APBI 1.5%, (LR 0, EF 1.5%)  
- WBI 1.4% (LR 1.4%) 
5y LRR 













WBI EBRT 15x2,67Gy 
WBI 15x2.4Gy with SIB 15x2.67Gy 
PBI 15x2.67Gy
Tumourbed localization either by 
clips or by postoperative clinical 
localization, US, MRI or CT. 
 
EBRT delivered with FIF IMRT 
with standard tangential field 
set up. This included non-target 
breast tissue medially and later-
ally of  tumourbed in high dose 
region.
Age ≥ 50y, BCS for unifocal IDC 
grade 1-3, pT1-2 (≤3cm), pN0-1 
(3 nodes or less involved), margin 
≥2mm
5y LR 
- WBI 1.1% 
- WBI SIB 0.2% 
- PBI 0.5%
 Intra-operative APBI – 











Mobetron: intra-operative delivery 
of  21Gy to tumourbed (no comple-
mentary WBI) 
EBRT: 25x2Gy with boost 5x2Gy
WBI with boost Age 48-75 years, ESBC maximal 
diameter 2.5cm, suitable for 
lumpectomy.
5y IBTR:  
- EBRT 0.4% 
-Mobetron 4.4% 
5y True LR:  




-­ 3-­9MeV  – 21Gy  à 90%  isodose at  13-­24mm
-­ Depth  <  4cm
-­ Delivery  time  low  (30’  extra  operation  time)  
-­ Mobilisation  of  breast  tissue  to  insert  protective  disc  
-­ Mobetron:  mobile  self-­shielded  linear  accelerator  
(US,  1997)  
-­ Novac/Liac:  mobile  unshielded  linear  accelerator  
(Italy)
Invasive technique
No  knowledge on  dose-­homogeneity
No  knowledge on  histology,  resection margins
Low  dose to surrounding organs
Elektrons 3-9MeV – 21Gy ! 90% isodose at 13-24mm
D pth < 4cm
Delivery time low (+30’ operation time)
Mobil sation of breast tissue to insert pr tective disc
! Mobetron: mobile self shielded mobile linear accelerator,
US, since 1997
• Novac/Liac: mobile unshielded linear accelerator, Italy
Low Energy X-ray 50kV over 20-45’
Depth low, RBE high, 20Gy ! at 1cm 5-7Gy
Conventional walls shield enough
Thungsten impregnated sheet
• Intrabeam: mobile X-ray source, max. 50kV
delivery Germany, since 1999
Intra-operative techniques
Catheter based Mammosite, Contura, Savi, Clearpath
   ! HDR afterloader – 10x/5 days (<29 days)
 
Axxent    ! electronic brachy: 50kV






-­ 3-­9MeV  – 21Gy  à 90%  is dos at  13-­24mm
-­ Depth  <  4cm
-­ Delivery  time  low  (30’  extra  operation  time)  
-­ Mobilisation  of  breast  tissu   to  insert  protective   isc  
-­ Mobetron:  mobile  self-­shielded  linear  accelerator  
(US,  1997)  
-­ Novac/Liac:  mobile  unshielded  linear  accelerator  
(Italy)
Invasive technique
No  knowledge on  dose-­homoge eity
No  knowledge on  histology,  resection margins
Low  dose to surrounding organs
Elektrons 3-9MeV – 21Gy ! 90% isodose at 13-24mm
D pth < 4cm
Delivery t me l w (+30’ operation time)
Mobil sation of breast tissue to insert pr tective disc
! Mobetron  obile self shielded mobile linear accelerator,
US, since 1997
• ovac/Liac: mobile unshielded linear accelerator, Italy
Low Energy X-ray 50kV over 20-45’
Depth low, RBE high, 20G  ! at 1cm 5-7Gy
Conventional walls shield enough
Thungsten impregnated sheet
• Intrabeam: mobile X-ray source, max. 50kV
delivery Germany, since 1999
Intra-operative techniques
Catheter based Mammosite, Contura, Savi, Clearpath
   ! HDR afterloader – 10x/5 days (<29 days)
 
Axxent    ! electronic brachy: 50kV
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EBRT +/- boost (tech-
nique not specified) 
Intrabeam pre-pathology 
(IORT) or post-pathology 
(re-opening wound) +/- 
WBI if  unforseen adverse 
features (margin <1mm, 
EIC, invasive lobular car-
cinom) or at the discretion 
of  the centre (margin 
1-10mm, N+, LVSI)
EBRT: conventional postopera-
tive EBRT +/- boost 
Intrabeam followed by EBRT: no 
EBRT boost
Unifocal IDC (MRI not re-
quired), age ≥45y undergoing 
lumpectomy
5y LR: 
- EBRT 1.3% 
- Intrabeam 3.3% 
Pre-pathology: 
-EBRT 1.1% 
- Intrabeam 2.1%  
Post-pathology: 




-­ 50kV  – 20Gy  à 5-­7Gy  at  10mm
-­ Depth  low,  RBE  high
-­ Delivery  time  20-­45’
-­ Thungsten  impregnated  sheet  
-­ Conventional  walls  shield  enough  
-­ Intrabeam:  mobile  X-­ray  source  (Germany,  1999)
Invasive technique
No  knowledge on  dose-­homogeneity
No  knowledge on  histology,  resection margins but  postoperative WBI  
possible
Low  dose to surroundingorgans
Elektrons 3-9MeV – 21Gy ! 90% isodose at 13-24mm
Depth < 4cm
Delivery time low (+30’ operation time)
Mobilisation of breast tissue to insert protective disc
! Mobetron: mobile self shielded mobile linear accelerator,
US, since 1997
• Novac/Liac: mobile unshielded linear accelerator, Italy
Low Energy X-ray 50kV over 2 -45’
Depth low, RBE high, 20Gy ! at 1cm 5-7Gy
Conventional walls shield enough
Thungsten impregnated sheet
• Intrabeam: mobile X-ray source, max. 50kV
delivery Germany, since 1999
Intra-operative techniques
Catheter based Mammosite, Contura, Savi, Clearpath
   ! HDR afterloader – 10x/5 days (<29 days)
 
Axxent    ! electronic brachy: 50kV
   ! conventional walls shield enough
Mammosite ConturaSavi




-­ 50kV  – 20Gy  à 5-­7Gy  at  10mm
-­ Depth  low,  RBE  high
-­ Delivery  time  20-­45’
-­ Thungsten  impregnated  sheet  
-­ Conventio al  w lls  sh eld  enough  
-­ Intrabeam:  mobile  X-­ray  source  (Germany,  1999)
Invasive technique
No  knowledge on  dose-­homogeneity
No  knowledge on  histol gy,  resection margins but  postoperative WBI  
possible
Low  dose to surroundingorgans
Elektrons 3-9MeV – 21Gy ! 90% isodose at 13-24mm
Depth < 4cm
Delivery time low (+30’ operation time)
Mobilisation of breast tissue to insert protective disc
! Mobetron: mobile self shielded mobile linear accelerator,
US, since 1997
• Novac/Liac: mobile unshielded linear accelerator, Italy
Low Energy X-ray 50kV over 2 -45’
Depth low, RBE high, 20Gy ! at 1cm 5-7Gy
Conventional walls shield enough
Thungsten impregnated sheet
• Intrabeam: mobile X-ray ourc , max. 50kV
delivery Germany, since 1999
Intra-operative techniques
Catheter based Mammosite, Contura, Savi, Clearpath
   ! HDR afterloader – 10x/5 days (<29 days
 
Axxent    ! electronic brachy: 50kV
   ! conventional walls shield enough
Mammosite ConturaSavi
Partially Intra-operative techniqu s
Balloon based
Table 3 - Overview of  trials on PBI with a median follow-up of  at least 5 yearsAbbreviations:  WBI = whole breast irradiation; SIB 
= simultaneously integrated boost; (A)PBI = (accelerated) partial breast irradiation; HDR = High-dose rate; PDR = pulsed-dose rate 
(brachytherapy); EBRT  =external beam radiotherapy; RCT = randomized controlled trial; CTV/PTV = clinical/planning target vol-
ume; LR = local recurrence; IBTR = in breast true recurrence; LRR = loco-regional recurrence; CI =confidence interval; IQR = inter-
quartile range; IDC/ILC = invasive ductal/lobular carcinoma; DCIS = ductal carcinoma in situ; EIC = extensive intraductal component; 
R0 = resection margin free; LVSI = lympho-vascular space invasion; IMRT = intensity modulated radiotherapy; IORT = intra-operative 
radiotherapy; VNPI = Van Nuys Prognostic Index; MV = megavolt; MeV = mega-electron volt; MRI = magnetic resonance imaging
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Who may benefit from APBI?
Both the ASTRO and the GEC-ESTRO groups have published guidelines indicating which 
patients may safely be treated with APBI and for which indications caution is still warranted 
or APBI should be avoided (table 4)[26-28]. Bringing these data together with the recom-
mendations of  ASTRO and GEC-ESTRO on patient selection, results in an overall limited 
window of  opportunity for APBI, as illustrated in table 5 and graphically represented in fig-
ure 7 (information based on breast cancer incidence in Belgium and combined with overall 
stage distribution, without correction for incidence of  stage per age group – features other 
than tumour size and lymph node involvement were not considered).
Fig 7 - Graphical illustration of  the window of  opportunity for APBI (at the condition of  favourable characteristics) versus omission of  
radiotherapy (**Hormone positive, T2 =<3cm, lymph node negative). Percentages are based on breast cancer incidence per age group 
in Belgium, 2015. At diagnosis, stage I disease is applicable in 43.2% of  all breast cancers (global percentage for Belgium, 2015)[2].
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ASTRO - 
2009
Update ASTRO - 
2017
ASTRO - 
2009 Update ASTRO - 2017
ASTRO - 
2009
Update ASTRO - 
2017 GEC-ESTRO - 2010
Suitable - outside clinical trial accept-
able
Cautionary - caution and concern applied 
when considering APBI outside of  a clinical 
trial
Unsuitable - APBI outside of  clinical 
trial not generally considered warranted
Low risk - outside clinical trial 
acceptable
Intermediate risk - APBI consid-
ered acceptable within clinical 
trial
High-risk: APBI is 
contra-indicated
Patient factors
Age ≥ 60 years ≥ 50 years 50-59 years
- 40-49 years if  all other criteria 
for “suitable” are met 
- ≥ 50 years if  at least 1 of  
following factors is applicable <50
- < 40 
- 40-49 if  criteria for 
“cautionary” are not 
met ≥50 40-50 ≤40 years
BRCA1/2 Not present NA Present NA NA NA
Pathologic factors
Tumour size ≤ 20mm 21-30mm ≥30mm ≤ 30mm ≤ 30mm >30mm
T stage T1 Tis or T1 T0 or T2 T2 T3-4 pT1-2 pT1-2 pT2 (>3cm)
Margins R0 ≥ 2mm R0 < 2mm Positive R0 ≥ 2mm R0 < 2mm Positive
Grade Any Any Any Any Any Any
LVSI No Limited/focal Extensive Not allowed Not allowed present
ER status Positive Negative NA Any Any Any
Multicentricity Unicentric only NA Present Unicentric Unicentric Multicentric
Multifocality






Multifocality allowed if  clin-
ically unifocal with total size 
2.1-3cm
Clinically unifocal with microscopically 
size >3cm of  if  clinically multifocal Unifocal Multifocal (≤2cm of  index lesion)
Multifocal (>2cm from 
index lesion)
Histology
Invasive ductal or other favorable 
types Invasive lobular NA
IDC, mucinous, tubular, medul-




Allowed if  all of: 
- screen-detected 
- Grade 1-2 
- Size ≤2.5cm 
- R0 ≥3mm ≤ 3cm
Pure DCIS ≤ 3cm if  criteria for 
suitable not fully met >3cm Not allowed Allowed Allowed
EIC Not allowed ≤ 3cm >3cm Not allowed Not allowed present
Associated LCIS Allowed Allowed Allowed Allowed Allowed Allowed
Nodal factors
N stage pN0 (i-,i+) NA pN1-3 pN0 pN1i, pN1a (3nodes) pNx, ≥pN2a (≥4N+)
Nodal surgery SN Biopsy or ALND NA None performed SN Biopsy or ALND SN Biopsy or ALND Any
Treatment factors Neo-adjuvant chemo Not allowed NA If  used Not allowed Not allowed If  used
Table 4 - Overview of  the ASTRO[26], updated ASTRO[27] and GEC-ESTRO guidelines[28] for APBI.Abbreviations: NA = not 
applicable; APBI = accelerated partial breast irradiation; R0/1/2 = resection margins free/microscopically involved/macroscopi-
cally involved; LVSI = lympho-vascular space invasion; ER = estrogen receptor;  IDC = invasive ductal carcinoma; ILC = invasive 
lobular carcinoma; DCIS = ductal carcinoma in situ; EIC = extensive intraductal component; LCIS = lobular carcinoma in situ; 
T-stage = size of  tumour; N-stage = lymph node involvement; SN = sentinel node; ALND =axillary lymph node dissection
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Age
pN0
Hormone positive tumour Hormone negative tumour




































*IF SLN or ALND performed, no BRCA 1/2, R0≥2mm, no LVSI, unicentric and unifocal, IDC or 
favorable subtype (mucinous, tubular, medullary or colloid), no pure DCIS, no EIC and no neo-adjuvant 
chemotherapy, otherwise WBI
** WBI covers WBI only as well as WBI with sequential boost or SIB.
 
Table 5 - Combination of  GEC-ESTRO and updated ASTRO-guidelines for APBI, combined with evidence from PRIME-trial  
(age limit 65 years) and CALGB 9343 trial (age-limit 70 years)
HEALTH  
ECONOMIC EVALUATION –  
BALANCING COSTS  
AND EFFECTS
Whereas clinical research investigates the efficacy and effectiveness of  new treatments, as 
described in the former section for accelerated WBI and APBI, the subject of  efficiency (‘Are 
new treatment strategies worthwhile from a health economic point of  view?) is addressed by 
health economic evaluations (HEE). With increasing healthcare costs and expenses, in the 
context of  ever tightening budgets, the interest for the balance between costs and effects has 
been steeply rising over the past 20 years. This can be observed in the increasing yearly num-
ber of  publications on HEE (figure 8), of  which most are based on cost-effectiveness (CEA) 
or cost-utility (CUA) analysis, techniques that relate the change in cost to the difference in 
health effects. Such economic exercises within the domain of  health care come at help for 
decision makers in allocating the available resources to strategies that maximise health, deci-
sions which may vary per country and depend on the available health care budget. 
Fig 8 – A steep rise of  the INTEREST in health economic evaluation over the past decade can be observed by a simple search in 
Pubmed ). The number of  breast cancer related HEE remains however low (dark blue).  
 
Types of  health economic evaluations
HEE cover a wide range of  approaches, depending on whether both costs and outcomes 
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for example, is less interesting than the approach where the cost of  a new intervention is 
compared with the gold standard, as in cost comparison analysis (CC). In addition, dif-
ferences in costs may be justified by differences in health effect: a less costly strategy may 
become less attractive if  it impairs survival or quality-of-life (QoL). Hence, increases or 
decreases in costs only show one part of  the equation, and should be evaluated in the light 
of  changes in clinical outcome, as is done in a full HEE.
When the incremental cost is divided by the incremental health effect, this results in an 
incremental cost-effectiveness ratio or ICER, with in the formula below, y being the new 
strategy and x the gold standard. This approach is referred to as cost-effectiveness analysis 
(CEA) or cost-utility analysis (CUA), depending on the health effect used.
Health effects represent the effectiveness of  a strategy; incremental effects are the 
additional outcome that can be obtained with a new treatment as compared to the 
standard. If  this effectiveness is expressed in natural units, ideally measured in life-
years gained (LYG), then the economic evaluation is referred to as cost-effectiveness 
analysis (CEA). 
However, other measures can be used. To obtain quality-adjusted life-years gained 
(QALYs), LYGs are multiplied with a factor between 0 and 1, articulating the im-
portance that individuals adhere to a clinical benefit (utility). Such analysis is called 
a cost-utility analysis (CUA). The term of  CEA is more commonly used and often 
covers both concepts. 
Two other HEE techniques are cost-minimization analysis (CMA) and cost-benefit 
analysis (CBA). A CMA compares the cost of  two equally effective strategies. The dif-
ference in costs represents the savings that can be obtained if  the least costly strategy 
is applied. In a CBA, health effects are also expressed in monetary units. An overview 
is given in figure 9.
ICER = ------------------------------------------------------------------------
∆ (Cost y – Cost x)
∆ (Effectiveness y – Effectiveness x)
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Fig 9: Overview of  the different types of  HEE, including a decision tree based on comparators and units used. 
 
 
Defining costs in health economic evaluation
It is important to understand that costs, used in HEE, may take many forms. The difference 
between direct versus indirect and medical versus non-medical costs is illustrated in figure 10.
Costs incorporate the quantity of  the resource used multiplied by the monetary value of  
a unit. This value can be either the unadjusted market price or the opportunity cost. Al-
though most HEE apply market prices, opportunity cost is a more correct approach. It is 
the value of  a foregone benefit, that cannot be used for a ‘best’ alternative as the resource 
is not available anymore[135]. 
The study perspective determines which costs (and health effects) must be included. Most 
HEE claim a societal perspective, but, as mentioned in the ISPOR Drug Cost Task Force 
Report, the term ‘societal’ is widely misunderstood and misused[136]. A ‘health system 
perspective’ would be a more accurate definition, as most HEE apply a payers’ perspective 
based on direct medical costs and expand these with indirect costs. A societal perspective 
includes all the costs and benefits regardless of  who incurs or obtains them, thus avoiding 
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leave, may be compensated for by an allowance. Including only the allowance as govern-
mental expenditure would overestimate the cost of  working incapacity. Although the nar-
rower ‘health system perspective’ risks to exclude potential benefits, Drummond states that 
“it may still lead to very similar decisions once account has been taken of  the restrictions on 
health care expenditure and non-health benefits that are likely to be displaced”[137].
Two methods for cost calculation of  interventions are used in HEE: most often, cost inputs 
are based on reimbursement data or charges claimed by the health-care provider. Reim-
bursement represents what is paid by the insurer and results from a bilateral negotiation, 
with different levels of  reimbursement per payer. Charges are what the hospital expects 
to receive for their services and are usually higher than the reimbursement received. The 
advantage of  reimbursement-based cost data relies in its’ simplicity. However, these data 
are rarely representative of  the real cost of  an intervention. Indeed, as reimbursement 
is the result of  negotiations between health care providers and financing organisations, 
it can display large regional differences and may be subject to sudden changes, due to 
budgetary savings.
Fig 10: Relation between perspective and types of  resource costs.
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A more precise method to define the cost of  an intervention is calculating the real costs 
incurred when using resources to deliver a treatment. These resource costs typically in-
clude personnel costs (salaries), the investment costs of  infrastructure and equipment, 
consumables, overhead. There are two commonly accepted cost-accounting techniques: 
micro-costing and activity-based costing (ABC). Micro-costing, a bottom-up approach 
requiring insight into the time investment of  the different resources, is interesting for 
calculating the cost of  specific treatments or process steps, as it multiplies the resources 
utilized with their related unit costs. The technique of  ABC assigns resource costs through 
the intermediary of  the care process activities involved[138]. It is more comprehensive 
and takes into account the relative weight of  indirect resource costs that cannot be directly 
assigned to the final product, i.e. the treatment. It also provides superior insight into highly 
variable costs. 
From an institutional perspective, reimbursement covering all real costs would signify the 
most ideal scenario, as no financial risk is carried by the provider. However, from a payers’ 
perspective, the lack of  an incentive to economize may lead to inefficient use of  health 
care budgets. Real costs are a dynamic concept, as initially high costs may decrease when 
learning curves are completed, new strategies change to standard practice, investments are 
amortized... These uncertainties, together with reimbursement tariffs being straight-for-
ward to use in cost-calculations, may explain why many HEE are reimbursement-based. 
Piggyback analyses versus health economic modelling
Although it is well recognized that comparative effectiveness is critical for supporting the 
appropriate use of  more advanced treatments, techniques and technologies, generating 
these data in radiotherapy remains challenging. 
An economic analysis embedded in a clinical trial comparing different treatment strat-
egies is known as a piggyback analysis[139]. In such approach, economic cost data are 
collected alongside a trial, which in itself  is designed to respond the clinical question. 
Although it may be the appropriate way to measure the economic impact of  medical 
interventions, it is, however, not evident to collect all long-term cost and outcome data 
necessary to perform the economic evaluation. 
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Hence, most HEE are based on modelling exercises, with the Markov model as the most 
frequently used. Such models are based on a predefined series of  health states at different 
time intervals, called cycles. The length of  such cycle depends on the nature of  the disease 
and the intervention being evaluated, and could be a month or a year. After each cycle, 
transition probabilities define how patients move between different health states. Each 
health state is associated with a cost and, for cost-utility analyses, a utility value. The out-
come of  such modelling exercise is calculated as the product of  the time that the average 
patient occupies the different health states weighted by the cost and utility of  each specific 
health state (figure 11)[140].
Fig 11 - Markov model decision tree example (adapted from https://www.treeage.com/) 
Visualizing the results of  an economic evaluation: the cost-effectiveness plane 
The results of  a CEA or CUA are expressed by the ICER, and can be represented on a 
cost-effectiveness plane, with the X-axis indicating incremental effectiveness and the Y-ax-
is incremental cost[141]. The different possible situations are illustrated in figure 12. An 






















A negative figure indicates the ICER is either dominant (lower cost for improved ef-
fectiveness – green quadrant, situation 1) or dominated (higher cost for impaired ef-
fectiveness – red quadrant, situation 2). In the former, it is strongly recommend-
ed to introduce the new intervention into daily care; in the latter, it should not. 
 
Fig 12 - Cost-effectiveness plane 
A positive result indicates a trade-off situation (grey quadrants), with an improved effec-
tiveness for a more expensive treatment as the most common situation (double positive 
situation, right upper quadrant). Such a result can be compared to a willingness-to-pay 
threshold, indicating how much a society accepts to pay as incremental cost per LYG or 
per QALY. This can be a fixed amount (e.g. 20.000-30.000£/QALY or 100.000$/QALY 
as applied by respectively the UK and the US) or a variable or undefined amount, as is the 
case in Belgium[142]. If  no fixed amount is defined, factors such as the innovative charac-
ter or need of  a new intervention, the available health care budget or the availability of  al-
ternative interventions are additionally taken into consideration to guide decision-making. 
In these trade-off situations, society aims at a maximal gain in effectiveness for minimal 
extra cost. In figure 12, situation 3 would be considered as an acceptable strategy, whereas 
situation 4 may be considered too costly.
56 57Accelerating Adjuvant Breast Radiotherapy Accelerating Adjuvant Breast Radiotherapy
A less frequent situation is the trade-off where a new strategy costs less, but comes with a 
loss in effectiveness (double negative situation). In this case, the focus will shift to minimal 
loss in effectiveness for a maximal reduction in cost. Hence, in case of  a double negative sit-
uation, a high cost reduction for a minimal loss in health effect would be preferred, which is 
the opposite of  the double positive right upper quadrant. In the illustration, situation 5 may 
therefore be regarded inacceptable whereas situation 6 could be considered acceptable.
Handling uncertainty in health economic evaluation
To address the inherent uncertainties of  a HEE, uncertainty analysis is applied. This technique 
assumes an acceptable range in costs or outcomes and evaluates the impact ranges have on the 
final cost-effectiveness result. In one-way sensitivity analysis, each variable is evaluated separate-
ly. Probabilistic sensitivity analysis (PSA) varies different variables at the same time through the 
means of  a Monte Carlo simulation, running hundreds to thousands of  times. The result of  
such exercise can be visualized as a cloud, located over the cost-effectiveness plane (figure 13). 
Fig 13 – Visualisation of  Monte Carlo based PSA (1000 simulations) with the example indicating that the new intervention is most 
probably less costly and more effective than the comparator. Ellipses represent 50% and 95% confidence intervals. Illustration from D. 
Angus et al. Pediatrics, 6/12/2003[143]
Heterogeneity takes into consideration the impact the chosen base case may have on 
the cost-effectiveness results. The impact of  heterogeneity may be explored through the 
means of  scenario analysis, recalculating cost-effectiveness if  a different population (e.g. 
age, social status, sexe…) or indication (e.g. tumor stage, co-morbidity…) is chosen. Even 
in the absence of  such analysis, heterogeneity should be discussed, to avoid inappropriate 
generalization of  the cost-effectiveness results.
Quality in health economic research
The results of  a HEE exercise, and ultimately whether they will be suitable to guide health 
care decision-making, strongly depend on the validity of  the input data and on the model 
used. In 2012, the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) published a report on ‘good research practices’ emphasizing the importance of  
transparency on the models used and validity of  the input data sources[144]. To improve 
conformity and quality in HEE reporting, the Consolidated Health Economic Evaluation 
Reporting Standards or CHEERS’ consensus was published, a checklist containing 24 
items indispensable for evaluating the validity and reliability of  a HEE[145]. 
It cannot be overstressed that, as for clinical research, high-quality and valid HEE data 
is indispensable. Only in the presence of  such data, correct decisions can be made about 
which new health care interventions to grant reimbursement, and which interventions 
conversely are too expensive for society to introduce in daily clinical practice.
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OBJECTIVES
Purpose of  my research
As described in the introduction of  my PhD, breast cancer radiotherapy has a well-de-
fined place in the multidisciplinary treatment of  breast cancer. It has been proven to be 
effective, with proportional gains in local control and overall survival being grossly stable 
across tumour stages and clinical indications. All in all, post-operative radiotherapy halves 
the risk of  any first recurrence and for each 4 local relapses averted, one life can be saved.
Yet, in contrast, the absolute gains in local control and survival do vary significantly across 
tumour stages and clinical indications. Consequently, in the more favorable situations of  
ESBC, it is often questioned - by the patient or the referring specialist - whether the ben-
efits anticipated are sufficient to run the risk of  toxicity and to subject the patient to the 
burden of  cumbersome travels to and from the hospital. This is especially the case for the 
elderly breast cancer patient, a patient population that is not only important, but is still on 
the rise. In this context, the long-standing paradigm of  normofractionated whole breast 
irradiation is clearing the field for the newer approaches of  acceleration and partial breast 
irradiation. Both have the aim to reduce the cost of  breast cancer radiotherapy, in terms 
of  toxicity, of  patient burden as well as in budgetary terms.
Before considering new health care interventions for introduction in daily clinical care, 
evidence must be generated, not only from a clinical, but also from a health economical 
perspective. In an indication as frequent as post-operative radiotherapy for breast cancer, 
the judicious selection of  the most appropriate treatment strategy for each specific clinical 
situation, is not only deemed to improve the care to the individual patient, but also allo-
cate the scarce health care resources and budget in the most efficient way. 
Based on these considerations, the central purpose of  my research was to 
examine the feasibility, toxicity and economic impact of  accelerated breast 
cancer radiotherapy, with the aim to provide the best outcome to each in-
dividual patient, at the lowest cost from a clinical as well as an economical 
perspective.
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Before considering the introduction of  partial breast irradiation in our standard approach 
of  prone breast radiotherapy, the first question to tackle was how to safely reduce the 
treated volume and ascertain accuracy in tumourbed delineation. This was investigated 
in a feasibility study evaluating interobserver variability and dosimetric impact of  a geo-
metrical approach to target volume delineation.
Based on the equivocal findings of  this study, and with the ambition to reduce treatment 
burden beyond the confines of  low risk indications only, a prospective phase 2 trial ex-
ploring the safety of  acceleration to 5 fractions in all indications for adjuvant breast radio-
therapy, including thoracic wall and lymph node irradiation, was conducted in an elderly 
patient population.
Health economic evaluations have the aim to support healthcare decision-making on the 
introduction of  new, often costlier, treatment strategies in daily practice. In order to do 
this correctly, the health economic information must be valid and of  high quality. To 
assess the validity of  the available evidence, economic evaluations on different types of  
breast cancer radiotherapy, retrieved by a systematic literature review, were subjected to 
a qualitative and quantitative analysis and a new method of  quantification was explored.
In a subsequent exercise, the available evidence on cost and cost-effectiveness of  different 
strategies in adjuvant breast radiotherapy was assembled. Despite the pitfalls inherent to 
HEE, some conclusions could be drawn on the efficiency of  new schedules and treatment 
techniques within this domain.
SCOPE OF THESIS  
IN FOUR OBJECTIVES
Objective 1: 
Partial breast irradiation: is it feasible in prone position? 
Evaluation of  a practical approach to obtain precise and accurate target volume delinea-
tion for accelerated partial breast irradiation in prone position.
Objective 2: 
Accelerated radiotherapy: can it be extended beyond partial breast irradia-
tion, without increasing acute toxicity? 
Evaluation if  accelerated breast irradiation may safely be expanded to a broader popula-
tion of  elderly patients with early as well as locally-advanced stage breast cancer.
Objective 3: 
Health economic evidence of  post-operative breast radiotherapy: is it valid?
Evaluation of  the quality of  the available health economic evidence on post-operative 
breast radiotherapy, and its validity to guide health care decision-making.
Objective 4: 
Post-operative breast radiotherapy: what are its cost and cost-effectiveness?
Evaluation of  the available health economic evidence on post-operative breast radiother-
apy regarding the balance between costs and effectiveness of  different techniques and 
fractionation schedules.
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Abstract 
Introduction In view of  the limited incremental benefit between whole breast irradi-
ation (WBI), accelerated partial breast irradiation (APBI) and omission of  radiotherapy 
in favourable early stage breast cancer (ESBC), APBI can only be justified if  it combines 
adequate target coverage with the lowest achievable toxicity. Interobserver exercises 
demonstrated the difficulty of  precise target delineation, especially in prone position; 
information on accuracy is even scarcer. We tested the impact of  inserting an additional 
indicatorclip, marking the depth of  the tumour in the breast, and the added value of  a 
preoperative CT in treatment position on precision and accuracy. 
Materials and methods In 12 patients, tumour bed delineation was performed by 4 
radiation oncologists, with CTVstandard (clinical target volume) based on standard delinea-
tion guidelines, CTVclip resulting from a 1-2cm symmetrical expansion with the indicator-
clip as centre and CTVclip_CT expanding from the midpoint between the indicatorclip and 
preoperative gross tumor volume (GTV) as centre. Precision was measured as the mean 
pairwise Jaccard index (JIpairs) between observers, accuracy as the mean overlap between 
GTV and respective CTVs.
Results JIpairs was 0.38 for CTVstandard, 0.75 for CTVclip and 0.59 for CTVclip_CT. Overlap 
rate of  GTV with CTVs was respectively 0.48, 0.67 and improved further to 0.88 for CT-
Vclip_CT. High-dose coverage of  GTV (D95 and D90) improved with an indicatorclip, but 
the most optimal result was reached when preoperative CT was added.
Conclusion If  EB-APBI in prone position is aimed for, an indicatorclip intended to mark 
the depth of  the tumour increases the probability of  accurate target coverage, but cannot 
entirely replace the added value of  a preoperative CT in treatment position. Avoiding the 
cost and effort of  such CT implies a risk of  missing the target., especially when small vol-
umes are aimed for. Increasing target volumes to reduces this risk, questions the concept 
of  APBI.
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INTRODUCTION
Adjuvant radiotherapy is an evidence-based part of  breast conserving therapy, improving lo-
cal control and overall survival[1]. These advantages however come at the cost of  radiation 
toxicity as well as burdensome treatment courses. In answer to these obstacles, accelerated 
partial breast irradiation (APBI) was introduced for early stage breast cancer (ESBC), with 
acceleration to address the problem of  protracted schedules and reduced target volumes to 
avoid the potential consequences of  high fraction doses in terms of  aesthetic outcome. At 
the same time, smaller volumes would facilitate sparing of  the surrounding organs at risk 
(OAR). Previous trials on adjuvant breast radiotherapy already indicated a relation between 
irradiated volumes and aesthetic outcome of  the breast, and direct proof  came recently with 
the IMPORT-LOW trial[2-4]. This trial, along with others, also suggested that APBI is a 
safe alternative to whole breast irradiation (WBI) while reducing toxicity[5-8]. However, a 
maximum of  5 years’ follow-up may be too short to draw definitive conclusions, especially 
in case of  favourable ESBC, where differences in survival only start to emerge afterwards 
[1, 9]. An even more radical solution to patient burden and toxicity was tested in the CAL-
GB 9343 and the PRIME trial, omitting radiotherapy in favourable subgroups[10, 11]. 
Although both trials reported an adverse impact on respectively loco-regional and local con-
trol, overall survival was equivalent[10, 11]. The limited incremental benefit between WBI, 
APBI and omission of  radiotherapy indicates that APBI can only be justified if  it combines 
adequate local control, hence adequate target coverage, with the lowest achievable toxicity.
The IMPORT-LOW trial evaluated hypofractionated straight-forward tangential-beam 
field-in-field IMRT for partial breast irradiation (PBI) as a robust and widely imple-
mentable technique, and results indicated equivalence for tumour control and overall 
survival between PBI and WBI[4]. However, the concept of  partial breast is challenged in 
this trial, as beam set-up resulted in high-dose delivered to off-target breast medially and 
laterally from the tumourbed, including part of  the axilla for targets located in the upper 
part of  the breast. Delivering high dose to up to half  the breast may also explain why 
difference in aesthetic outcome was altogether limited.
In EB-APBI, prone position may help tackling volume and toxicity issues: it reduces the 
latero-lateral beam travelling distance and increases the antero-posterior diameter, both 
resulting in reduced high-dose volumes compared to supine position[12]. These dosim-
etric advantages however come at the cost of  increased uncertainty in target delineation, 
most pronounced in the antero-posterior direction[13]. Interobserver delineation exercis-
es have demonstrated the difficulties of  tumourbed delineation, even in supine position 
with seroma present. Clips come at help, but not all clips are relevant, some are even 
misleading (figure 1). Addressing this uncertainty with larger target volumes would forego 
the primary goal of  APBI, volume-reduction.
In search of  combining precision (high interobserver conformity) with accuracy (high 
probability of  primary tumour coverage) in prone position and after full thickness closure 
(FTC), we tested in an interobserver exercise the impact of  inserting an additional indica-
torclip, intended for marking the depth of  the tumour in the breast. To test accuracy, the 
resulting postoperative CTVs were compared with the GTV on preoperative CT in treat-
ment position. Tangential-beam APBI using intensity modulated radiotherapy (IMRT) 
was compared with three-beam IMRT to evaluate the relevance of  accuracy and the 
dosimetric impact of  beam set-up on low- as well as high-isodose volumes. 
Material and methods
Following local Ethics Committee approval of  the study, seventeen patients with his-
tologically confirmed clinical stage I-II breast tumours (cT1-2 cN0), candidate for tu-
mourectomy, signed informed consent and were enrolled between May and December 
2014. Patient, tumour and treatment characteristics are listed in table 1. Five patients 
were excluded after preoperative CT because of  switch to supine position: in one patient, 
multi-centricity necessitated mastectomy and in four a positive sentinel node was found, 
requiring lymph node dissection and irradiation. In the 12 remaining patients, the tumour 
was visualized by harpoon in eight patients with non-palpable tumours and by contrast in 
four patients with palpable tumours.
The pre-operative CT scan was performed on a large bore Toshiba CT, one day before 
tumourectomy and following the standard image acquisition protocol (120kV, 70mAs, 
3-5mm slices). Patients were installed in prone position on the breast board [23]. Con-
trast-enhancement was performed with 100cc IV Visipaque (2cc/sec, scanning started 
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100-120sec after start of  injection). Tattoos were applied to help ensuring the same posi-
tion on postoperative planning CT.
Surgeons were requested to insert clips according to the following protocol: incision and 
localization of  the tumour in the breast with insertion of  a 9mm large titanium “indica-
torclip” in the cavity wall at the depth of  the ‘resection lump’, to indicate antero-posterior 
tumour location as precisely as possible. Following excision of  the tumour, usual “cavity 
wall” clips (6mm, titanium), including a deep “pectoral fascia” clip, were placed accord-
ing to routine practice. FTC was performed in all patients, none underwent oncoplastic 
surgery. Four to five weeks after tumourectomy, patients underwent a planning CT-scan in 
the same position and under the same conditions as preoperatively, but without contrast.
Delineation was performed by four experienced in-house radiation oncologists using ver-
sion 9.8 of  the Pinnacle Treatment Planning software. For CTVstandard, volumes were de-
lineated on the planning CT-scan according to existing guidelines, aided by pre-operative 
information (including surgical and histological reports and preoperative imaging but not 
the preoperative CT in treatment position)[24].
For CTVclip, the indicatorclip was located on simulation CT and symmetrically expanded 
from the centre with a 20mm radius[21, 22], minus the minimal surgical margin (max-
imally 10mm). Expansion was limited to the skin, shrunk with 5mm, and excluded the 
thoracic wall. No other volume corrections were allowed.
The preoperative CT in treatment position was only then fused with the simulation CT, 
the primary tumour was delineated as GTV and a CTVclip_CT was calculated by Gratis, 
an in house developed vector-based planning system[25], as an automatic expansion from 
the calculated midpoint between clip and preoperative GTV. 
Mean distance between centres of  volumes (dCoV) and mean of  pairwise volume com-
parisons, using the Jaccard formula (JIpairs), were calculated to evaluate inter-observer vari-
ability of  CTVs. Pairwise comparison avoids the influence of  the number of  observers 
on the final results[14]. Overlap coefficient (OC) was calculated as the ratio of  the preop-
erative GTV falling within the CTVs. Distance between indicatorclip and preoperative 
location of  the tumour and between CTVs and OARs were calculated with Gratis.
Finally, APBI treatment plans were created per delineation technique, prescribing 28.5Gy 
in 5 fractions to the PTV (CTV + 5mm, excluding skin minus 5mm and thoracic wall) 
with dose fall-off from 28.5Gy to 20Gy in a surrounding rim of  1cm. A 2- and a 3-beam 
set-up with IMRT were applied, with identical gantry and collimator angle per patient, 
and couch rotations for the 3-beam set-up (15° and 340°).
Results are reported as means with 95% confidence intervals. The Wilcoxon signed rank 
test was used to compare the delineation techniques, Friedman’s 2-way test when more 
than 2 results are compared. Significant difference was assumed when a confidence level 
of  95% was reached with an alpha-error of  5%.
Results
Results are listed in table 2 and 3. Volumes were small, but symmetric expansion resulted 
in somewhat higher volumes for CTVclip compared to standard delineation, due to larger 
laterolateral and cranio-caudal diameters and despite smaller antero-posterior diameter. 
Low mean dCoV for CTVclip, indicates good recognisability of  the indicatorclip. This led 
to a high JIpairs for CTVclip compared to CTVstandard (0.75 versus 0.38, p=0.003). When ad-
aptation of  the centre was allowed for CTVclip, JIpairs decreased to 0.59, reflecting a lower 
agreement on delineation of  the GTV, for which a mean dCoV of  7mm was found (1mm 
if  contrast-located versus 10mm if  harpoon-located, p=0.03).
Overlap coefficient of  GTV with CTVs as a proxy for accuracy, was better for indica-
torclip-based delineation than for standard delineation (0.67 versus 0.48, p<0.05) and 
improved even further to 0.88 when information of  the preoperative CT was added.
Distance of  CTVs to heart and ipsilateral lung was not significantly different for both 
delineation techniques.
Dosimetric characteristics are listed in table 3. Coverage of  GTV (D95) increased with 
clip-based delineation, and further improved after adding of  the preoperative CT. The 
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risk of  relevant underdosing was estimated by the number of  patients with 95% of  the 
GTV receiving less than 95 and 90% of  the prescribed dose. Standard delineation result-
ed more often in severe underdosing or fails then clip-based expansion; the risk increased 
with 3- beam set-up, as downside of  sparing off-target breast tissue from high dose. Heart 
and ipsilateral lung dose did not differ significantly (mean heart D2 0.8-1Gy and ipsilat-
eral lung V10 0.2-0.3Gy).
Discussion
Conformity exercises demonstrate that even in controlled circumstances, precision of  
tumour bed delineation in breast cancer is low: breast tissue is a homogeneous struc-
ture with little reference points for localization. When prone position is applied, the ante-
ro-posterior diameter of  the breast increases and landmarks for delineation change. Tis-
sue distortion is a radiological sign, indicating high-density regions (glandular tissue and 
oedema) versus fat tissue. In supine position, (a)symmetry between left and right breast 
may to some extent help to differentiate between oedema and glandular structures, but 
not in prone position, where compression of  the contralateral breast on the breast board 
precludes this comparison. Indirect tumour bed localizers such as clips, seroma or tissue 
distortion do not always correlate with preoperative imaging. Although they indicate the 
surgical trajectory, tunneling upon the pectoral fascia may lead to unnecessarily large ir-
radiated volumes, close to lungs and heart, thus losing the advantages of  prone position 
and partial breast irradiation[15]. The omission of  ‘irrelevant clips’ may solve this, how-
ever at the cost of  lower interobserver conformity, even if  preoperative mammography is 
available[16]. As already suggested by Kirby et al., surgeons plays an important role and 
should be informed on the implication of  clips on irradiated volumes[17]. Insertion of  
a minimum of  5-6 clips is recommended, but re-resections may accidently remove such 
clips. Kirova et al. found that preoperative CT (supine position) mainly corrected for 
left-right discrepancy in tumourbed delineation. According to Verhoeven et al., this does 
not translate into a better jaccard index[18]. However, with folding of  the breast over the 
thoracic wall, antero-posterior uncertainty is reduced by natural borders.
Daily practice confirms this target uncertainty. In case of  PBI, geographical miss of  the 
region at risk is not corrected for by the whole breast component. In view of  above men-
tioned results on delineation conformity, and before starting a trial on EB-APBI in prone 
position, this feasibility trial was conceived for evaluating how to improve precision and 
accuracy in tumourbed delineation. Recognisability of  the marker was good and result-
ed in an interobserver conformity for CTVclip comparable to preoperative exercises[19]. 
Overlap rate of  GTV with CTVclip compared to CTVstandard improved with 40%, indicat-
ing increased accuracy, even if  based on ‘blind’ expansion from this indicatorclip only. Fu-
sion of  images with the preoperative CT in treatment position further enhanced overlap 
rates, be it at the cost of  interobserver conformity, which decreased to 0.59. This can be 
explained by discrepancy in GTV delineation, especially after harpoon-localization.
The dosimetric impact of  delineation uncertainty was tested in a planning exercise. When 
a third beam was added, high-dose volumes decreased and low-dose volumes increased. 
Although GTV coverage, represented as the dose received by 95% of  the volume, did not 
differ significantly between delineation strategies or beam set-ups, the GTV D95 receiving 
less than 95% and even more pronounced, 90% of  the prescribed dose, occurred far more 
often with standard delineation. Reducing high-dose volumes by adding a third beam 
comes at the cost of  a higher probability to miss the target. More importantly, delineation 
based on clips, seroma and tissue distortion only may be misleading. It may seem para-
doxical that underdosing still occurred even after adding the preoperative CT. However, 
CTVclip_CT was based on a straightforward expansion from the midpoint between clip and 
preoperative GTV. Such a situation is illustrated in figure 2.
The results invite debate: first, what is the risk of  clips inserted randomly in the cavity 
walls, potentially marking an irrelevant part of  the surgical trajectory? Introduction of  at 
least 5 clips improves delineation precision, but may not translate into accuracy. A preop-
erative MRI may correct for misleading clip location, but is rarely available. Large high-
dose volumes reduce uncertainty, but undermine the concept of  APBI.
The most intriguing question is how accurate we need to be. In ESBC, omission of  ra-
diotherapy has little to no impact on survival[10, 11]. The main goal of  radiotherapy in 
this favourable cohort relies in prevention of  relapses, but in favourable breast cancer, ra-
diotherapy has only a limited benefit on local control[1]. Moreover, patients may relapse 
despite WBI. Where surgeons’ results are exposed in pathological reports, target miss in 
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radiotherapy is obscured by the low recurrence probabilities of  ESBC. Do low relapse 
rates justify additional imaging for improving target coverage when APBI is aimed for, or 
can we allow a more liberal approach, either by increasing the volume to compensate for 
uncertainty or by accepting the odds of  failure? If  target coverage is the primary goal, 
large volumes will do, but WBI would bring even more security for an overall small cost 
in toxicity. If  reduction of  toxicity and improvement of  aesthetic outcome are pursued, 
dedicated preoperative imaging seems needed to avoid fails in target coverage. The intro-
duction of  an indicatorclip may suffice to improve boost-delineation, but is in our view an 
insufficient compromise for APBI.
A preoperative CT in treatment position does come at a cost. If  APBI is aimed for, intro-
ducing this additional step into the treatment process requires an optimal coordination 
between the radiology, surgery and radiotherapy departments. In only 70% of  the patients 
enrolled in our study the preoperative images could be used for target delineation, which 
is lower than the 86% of  fusible (supine) CT-scans observed by Boersma et al[16]. Cen-
soring was in all cases due to upstaging of  the disease. Upstaging has also been reported 
in the TARGIT trial and ELIOT trial. Pre-operative imaging may be redundant if  APBI 
is replaced by WBI, but not useless, as upstaging will often require a tumourbed boost.
Some additional cautionary remarks must be made. As tumour spread is not spherical 
and can be located eccentrically in the resection specimen, Bartelink et al. have suggested 
asymmetric application of  histopathologic resection margins for expansion to CTV[20]. 
However, in view of  the disappointing results of  a breast specimen orientation exercise 
by Molina et al., symmetric expansion minus the minimal margin was estimated a safer 
option[21]. Asymmetrical expansion may further reduce CTVclip volumes, but potentially 
at the cost of  accuracy. The impact of  an indicatorclip and preoperative imaging was only 
tested in prone position, and cannot be translated to supine. The number of  patients was 
kept low intentionally, as this was only a feasibility trial exploring the prerequisites for safe 
EB-APBI. Non-palpable tumours were located by harpoon instead of  contrast, which in 
retrospect increased uncertainty. With small tumours being the primary indication for 
APBI, combining both techniques could have brought additional insight in the value of  
harpoon-based GTV localization. The study was single-centre. All observers were famil-
iar with tumourbed delineation based on standard guidelines, not with the new proce-
dure, including fusion with preoperative CT for GTV delineation. However, increased 
experience would probably have further favoured the experimental arm.
In conclusion, if  EB-APBI in prone position is aimed for, an indicatorclip clearly intend-
ed to mark the depth of  the tumour increases the probability of  covering the primary 
tumour location, but cannot entirely replace the additional value of  a preoperative CT 
in treatment position. Avoiding the cost and effort of  such a preoperative CT, implies 
accepting a risk of  missing the target, especially when small volumes are aimed for. In-
creasing target volumes may reduce this risk, but questions the concept of  APBI. With 
shorter treatment schedules and lower costs of  EB-APBI compared to WBI[22], adding 
a preoperative CT may be considered a marginal expenditure for improving accuracy. 
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TABLES
 
































1 NST 2 10 11 3 No 5 yes yes
2 NST 3 27 30 10 Yes 4 yes yes
5 Pl_lobul 2 13 14 4 No 5 yes yes
8 NST 1 12 8 3 No 3 yes no
Har-
poon
3 Lobular 1 9 5 4 No 5 yes no
4 NST 2 6 11 4 No 5 yes yes
6 NST 3 16 18 0 No 4 no yes
7 NST 2 7 10 4 No 4 yes no
9 NST 1 12 8 7 No 1 no yes
10 NST 1 3 5 3 No 1 no yes
11 NST 2 8 8 1 No 4 no yes
12 Lobular 2 12 1 3 No 6 no no
Abbreviations: NST = non special type (invasive ductal type). Pl_lobul = Pleiomorph lobular carcinoma
Table 2: Comparison of  delineation methods following standard guidelines versus a de-





GTV CTVstandard CTVclip CTVclip_CT













OC (GTV vs 





82 83Accelerating Adjuvant Breast Radiotherapy Accelerating Adjuvant Breast Radiotherapy
Table 3: Dosimetric results comparing different delineation methods and beam set-up. 
Mean 
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Figure 1: Illustration of  situation with non-informative postoperative clips. 
Illustration of  a patient with preoperative MRI indicating a tumour location distant from the thoracic wall. However, on postoperative 
simulation CT all clips were located close to the thoracic wall. For tumourbed delineation (WBI plan with SIB) none of  the clips were 
enclosed. Abbreviations: WBI – whole breast irradiation; SIB – simultaneously integrated boost
the breast. Delivering high dose to up to half the breast may
also explain why difference in esthetic outcome was
altogether limited.
In EB-APBI, prone position may help tackling volume and
toxicity issues: it reduces the latero-lateral beam traveling dis-
tance and increases the antero-posterior diameter, both
resulting in reduced high-dose volumes compared to supine
position [12]. These dosimetric advantages however come
at the cost of increased uncertainty in target delineation,
most pronounced in the antero-posterior direction [13].
Interobserver delineation exercises have demonstrated the
difficulties of tumor bed delineation, even in supine position
with seroma present. Clips come at help, but not all clips are
relevant, some are even misleading (Figure 1). Addressing
this uncertainty with larger target volumes would forego the
primary goal of APBI, volume-reduction.
In search of combining precision (high-interobserver con-
formity) with accuracy (high probability of primary tumor
coverage) in prone position and after full thickness closure
(FTC), we tested in an interobserver exercise the impact of
inserting an additional indicator clip, intended for marking
the depth of the tumor in the breast. To test accuracy, the
resulting postoperative clinical target volumes (CTVs) were
compared with the gross tumor volume (GTV) on preopera-
tive CT in treatment position. Tangential-beam APBI using
intensity-modulated radiotherapy (IMRT) was compared with
three-beam IMRT to evaluate the relevance of accuracy and
the dosimetric impact of beam set-up on low- as well as
high-isodose volumes.
Material and methods
Following local Ethics Committee approval of the study, 17
patients with histologically confirmed clinical stage I–II breast
tumors (cT1–2 cN0), candidate for tumorectomy, signed
informed consent and were enrolled between May and
December 2014. Patient, tumor and treatment characteristics
are listed in Table 1. Five patients were excluded after pre-
operative CT because of switch to supine position: in one
patient, multi-centricity necessitated mastectomy and in four
a positive sentinel node was found, requiring lymph node
dissection and irradiation. In the 12 remaining patients, the
tumor was visualized by harpoon in eight patients with non-
palpable tumors and by contrast in four patients with palp-
able tumors.
The preoperative CT scan was performed on a large-bore
Toshiba CT (Aquilion Large Bore, Toshiba), 1 day before
tumorectomy and following the standard image acquisition
protocol (120 kV, 70mA, 3–5mm slices). Patients were
installed in prone position on the breast board. Contrast
enhancement was performed with 100 cc IV Visipaque, GE
Healthcare (2 cc/s, scanning started 100–120 s after start of
injection). Tattoos were applied to help ensuring the same
position on postoperative planning CT.
Surgeons were requested to insert clips according to the
following protocol: incision and localization of the tumor in
the breast with insertion of a 9-mm large titanium ‘indicator
clip’ in the cavity wall at the depth of the ‘resection lump’, to
indicate antero-posterior tumor location as precisely
as possible. Following excision of the tumor, usual ‘cavity
wall’ clips (6mm, titanium), including a deep ‘pectoral fascia’
clip, were placed according to routine practice. FTC was per-
formed in all patients, one underwent oncoplastic surgery.
Four to five weeks after tumorectomy, patients underwent a
planning CT scan in the same position and under the same
conditions as preoperatively, but without contrast.
Delineation was performed by four experienced in-house
radiation oncologists using version 9.8 of the Pinnacle
Figure 1. Illustration of situation with non-informative postoperative clips.
Illustration of a patient with preoperative MRI indicating a tumor location dis-
tant from the thoracic wall. However, on postoperative simulation CT, all clips
were located close to the thoracic wall. For tumor bed delineation (WBI plan
with SIB) none of the clips were enclosed. WBI: whole breast irradiation; SIB:
simultaneously integrated boost.
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Figure 2: Illustration of  dosimetry in a worst-case GTV-coverage
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Dosimetry in patient with despite a pT1a tumour (1mm diameter), the worst coverage result of  GTV (black), which is located very medially 
and more peripherally in the breast than estimated by clips and tissue distortion. Two additional resection specimen had been excised per-
operatively, on CT only one clip was left behind. A CT-slice including the GTV is chosen for illustration. In this patient, CTVstandard and 
CTVclip did not overlap with GTV (distance between indicatorclip and GTV was 23mm), whereas an overlap ratio of  0.67 was reached for 
CTVclip_CT. GTV D95 is respectively 17.7Gy, 16.5Gy and 20.6Gy for 2-beam set-up and 20.0Gy, 11.9Gy and 24.8Gy for 3-beam set-up.
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Abstract
Rationale More than 50% of  breast cancer cases occur in women aged 65 years or more. 
Adjuvant radiotherapy improves local control and overall survival, but is often omitted in 
older women because of  concerns over treatment burden or logistical obstacles, even in 
poor prognostic groups. Accelerated radiotherapy might be an alternative to overcome 
these obstacles, at the condition of  technical feasibility and acceptable toxicity in this 
frailer patient population.
Research question In this prospective phase I-II trial, we investigated the safety and 
feasibility of  delivering external beam radiotherapy in 5 fractions to the breast or thoracic 
wall, including boost and/or lymph nodes if  needed.
Methods Ninety-five patients aged 65 years or more, referred for adjuvant radiother-
apy, were treated in 5 fractions over 12 days with a total dose of  28.5Gy/5.7Gy to the 
breast or thoracic wall and, if  indicated, 27Gy/5.4Gy to the lymph node regions and 
32.5Gy/6.5Gy-34.5Gy/6.9Gy to the tumour bed. The primary endpoint was clinically 
relevant dermatitis (≥ grade 2).
Results Mean follow-up time was 5.6 months and mean age was 73.6 years. Clinically 
relevant dermatitis was observed in 11.6% of  patients and only occurred in breast irradi-
ation with boost (17.5% grade 2-3 versus 0% in the no-boost group). Although doses were 
high, treatment delivery with IMRT was swift, except for complex treatments including 
lymph nodes where single-arc VMAT was needed to reduce beam-on time.
Conclusion Accelerated radiotherapy in 5 fractions was technically feasible and resulted 
in low acute toxicity. Clinically relevant erythema was only observed in patients receiving 
a boost, but still at an acceptable rate.
Implications/application Although the follow-up is still short, the results on acute 
toxicity after accelerated radiotherapy were encouraging. A 5-fraction schedule is well 
tolerated in the elderly and may lower the threshold for radiotherapy in this population.
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Introduction
Breast cancer is the most frequent cancer type worldwide: with an incidence of  1,677,000 
cases annually it represents 11.9% of  all cancers diagnosed[1]. Along with an evidence-based 
indication for radiotherapy of  87%, it is the cancer type with the highest radiotherapy needs 
globally. Radiotherapy plays an important role in local control, but also improves survival[2-4]. 
Whereas optimal access to radiotherapy is a precondition to obtain these clinical benefits, sub-
stantial gaps in radiotherapy access exist, not only in low- and middle-income countries where 
lack of  resources may be the dominating factor, but even in regions with a higher welfare such 
as Europe, Canada and Australia[5-8]. In these countries, other barriers may determine the 
observed underutilization, of  which age is a well-recognized one[9]. Hence, where advanced 
age is associated with lower stage and more favorable prognostic outcomes, survival is para-
doxically worse compared to younger cohorts, as many patients go undertreated due to factors 
such as co-morbidity, physician’s bias, cost and psychosocial issues[10-12].
In 2007 the International Society of  Geriatric Oncology (SIOG) published guidelines rec-
ommending patients over 70 years be treated according to standard guidelines, with ex-
ceptions for cases with significant co-morbidity or low functional status[13].  However, ra-
diotherapy, chemotherapy and hormonal therapy continue to be offered less frequently to 
patients of  advancing age, resulting in higher mortality for early stage breast cancer[14, 15]. 
Although increase of  co-morbidity and frailty is a gradual process, no uniform age threshold can 
be found for the decline in adherence to treatment guidelines, suggesting a psychological trigger 
rather than purely physiological considerations[12]. The most negative effect on overall survival 
and disease-specific survival is observed for radiotherapy[16, 17], especially in hormone receptor 
negative breast cancer, where omission of  radiotherapy results in higher numbers of  deaths from 
breast cancer than from cardiovascular disease, even in the age group over 80 years[18].
Living far from radiation facilities or having insufficient insurance coverage are estab-
lished obstacles to receiving radiotherapy[19-21]. Yet, even in countries with adequate so-
cial security and wide availability of  radiotherapy facilities, uptake decreases with age[9]. 
Although radiotherapy treatment for breast cancer has moved towards hypo-fractionation 
as the new gold standard, older patients still remain reluctant to undergo radiotherapy.  
For elderly patients with very early stage breast cancer, single fraction intra-operative techniques 
may lower the threshold of  access to radiotherapy[22, 23] or radiotherapy can even be omit-
ted[24, 25]. This is not the case in locally advanced stages or when poor prognostic character-
istics are present[25, 26] and whole breast irradiation (WBI) or thoracic wall irradiation (TWI) 
along with lymph node irradiation (LNI) are indicated. In these cases, accelerated delivery in 
5 fractions may overcome resistance to adequate loco-regional treatment, provided it does not 
come at the cost of  higher toxicity in this frail subset of  the population. External beam radio-
therapy (EBRT) for WBI in 5 fractions has been tested in several studies, yet little remains known 
about acceleration for TWI, or in case lymph nodes should be included or a boost added[27-31]. 
In preparation for a randomized controlled trial comparing 5 to 15 fractions over 10 or 
15 days, a phase I-II study was performed, including all breast cancer stages in women of  
65 years of  age and over.  
This paper reports on the feasibility of  accelerated radiotherapy to the breast, thoracic 
wall and lymph nodes and on the first clinical results, more specifically on acute toxicity. 
Materials and Methods 
Patient selection 
All female patients of  65 years or older, referred for adjuvant radiotherapy after breast 
cancer surgery – breast-conserving or mastectomy - were offered the study protocol and 
included after signing the informed consent, approved by the ethics committee of  our 
institution. The exclusion criteria were the need for bilateral breast irradiation or re-irra-
diation, or the need for boost after mastectomy.
Image acquisition 
Patients were simulated on a large bore Toshiba CT, with intravenous injection of  contrast 
(Visipaque, 100cc) in case of  LNI and if  not contra-indicated. Prone positioning was of-
fered if  WBI +/- simultaneously integrated boost (SIB) without LNI was prescribed[32]. 
TWI and LNI were performed in a supine position.
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Target volumes and doses
Target volumes and organs at risk (OARs) were delineated according to standard guide-
lines[33-35]. If  the ratio of  positive over resected lymph nodes was below 40%, LNI 
included axillary level 2-4. If  40% or more of  resected lymph nodes proved patholog-
ically invaded by tumour, level 1 was added to the target[36]. The internal mammary 
chain was never included. Target doses were prescribed at the D50, and consisted of  
28.5Gy/5.7Gy for WBI or TWI and 27Gy/5.4Gy for the lymph node regions. If  indi-
cated according to our hospital’s guidelines, a SIB of  32.5Gy/6.5Gy was delivered and 
increased to 34.5Gy/6.9Gy in case of  positive resection margins (Figure 1).
Equivalent doses in 2Gy fractions were calculated using an α/β ranging between 2.8-
4.6Gy[37-40] for breast tumour and breast toxicity, resulting in an EQD2 range of  44.5-
50.5Gy for the breast or thoracic wall (5x5.7Gy) and 54.7-63Gy for the boost dose (5x6.5Gy). 
For cases with involved margins, the resulting EQD2 for the boost was 60.1-69.7Gy.  
For the lymph node regions, a compromise was chosen between a high enough dose for tu-
mour control and avoidance of  any brachial plexopathy. With an α/β of  1.5Gy, a schedule of  
27Gy/5.4Gy results in an EQD2 of  53.2Gy, far below the limit of  66Gy and below the max-
imum doses reported for stereotactic radiotherapy[41-43]. Applying the α/β of  2.8-4.6Gy, 
lymph node dose resulted in an acceptable EQD2 of  40.9-46.1Gy for breast tumour control. 
 Planning parameters and treatment techniques 
The optimal irradiation plan was calculated using software developed at Ghent University 
Hospital (GUH) and integrated into the GRATISTM 3D-planning system (developed by 
G.W. Sherouse). Treatment was delivered with step and shoot intensity-modulated radiother-
apy (IMRT). For WBI administered in the prone position, tangential field-IMRT (TF-IM-
RT) was sufficient to obtain qualitative dosimetry. In the supine position, multi-beam-IMRT 
(MB-IMRT) was used to increase dose homogeneity and to reduce dose to the OARs[44]. 
SIB always required MB-IMRT (or volumetric modulated arc therapy - VMAT), in some 
cases with non-coplanar beams. MB-IMRT or VMAT was used in cases involving LNI to 
obtain adequate coverage of  the breast, boost and lymph nodes, without the need for field 
matching. Simultaneous delivery of  the prescribed dose to all target volumes was chosen to 
avoid any risk of  overlap, especially in the region of  the brachial plexus. 
VMAT was preferred over IMRT and concatenated into one or two arcs when MB-IM-
RT resulted in a high number of  gantry positions with a long beam-on time. This method 
reduced the delivery time of  simultaneously 5.7Gy, 5.4Gy and 6.5Gy from 8-12 minutes 
to 3-4 minutes per fraction. Breath-hold for left-sided prone irradiation has not yet been 
introduced, because a longer bream-on time in patients with compromised mobility and 
reduced breath-hold capacity had not been tested before accrual started.
The dose was prescribed to the planning target volume (PTV, 7mm margin from CTV). 
For the OARs, the constraints of  Benedict et al.[41] were respected for heart, lungs, ribs, 
esophagus, trachea and brachial plexus. A V20 with normofractionation was translated 
to a V13<20% (α/β of  2-3Gy)[45] to avoid acute pneumonitis in the ipsilateral lung. 
Contralateral breast doses were kept as low as possible, but in cases of  conflict between 
heart/lung dose versus contralateral breast, the heart was given priority for these elderly 
patients. In LNI cases, the brachial plexus was contoured in order to have correct esti-
mates of  the doses delivered to the plexus[35].  
Treatment delivery schedule 
Radiation treatment was delivered over 12 days, on week days only, with an interval of  
at least one day between 2 fractions (e.g. Tuesday – Thursday – Monday – Wednesday – 
Friday). Each fraction was preceded by CBCT positioning verification. 
 Outcome evaluation 
Dermatitis was evaluated using the CTCAE v.4.03 toxicity score, with measurement be-
fore, during and 2-4 weeks after radiotherapy. Desquamation was scored as none, dry or 
moist. Edema, pain, pruritus and fatigue were also registered. The worst score registered 
for each item was reported. Determination of  the time point for evaluation of  acute tox-
icity was based on evidence from the Fast-Forward Trial, describing highest prevalence of  
grade 2-3 toxicity at 1-4 weeks after the start of  treatment[29]. 
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Long-term follow-up in the radiotherapy department was limited to 6 months in the first 
year and every twelve months thereafter in order to limit the additional burden of  consul-
tations in this specific patient group.
Statistics
The population was divided into two independent strata for sample size calculation –  one 
without and one with LNI.
The Wilson Confidence Interval for binomial proportion was applied, a 2-sided exact meth-
od for power analysis, using the “SAS Power and Sample Size” routine. To obtain a condi-
tional probability of  95% with an alpha-error of  0.05, a total of  50 patients was needed in 
the WBI-only group and 45 patients in the LNI included group, allowing for 10% drop out.
Acceleration was considered acceptable if  acute moist desquamation stayed below 20% 
for the “no LNI” group and 35% for the “LNI” group.
A stopping rule was included, discontinuing recruitment in the ‘LNI’ arm if  EMG-con-
firmed radiation induced brachial plexopathy (RIBP) would occur in 2 of  the first 10 
patients, or in 3 patients overall.
Results
Patient characteristics
Ninety-five patients were included in this analysis. Characteristics of  patients, tumour 
and treatment are described in Table 1. Mean age was 73.6 years, with 65% of  patients 
above 70 years. Two patients had not reached 65 years at the time of  inclusion. The mean 
follow-up time was 5.6 months.
Forty-five percent of  patients were diagnosed with early (stage I) breast cancer, 35% 
with stage II and 20% with stage III or locally-advanced. Poor prognostic subtyping was 
found in 45% of  patients, with 9.5% ‘triple negative’ and 35.8% Luminal B type. Hor-
mone-negative disease was found in 17 patients (17.9%), of  whom 7 did not receive any 
chemotherapy. In 16 patients HER2 was amplified. In 6 of  these patients Trastuzumab 
was not started. Seventy-eight patients tested positive for ER and/or PR, two of  whom 
did not receive any anti-hormonal therapy. Because the population was limited to patients 
referred for adjuvant radiotherapy, no data can be derived on percentage of  indications 
for whom radiotherapy was omitted.
One patient with triple-negative advanced stage breast cancer died due to loco-regional 
recurrence and distant metastasis, diagnosed 6 months after radiotherapy. All other pa-
tients remained without relapse.
Overall, prone irradiation was an option in 54 patients (WBI without LNI) of  whom 37 
(11 above 75 years) were amenable to prone positioning.  
Dosimetric results 
Good accordance of  planning to dosimetry constraints was found except for TWI and LNI, 
where underdosing of  D95 of  PTV was observed. Results including doses to target and to 
OARs are reported in Table 2. In the 22 left-sided WBI patients, a reduction of  heart dose and 
ipsilateral lung dose was observed for prone versus supine, without use of  any breath-holding 
technique (p < 0.001, Mann-Whitney U test). The boxplot distribution is shown in Figure 3. 
Heart and ipsilateral lung dose increased significantly when LNI was applied. For the ip-
silateral lung, Dmean increased from 1.5Gy without LNI (p < 0.001) to 5.3Gy with LNI, 
and the V13Gy from 2.9% to 15.1% (p < 0.001). In left-sided treatment, Dmean for the 
heart increased from 1.3Gy without LNI to 2.2Gy with LNI (p < 0.001) and heart D2 
similarly increased from 7.1Gy to 14.2Gy (p <0.001).
 Acute toxicity 
Grade 3 dermatitis was observed in one patient (WBI + SIB + LNI in supine position) 
who developed a small zone of  moist desquamation in the inframammary fold shortly 
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after radiotherapy. A second patient developed an intense grade 2 dermatitis, covering the 
entire breast. In all other patients, grade 2 dermatitis was less pronounced.
As dermatitis and desquamation were uncommon, we aggregated grades into a subclin-
ical group (grade 0-1) and a clinical group (grade 2-3) before evaluating the impact of  
variables on the occurrence of  acute toxicity. Applying Fisher’s exact test, no statistically 
significant relation could be found between patient, tumour and treatment characteristics 
and toxicity, except for boost versus no boost (17.4% vs. 0%, p=0.01). Clinically relevant 
toxicity occurred only in the group with boost (Figure 2, Table 3).
No symptoms indicating RIBP have been registered so far, but the follow-up time is still 
very short.
Discussion
Undertreatment in the older population impacts local control and disease free survival, 
especially in the intermediate and high risk groups[16, 18]. Acceleration to 5 fractions 
in less than 2 weeks may possibly overcome resistance to adjuvant radiotherapy. How-
ever, the feasibility and safety of  accelerated treatment need validation before applying 
these schedules beyond clinical trials. Since many patients present with advanced tu-
mour stages, this trial was conceived to test acceleration for all indications, including 
SIB, TWI and LNI. 
In 2005, Ortholan et al. reported on weekly hypofractionated WBI (71.5%) and TWI 
(28.5%) in 150 patients above 70 years[27]. In 73.5% of  patients, no dermatitis was ob-
served and it was limited to grade 1 and grade 2 in 18.6% and 9.4% respectively. These 
results are superior to our trial (52.6% of  grade 1 dermatitis for WBI and TWI combined) 
despite a comparable WBI vs. TWI ratio. Our shorter delivery time may have impacted 
toxicity. However, toxicity scales differed, with possibly an upward shift of  faint erythema 
towards grade 1 with the CTCAE toxicity scale. By comparison, the FAST Forward Trial 
switched from RTOG to CTCAE toxicity scale during the trial, with similar results for 
CTCAE-scored grade 1 toxicity compared to our trial (63% and 58% grade 1 dermatitis 
for 27Gy/5.4Gy and 26Gy/5,2Gy respectively)[29, 46].  
Kirova et al. (2009) retrospectively compared an accelerated weekly schedule (32.5Gy/6.5Gy) 
with normofractionation in elderly patients and reported reassuring loco-regional control 
and cause-specific survival[28]. Groups were not equally balanced for age, performance sta-
tus, tumour size or presence of  lymph node dissection, disfavoring the accelerated schedule. 
LNI and boost were limited to the normofractionation group. Nevertheless, five-year results 
were equivalent. A worse cause-specific survival at 7 years did not depend on the treatment 
schedule. Only lymph node status, hormonal receptors and mitotic index were retained as 
independent prognostic factors. RTOG acute toxicity scores were similar for both groups.
A retrospective analysis of  acceleration to five fractions by Rovea et al. (32.5Gy/6.5Gy or 
30Gy/6Gy weekly) showed no toxicity in 71.8% and grade 1 in 22.6% of  patients with 
only 6.1% clinically relevant dermatitis, lower than in our breast-only subgroup (14.8%) 
but again these were scored with the RTOG/EORTC toxicity criteria[31].
In the FAST-Forward Trial delivery was accelerated to 5 days, with WBI delivered daily 
in 5x5.2Gy or 5.4Gy. RTOG grade 3 acute toxicity appeared in 5.6-9.8% of  patients 
(26-27Gy) and CTCAE grade 3 toxicity in 2.4-0% respectively. These results are in line 
with our findings (1.1% grade 3 toxicity). Grade 1 and 2 dermatitis were 63% and 27% 
respectively, which is comparable to our 53.7% and 14.8% in the WBI +/- SIB group.
In our study, overall acute toxicity remained low (11.6% clinically relevant dermatitis) and 
was limited to patients with SIB. Only one patient developed moist desquamation, located 
in the inframammary fold. Using a strict interpretation of  the CTCAE criteria, this is a 
grade 2 toxicity, as the inframammary fold can be categorized as ‘skin fold’. The region 
did not correlate with a ‘hot spot’ but with the location of  tangential beam incidence re-
sulting in skin scraping and loss of  dose build-up.
Older patients referred for radiotherapy often present with locally-advanced breast can-
cer, needing LNI. IMRT or VMAT permit simultaneous delivery of  different doses with 
avoidance of  field overlap. In 2000, Johansson reported on long term RIBP after hypof-
ractionation for breast cancer. His analysis showed higher doses to the brachial plexus than 
intended due to positioning problems. Ten years earlier, Powell compared hypofractionation 
45Gy/3Gy with 54Gy/1.8Gy using a 3- or 4-field technique[42, 47]. Both reported that 
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larger daily fractions (3-4Gy) to doses of  44-54Gy were associated with RIBP. Whereas 
Johansson clearly described overlap problems leading to unwanted high total doses, Powell 
seemed confident that this is not possible with a 4-field technique. RIBP is described as a 
slow process over a latency period of  1 to 4 years, continuing even after 5 years[48]. So 
far no RIBP occurred in our study, but the results are still very preliminary[49]. Although 
27Gy/5.4Gy is gentler in terms of  BED and EQD2 (α/β = 1.5-2Gy), follow-up with active 
questioning for sensory or motor nerve damage will further screen for RIBP[50].
Dosimetric results were satisfying. For left sided irradiation including LNI, the heart 
Dmean of  1.8Gy stayed far below the dose reported in a recent review, describing a 
Dmean 5.6Gy for this situation[51]. Breath-hold techniques to further lower heart dose 
were not yet introduced because this has not yet been validated technically.
This feasibility trial precedes a randomized trial that will compare efficacy and toxicity 
of  5 versus 15 fractions. Tumour bed boost dose will be lowered in the upcoming trial in 
answer to the observed increased toxicity in the boost group.
In conclusion, accelerated delivery of  adjuvant radiotherapy for breast cancer in 5 frac-
tions is feasible and does not appear to increase acute toxicity compared to published 
data on normo- or moderate hypofractionation. The effects on loco-regional control and 
chronic toxicity will be further analyzed in a planned randomized controlled trial com-
paring 5 with 15 fractions. 
 
FIGURES
Figure 1: Inclusion flowchart
In-house decisional tree for target and dose prescription in accelerated schedule. Inclusion 
is based on hospital guidelines for adjuvant radiotherapy.
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Introduction
Breast cancer is the most frequent cancer type worldwide:
with an incidence of 1,677,000 cases annually, it represents
11.9% of all cancers diagnosed (1). Along with an
evidence-based indication for radiation therapy of 87%, it is
the cancer type with the highest radiation therapy needs
globally. Radiation therapy plays an important role in local
control but also improves survival (2-4). Whereas optimal
access to radiation therapy is a precondition to obtaining
these clinical benefits, substantial gaps in radiation therapy
access exist, not only in low- and middle-income countries
where lack of resources may be the dominating factor, but
even in regions with a higher welfare, such as Europe,
Canada, and Australia (5-8). In these countries, other bar-
riers may determine the observed underutilization, of which
age is a well-recognized one (9). Hence, where advanced
age is associated with lower stage and more favorable
prognostic outcomes, survival is paradoxically worse
compared with younger cohorts, because many patients go
undertreated owing to factors such as comorbidity, physi-
cian bias, cost, and psychosocial issues (10-12).
In 2007, the International Society of Geriatric Oncology
published guidelines recommending that patients aged
>70 years be treated according to standard guidelines, with
exceptions for cases with significant comorbidity or low
functional status (13). However, radiation therapy, chemo-
therapy, and hormonal therapy continue to be offered less
frequently to patients of advancing age, resulting in higher
mortality for early-stage breast cancer (14, 15).
Although increase of comorbidity and frailty is a gradual
process, no uniform age threshold can be found for the
decline in adherence to treatment guidelines, suggesting a
psychological trigger rather than purely physiologic con-
siderations (12). The most negative effect on overall sur-
vival and disease-specific survival is observed for radiation
therapy (16, 17), especially in hormone receptorenegative
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Fig. 1. Inclusion flowchart. In-house decisional tree for target and dose prescription in the accelerated schedule. Inclusion
is based on hospital guidelines for adjuvant radiation therapy.
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Figure 2: Boxplot illustrating the effect of  position on heart and lung dose
Prone positioning significantly reduced heart and lung dose. The boxplot illustrates the 
mean, minimum, maximum, 25% and 75% doses to heart (Dmean and D2) and ipsilat-
eral lung (Dmean and V13) for patients with left sided WBI +/- SIB (no LNI), treated in 
prone (n=11) or supine (n=11) position. For the ipsilateral lung, the maximum percentage 
of  volume receiving 13Gy (V13Gy) was 0.6% in prone (to small for visualization).
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radiation therapy, no data can be derived on percentage of in-
dications for which radiation therapy was omitted.
One patient with triple-negative advanced-stage breast
cancer died of locoregional recurrence and distant metas-
tasis, diagnosed 6 months after radiation therapy. All other
patients remained without relapse.
Overall, prone irradiation was an option in 54 patients
(WBI without LNI), of whom 37 (11 aged >75 years) were
amenable to prone positioning.
Dosimetric results
Good accordance of planning to dosimetry constraints was
found except for TWI and LNI, for which underdosing of
D95 of planning target volume was observed. Results
including doses to target and to OARs are reported in
Table 2. In the 22 left-sided WBI patients, a reduction of
heart dose and ipsilateral lung dose was observed for prone
versus supine, without use of any breath-holding technique
(P<.001, Mann-Whitney U test). The box-plot distribution
is shown in Figure 2.
Heart and ipsilateral lung dose increased significantly
when LNI was applied. For the ipsilateral lung, Dmean
increased from 1.5 Gy without LNI (P<.001) to 5.3 Gy
with LNI, and the V13Gy from 2.9% to 15.1% (P<.001). In
left-sided treatment, the Dmean for the heart increased from
1.3 Gy without LNI to 2.2 Gy with LNI (P<.001), and heart
D2 similarly increased from 7.1 Gy to 14.2 Gy (P<.001).
Acute toxicity
Grade 3 dermatitis was observed in 1 patient
(WBI þ SIB þ LNI in supin position) wh developed a
small zone of moist desquamation in the inframammary fold
shortly after radiation therapy. A second patient developed
an intense grade 2 dermatitis, covering the entire breast. In
all other patients grade 2 dermatitis was less pronounced.
Because dermatitis and desquamation were uncommon,
we aggregated grades into a subclinical group (grade 0-1)
and a clinical group (grade 2-3) before evaluating the
impact of variables on the occurrence of acute toxicity.
Applying Fisher exact test, no statistically significant
relation could be found between patient, tumor, and treat-
ment characteristics and toxicity, except for boost versus no
boost (17.4% vs 0%, PZ.01). Clinically relevant toxicity
occurred only in the group with boost (Fig. 3, Table 3).
No symptoms indicating RIBP have been registered to
date, but the follow-up time is still very short.
Discussion
Undertreatment in the older population impacts local control
and disease-free survival, especially in the intermediate- and
high-risk groups (16, 18). Acceleration to 5 fractions in less
than 2 weeks may possibly overcome resistance to adjuvant
radiation therapy. However, the feasibility and safety of
accelerated treatment need validation before applying these
schedules beyond clinical trials. Becausemanypatients present
with advanced tumor stages, this trial was conceived to test
acceleration for all indications, including SIB, TWI, and LNI.
In 2005 Ortholan et al (27) reported on weekly hypo-
fractionated WBI (71.5%) and TWI (28.5%) in 150 patients
aged >70 years. In 73.5% of patients no dermatitis was
observed, and it was limited to grade 1 and grade 2 in
18.6% and 9.4%, respectively. These results are superior to
ur trial (52.6% of grade 1 dermatitis for WBI and TWI
combined) despite a comparable WBI versus TWI ratio.
Our shorter delivery time may have impacted toxicity.
However, toxicity scales differed, with possibly an upward
shift of faint erythema toward grade 1 with the CTCAE
toxicity scale. By comparison, the FAST-Forward Trial
switched from the Radiation Therapy Oncology Group
(RTOG) to the CTCAE toxicity scale during the trial, with
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radiation therapy, no data can be derived on percentage of in-
dications for which radiation therapy was omitted.
One patient with triple-negative advanced-stage breast
cancer died of locoregional recurrence and distant metas-
tasis, diagnosed 6 months after radiation therapy. All other
patients remained without relapse.
Overall, prone irradiation was an option in 54 patients
(WBI without LNI), of whom 37 (11 aged >75 years) were
amenable to prone positioning.
Dosimetric results
Good accordance of planning to dosimetry constraints was
found except for TWI and LNI, for which underdosing of
D95 of planning target volume was observed. Results
including doses to target and to OARs are reported in
Table 2. In the 22 left-sided WBI patients, a reduction of
heart dose and ipsilateral lung dose was observed for prone
versus supine, without use of any breath-holding technique
(P<.001, Mann-Whitney U test). The box-plot distribution
is shown in Figure 2.
Heart and ipsilateral lung dose increased significantly
when LNI was applied. For the ipsilateral lung, Dmean
increased from 1.5 Gy without LNI (P<.001) to 5.3 Gy
with LNI, and the V13Gy from 2.9% to 15.1% (P<.001). In
left-sided treatment, the Dmean for the heart increased from
1.3 Gy without LNI to 2.2 Gy with LNI (P<.001), and heart
D2 similarly increased from 7.1 Gy to 14.2 Gy (P<.001).
Acute toxicity
Grade 3 dermatitis was observed in 1 patient
(WBI þ SIB þ LNI in supine position) who developed a
small zone of moist desquamation in the inframammary fold
shortly after radiation therapy. A second patient developed
an intense grade 2 dermatitis, covering the entire breast. In
all other patients grade 2 dermatitis was less pronounced.
Because dermatitis and desquamation were uncommon,
we aggregated grades into a subclinical group (grade 0-1)
and a clinical group (grade 2-3) before evaluating the
impact of variables on the occurrence of acute toxicity.
Applying Fisher exact test, no statistically significant
relation could be found between patient, tumor, and treat-
ment characteristics and toxicity, except for boost versus no
boost (17.4% vs 0%, PZ.01). Clinically relevant toxicity
occurred only in the group with boost (Fig. 3, Table 3).
No symptoms indicating RIBP have been registered to
date, but the follow-up time is still very short.
Discussion
Undertreatment in the older population impacts local control
and disease-free survival, especially in the intermediate- and
high-risk groups (16, 18). Acceleration to 5 fractions in less
than 2 weeks may possibly overcome resistance to adjuvant
radiation therapy. However, the feasibility and safety of
accelerated treatment need validation before applying these
schedules beyond clinical trials. Becausemanypatients present
with advanced tumor stages, this trial was conceived to test
acceleration for all indications, including SIB, TWI, and LNI.
In 2005 Ortholan et al (27) reported on weekly hypo-
fractionated WBI (71.5%) and TWI (28.5%) in 150 patients
aged >70 years. In 73.5% of patients no dermatitis was
observed, and it was limited to grade 1 and grade 2 in
18.6% and 9.4%, respectively. These results are superior to
our trial (52.6% of grade 1 dermatitis for WBI and TWI
combined) despite a comparable WBI versus TWI ratio.
Our shorter delivery time may have impacted toxicity.
However, toxicity scales differed, with possibly an upward
shift of faint erythema toward grade 1 with the CTCAE
toxicity scale. By comparison, the FAST-Forward Trial
switched from the Radiation Therapy Oncology Group
(RTOG) to the CTCAE toxicity scale during the trial, with
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maximum, and 25% and 75% doses to heart (Dmean and D2)
and ipsilateral lung (Dmean and V13) for patients with left-
sided whole-breast irradiation with or without simulta-
neously integrated boost (no lymph node irradiation), treated
in the prone (nZ11) or supine (nZ11) position. For the
ipsilateral lung, themaximumpercentage of volume receiving










Fig. 3. Toxicity. Highest grade toxicity occurring during
treatment or in the first weeks after radiation therapy
(percentage).
Volume 98 � Number 4 � 2017 Accelerated breast irradiation in the elderly 927
 TABLES
 Table 1: Patient and tumour characteristics 
 
breast cancer, where omission of radiation therapy results
in higher numbers of deaths from breast cancer than from
cardiovascular disease, even in those aged >80 years (18).
Living far from radiation facilities or having insufficient
insurance coverage are established obstacles to receiving
radiation therapy (19-21). Yet even in countries with
adequate social security and wide availability of radiation
therapy facilities, uptake decreases with age (9). Although
radiation therapy treatment for breast cancer has moved
toward hypofractionation as the new gold standard, older
p tients still emain reluctant to undergo radiation therapy.
For elderly patients with very early stage breast cancer,
single-fraction intraoperative techniques may lower the
threshold of access to radiation therapy (22, 23), or radia-
tion therapy can even be omitted (24, 25). This is not the
case in locally advanced stages or when poor prognostic
characteristics are present (25, 26) and whole-breast irra-
diation (WBI) or thoracic wall irradiation (TWI) along with
lymph node irradiation (LNI) are indicated. In these cases
accelerated delivery in 5 fractions may overcome resistance
to adequate locoregional treatment, provided it does not
come at the cost of higher toxicity in this frail subset of the
population. External beam radiation therapy for WBI in 5
fractions has been tested in several studies, yet little re-
mains known about acceleration for TWI, or in case lymph
nodes should be included or a boost added (27-31).
In preparation for a randomized, controlled trial
comparing 5 versus 15 fractions over 10 or 15 days, a phase
1 to 2 study was performed, including all breast cancer
stages in women aged 65 years.
This article reports on the feasibility of accelerated radi-
ation therapy to the breast, thoracicwall, and lymphnodes and
on the first clinical results, more specifically on acute toxicity.
Methods and Materials
Patient selection
All female patients age 65 years, referred for adjuvant ra-
diation therapy after breast cancer surgerydbreast-
conserving or mastectomydwere offered the study protocol
and included after signing the informed consent form,
approved by the ethics committee of our institution. The
exclusion criteria were the need for bilateral breast irradia-
tion or re-irradiation, or the need for boost after mastectomy.
Image acquisition
Patients were simulated on a large-bore Toshiba Aquillion
CT scanner (Toshiba Medical Systems, Tokyo, Japan), with
intravenous injection of contrast (iodixanol, 100 mL) in case
of LNI and if not contraindicated. Prone positioning was
offered if WBI with or without simultaneously integrated
boost (SIB) without LNI was prescribed (32). Thoracic wall
irradiation and LNI were performed in a supine position.
Target volumes and doses
Target volumes and organs at risk (OARs) were delineated
according to standard guidelines (33-35). If the ratio of
positive over resected lymph nodes was <40%, LNI
included axillary level 2 to 4. If 40% of resected lymph
nodes proved pathologically invaded by tumor, level 1 was
added to the target (36). The internal mammary chain was
nev r i cluded. Target doses were prescrib d at the D50 and
consisted of 28.5 Gy/5.7 Gy for WBI or TWI and 27 Gy/
5.4 Gy for the lymph node regions. If indicated according
to our hospital’s guidelines, a SIB of 32.5 Gy/6.5 Gy was
delivered and increased to 34.5 Gy/6.9 Gy in case of pos-
itive resection margins (Fig. 1).
Equivalent doses in 2-Gy fractions (EQD2s) were
calculated using an a/b ranging between 2.8 and 4.6 Gy
(37-40) for breast tumor and breast toxicity, resulting in an
EQD2 range of 44.5 to 50.5 Gy for the breast or thoracic
wall (5  5.7 Gy) and 54.7 to 63 Gy for the boost dose
(5  6.5 Gy). For cases with involved margins, the resulting
EQD2 for the boost was 60.1 to 69.7 Gy.
Table 1 Patient and tumor characteristics
Characteristic n %









Ductal type 78 82.1
Lobular typ 13 13.7
Mucinous 3 3.2








Stage I (T1N0 or N1mi) 43 45.3
Stage II (T1N1, T2N0-1, T3N0) 33 34.7
Stage III (T3N1, T1-3N2, T4N0-3) 19 20
IHC subtype
Luminal A (ER and/or PR pos, Ki67 <14%) 34 35.8
Luminal B (ER and/PR pos, Ki67 >14%) 34 35.8
Luminal Her2 (ER and/or PR pos, HER2 pos) 10 10.5
HER2 (ER neg, HER2 pos) 6 6.3
Triple negative 9 9.5
Unknown 2 2.1
Abbreviations: ERZ estrogen receptor; IHCZ immunohistochemistry;
posZ positive; PRZ progesterone receptor.
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Table 2: Dose characteristics for target and OARs 
For the lymph node regions, a compromise was chosen
between a high enough dose for tumor control and avoid-
ance of any brachial plexopathy. With an a/b of 1.5 Gy, a
schedule of 27 Gy/5.4 Gy results in an EQD2 of 53.2 Gy,
far below the limit of 66 Gy and below the maximum doses
reported for stereotactic radiation therapy (41-43).
Table 2 Dose characteristics for target and organs at risk
No LNI Prone
WBI - SIB
Number of patients n Z 32
Dosimetric parameters Dmean (Gy) D95 (Gy) D2 (Gy) V13 (%)
Total dose 29.6 (28.9-31.1) 27.7 (27.1-28.5) 33.1 (32.5-34.2) NA
Heart* 0.8 (0.4-1.8) NA 4.5 (1.3-20.0) NA
Ipsilateral lung 0.6 (0.2-1.9) NA NA 0.6 (0-5.7)
WBI - No SIB
Number of patients n Z 5
Dosimetric parameters Dmean (Gy) D95 (Gy) D2 (Gy) V13 (%)
Total dose 28.6 (28.6-28.7) 27.5 (27.2-27.7) 29.9 (29.7-30.1) NA
Heart* - - - -
Ipsilateral lung 0.8 (0.3-1.5) NA NA 1.3 (0-4.1)
Supine
WBI - SIB
Number of patients n Z 13
Dosimetric parameters Dmean (Gy) D95 (Gy) D2 (Gy) V13 (%)
Total dose 29.6 (29.2-30.3) 27.6 (27.1-28.3) 33.3 (32.8-33.8) NA
Heart* 1.9 (0.8-3.1) NA 11.1 (2.3-22.8) NA
Ipsilateral lung 3.3 (1.9-6.1) NA NA 7 (1.0-22.1)
WBI - No SIB
Number of patients n Z 4
Dosimetric parameters Dmean (Gy) D95 (Gy) D2 (Gy) V13 (%)
Total dose 28.6 (28.4-28.8) 27.4 (27.0-27.8) 30 (29.7-30.1) NA
Heart* 1.2 (1.0-1.4) NA 3.8 (3.4-4.1) NA
Ipsilateral lung 3.3 (3.1-3.4) NA NA 7.2 (4.7-9.4)
TWI - No SIB
Number of patients n Z 2
Dosimetric parameters Dmean (Gy) D95 (Gy) D2 (Gy) V13 (%)
Total dose 28.5 (28.4-28.8) 27.1 (26.6-27.5) 30.2 (30.0-30.4) NA
Heart* - NA - NA
Ipsilateral lung 3.2 (2.7-3.7) NA NA 8.3 (7.0-9.5)
LNI Supine
WBI - SIB
Number of patients n Z 18
Dosimetric parameters Dmean (Gy) D95 (Gy) D2 (Gy) V13 (%)
Total dose 29.4 (28.9-30.1) 27 (22.3-28.1) 32.9 (30.5-34.4) NA
Heart* 2 (0.9-3.1) NA 12.9 (3.4-22.2) NA
Ipsilateral lung 5.3 (3.0-7.3) NA NA 15 (5.3-22.8)
TWI - no SIB
Number of patients n Z 21
Dosimetric parameters Dmean (Gy) D95 (Gy) D2 (Gy) V13 (%)
Total dose 28.6 (28.1-29) 26.6(22.1-27.6) 30.5(30.0-31.2) NA
Heart* 2.4 (1.1-3.7) NA 15.1(3.8-26.0) NA
Ipsilateral lung 5.4 (2.9-7.0) NA NA 15.2 (4.2-23.3)
Abbreviations: LNI Z lymph node irradiation; NA Z not applicable; SIB Z simultaneously integrated boost; TWI Z thoracic wall irradiation; WBI
Z whole-breast irradiation.
Values are mean results (range) of planning target volume dose, heart doses for left-sided treatment only (*), and ipsilateral lung dose and lung volume
receiving 13 Gy.
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similar results for CTCAE-scored grade 1 toxicity
compared with our trial (63% and 58% grade 1 dermatitis
for 27 Gy/5.4 Gy and 26 Gy/5.2 Gy, respectively) (29, 46).
Kirova et al (28) retrospectively compared an acceler-
ated weekly schedule (32.5 Gy/6.5 Gy) with normo-
fractionation in elderly patients and reported reassuring
locoregional control and cause-specific survival. Groups
were not equally balanced for age, performance status,
tumor size, or presence of lymph node dissection, dis-
favoring the accelerated schedule. Lymph node irradiation
and boost were limited to the normofractionation group.
Nevertheless, 5-year results were equivalent. A worse
cause-specific survival at 7 years did not depend on the
treatment schedule. Only lymph node status, hormonal re-
ceptors, and mitotic index were retained as independent
prognostic factors. The RTOG acute toxicity scores were
similar for both groups.
A retrospective analysis of acceleration to 5 fractions by
Rovea et al (31) (32.5 Gy/6.5 Gy or 30 Gy/6 Gy weekly)
showed no toxicity in 71.8% and grade 1 in 22.6% of pa-
tients, with only 6.1% clinically relevant dermatitis, lower
than in our breast-only subgroup (14.8%), but again these
were scored with the RTOG/European Organization for
Research and Treatment of Cancer toxicity criteria.
In the FAST-Forward Trial delivery was accelerated to
5 days, with WBI delivered daily in 5  5.2 Gy or 5.4 Gy.
Radiation Therapy Oncology Group grade 3 acute toxicity
appeared in 5.6% to 9.8% of patients (26-27 Gy) and CTCAE
grade 3 toxicity in 2.4% to 0%. These results are in line with
our findings (1.1% grade 3 toxicity). Grade 1 and 2 dermatitis
were 63% and 27%, respectively, which is comparable to our
53.7% and 14.8% in the WBI with or without SIB group.
In our study overall acute toxicity remained low (11.6%
clinically relevant dermatitis) and was limited to patients
with SIB. Only 1 patient developed moist desquamation,
located in the inframammary fold. Using a strict interpre-
tation of the CTCAE criteria, this is a grade 2 toxicity,
because the inframammary fold can be categorized as “skin
fold.” The region did not correlate with a “hot spot” but
with the location of tangential beam incidence resulting in
skin scraping and loss of dose build-up.
Older patients referred for radiation therapy often
present with locally advanced breast cancer, needing LNI.
Intensity modulated radiation therapy or VMAT permit
simultaneous delivery of different doses with avoidance of
field overlap. In 2000 Johansson (47) reported on long-
term RIBP after hypofractionation for breast cancer. His
analysis showed higher doses to the brachial plexus than
intended, owing to positioning problems. Ten years earlier,
Powell et al (42) compared hypofractionation 45 Gy/3 Gy
with 54 Gy/1.8 Gy using a 3- or 4-field technique. Both
reported that larger daily fractions (3-4 Gy) to doses of 44
to 54 Gy were associated with RIBP. Whereas Johansson
clearly described overlap problems leading to unwanted
high total doses, Powell et al seemed confident that this is
not possible with a 4-field technique. Radiation-induced
brachial plexopathy is described as a slow process over
a latency period of 1 to 4 years, continuing even after
5 years (48). To date, no RIBP occurred in our study, but
the results are still very preliminary (49). Although 27 Gy/
5.4 Gy is gentler in terms of biologically equivalent dose
and EQD2 (a/b Z 1.5-2 Gy), follow-up with active
questioning for sensory or motor nerve damage will
further screen for RIBP (50).
Dosimetric results were satisfying. For left-sided irra-
diation including LNI, the heart Dmean of 1.8 Gy stayed far
below the dose reported in a recent review, describing a
Dmean of 5.6 Gy for this situation (51). Breath-hold tech-
niques to further lower heart dose were not yet introduced
because this has not yet been validated technically.
This feasibility trial precedes a randomized trial that will
compare efficacy and toxicity of 5 versus 15 fractions.
Tumor bed boost dose will be lowered in the upcoming trial
in answer to the observed increased toxicity in the boost
group.
In conclusion, accelerated delivery of adjuvant radiation
therapy for breast cancer in 5 fractions is feasible and does
not seem to increase acute toxicity compared with pub-
lished data on normo- or moderate hypofractionation. The
effects on locoregional control and chronic toxicity will be
further analyzed in a planned randomized, controlled trial
comparing 5 with 15 fractions.
Table 3 Toxicity results
Group
Prone Supine
SIB No SIB SIB No SIB
Grade 0-1 Grade 2-3 Grade 0-1 Grade 2-3 Grade 0-1 Grade 2-3 Grade 0-1 Grade 2-3
No LNI
WBI 27 (84.4) 5 (15.6) 5 (100) 0 10 (76.9) 3 (23.1) 4 (100) 0
TWI - - - - - - 2 (100) 0
With LNI
WBI - - - - 15 (83.3) 3 (16.7) - -
TWI - - - - - - 21 (100) 0
Abbreviations as in Table 2.
Incidence by number (percentage) of highest-grade dermatitis (Common Terminology Criteria for Adverse Events version 4.03) during or in the first
weeks after radiation therapy in relation to target and positioning.
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Abstract
Background Evolving practice in adjuvant breast radiotherapy inevitably impacts 
healthcare budgets. This is reflected in a rise of  health economic evaluations (HEE) in this 
domain. The available HEE literature was analysed qualitatively and quantitatively, using 
available instruments. 
Methods HEEs published between 1/1/2000 and 31/10/2016 were retrieved through 
a systematic search in Medline, Cochrane and Embase. A quality-assessment using 
CHEERS (Consolidated Health Economic Evaluation Reporting Standards) was trans-
lated into a quantitative score and compared with Tufts Medical Centre CEA registry and 
Quality in Health Economic Studies (QHES) results.
Results Twenty cost-effectiveness analyses (CEA) and thirteen cost comparisons (CC) 
were analysed. In qualitative evaluation, valuation or justification of  data sources, popu-
lation heterogeneity and discussion on generalizability, in addition to declaration on fund-
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ing, were often absent or incomplete. After quantification, the average CHEERS-scores 
were 74% (CI 66.9-81.1%) and 75.6% (CI 70.7-80.5%) for CEAs and CCs respectively. 
CEA-scores did not differ significantly from Tufts and QHES-scores.
Conclusion Quantitative CHEERS evaluation is feasible and yields comparable results 
to validated instruments. HEE in adjuvant breast radiotherapy is of  acceptable quality, 
however, further efforts are needed to improve comprehensive reporting of  all data, indis-
pensable for assessing relevance, reliability and generalizability of  results.
Introduction
In adjuvant breast radiotherapy, the past two decades brought important treatment 
changes: the use of  hypofractionation in the context of  breast-conserving treatment has 
been established[1, 2] and new techniques and technologies for per- and postoperative 
irradiation were introduced such as intensity-modulated radiotherapy (IMRT), partial 
breast irradiation and intra-operative radiotherapy approaches[3, 4]. Breast cancer being 
the second most common cancer type worldwide[5] and the most frequent indication for 
radiotherapy[6, 7], such evolutions will inherently have an impact on healthcare budgets. 
Indeed, increasing possibilities in medicine typically come with increasing costs and put health-
care budgets under strain[8]. Healthcare policy deals with allocation and re-allocation of  the 
available financial means, according to the principles of  communicating vessels – each expen-
diture precludes expenses in other healthcare domains. The methodology applied to analyse 
if  new interventions or strategies are worthwhile from an economic point of  view, is referred 
to as health economic evaluation (HEE). Not surprisingly, the interest for HEEs has increased 
considerably over the last decades, as can be observed by a simple PubMed search, showing an 
evolution from a few HEE publications annually in the seventies until over 1500 per year to-
day. HEE encompasses different techniques and concepts. In short, whereas cost comparison 
(CC) is limited to the costs of  standard versus new strategies, cost-effectiveness analysis (CEA) 
relates a change in costs (i.e. incremental cost) to the difference in health effects, expressed in 
natural units such as life years gained. In case of  a cost utility analysis (CUA), the difference 
in health effect is expressed as quality adjusted life years gained. The perspective of  HEE 
indicates from which viewpoint costs are calculated (provider, payer, patient or society). The 
type of  costs can be based on the real costs of  the resources used (materials, labour activities, 
infrastructure, overhead…) or on reimbursement or charges.
Transparency of  reporting is a fundamental element to evaluate quality, reliability, rel-
evance and generalizability of  HEE results. To address this question, quality checklists 
guide researchers as well as editors towards qualitative HEEs. The ‘Drummond’, the 
‘British Medical Journal’ and the ‘Consensus on Health Economic Criteria’ checklists are 
well-known instruments for qualitative evaluation[9-11]. In 2013, the International Soci-
ety for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force published the 
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Consolidated Health Economic Evaluation Reporting Standards statement (CHEERS), 
with the objective to further standardize reporting of  economic evaluations[12]. Although 
not intended for quantification, its structure predisposes to ranking, as has been undertak-
en for the first time by Mangham-Jefferies et al.[13]. In contrast, the Quality of  Health 
Economic Studies (QHES) and Tufts Medical Centre scores are instruments intended and 
validated for quantitative benchmarking[14, 15]. 
We performed a qualitative and quantitative evaluation of  HEE publications focusing on 
adjuvant breast radiotherapy, retrieved through a systematic literature review. CHEERS 
was used for quality evaluation and subsequently applied as a quantitative scoring system, 
of  which the results were compared with Tufts and QHES evaluation. This article reports 
on the results of  this qualitative and quantitative evaluation and comparison, and de-
scribes remaining shortcomings and methodological questions in the available literature 
of  HEE in adjuvant breast radiotherapy.
Materials & Methods
Systematic literature review
A systematic literature review was performed, according to PRISMA guidelines (2009, 
www.prisma-statement.org). Medline, Embase and Cochrane libraries were searched for 
publications on HEE in adjuvant breast radiotherapy, published between 1/1/2000 and 
30/11/2016. A detailed description of  the search strategy can be found in appendix 1. 
After removal of  duplicates, titles were screened for referral to either economic aspects or 
adjuvant breast cancer irradiation. Subsequent abstract screening was based on presence 
of  both aspects. Final selection required comparison of  different radiotherapy strategies 
in adjuvant breast cancer, specifying radiotherapy cost either as a result of  a real costing 
exercise or of  reimbursement/charges. Only original articles and health technology as-
sessments were included and underwent full manuscript review. When publications were 
based on the same set of  resource input data, the most relevant paper was selected for 
final evaluation. Conference abstracts, reviews and position papers were excluded. Bibli-
ography of  the selected publications was hand-searched to complete the database.
Qualitative evaluation
The CHEERS checklist is a 24-item checklist, used to improve reporting quality in health 
economic research[12]. All 24 items were checked per article by two observers (YL and 
CM). In case of  disagreement, a consensus was reached through discussion. To improve 
uniformity of  interpretation, the same criteria were re-evaluated in a cross-sectional way, 
going through all articles per item. For the articles on CC, evaluation was limited to the 
13 relevant items (appendix 2). 
Quantitative evaluation
Tufts and QHES scores were obtained for quantitative benchmarking of  articles on 
cost-effectiveness. Tufts scores were extracted from the Tufts Medical Centre CEA regis-
try[16], an inventory of  over 5500 CEAs on diseases and treatments. Besides a summary 
of  topic, method and results, it contains a subjective assessment about overall quality of  
the analysis, reflected as a score between 1 (low quality) and 7 (high quality). 
The QHES is a dichotomous scoring system, again only intended for cost-effectiveness anal-
ysis and based on 16 items, allocating a score 0 (not fulfilled) or 1 (fulfilled) per item[14, 15]. 
Each score is multiplied by a weight, varying between 1 and 9, to obtain a total score on 100 
points. An intermediate appreciation is not allowed, even though several criteria cover differ-
ent sub-items or request appreciation of  the content. To address this interpretational problem, 
responsible for inter-observer differences[17], the QHES score was defined twice per article: 
first only accepting the item as ‘fulfilled’ if  all sub-items were met, to obtain a minimum score. 
For the maximum score, ‘fulfilled’ was applied if  at least one of  the sub-items was met. The 
midrange of  minimum and maximum score was used as a proxy for multi-observer evaluation.
To compare Tufts and QHES results with the qualitative CHEERS evaluation, CHEERS 
was translated into a quantitative score. Because each item focuses on one single aspect, 
equal weights were allocated, with a score ‘2’ if  complete, ‘1’ if  partially respected and ‘0’ 
if  applicable but not mentioned. This method corresponds to the scores of  respectively 1, 
0.5 and 0 as proposed by Mangham-Jefferies et al., who also accorded an equal weight to 
all items[13].
114 115Accelerating Adjuvant Breast Radiotherapy Accelerating Adjuvant Breast Radiotherapy
Resulting scores of  the three instruments were then transformed into percentages to allow 
comparison.
Statistical analysis
Instruments were compared using the paired, non-parametric Wilcoxon rank test for con-




Overall, 9356 titles were found, yielding 7217 publications after removal of  duplicates, 104 
after screening titles and abstracts. Thirty-eight articles were excluded because of  confer-
ence paper, abstract or editorial. Main reason for exclusion of  articles on the final list, was 
1) only total breast cancer cost, encompassing screening, diagnosis, surgery and/or systemic 
therapy (14 articles), 2) no explicit cost methodology (8) and 3) general radiotherapy cost on 
different types of  cancer (4). The CONSORT diagram is illustrated in figure 1.
An overview of  the selected publications is to be found in appendices 3 and 4. Twenty out 
of  the 33 publications represented a full economic evaluation, examining both costs and 
effectiveness (CEA) or utilities (CUA), for the purpose of  readability conjointly referred 
to as CEA[18-37]. The other 13 publications were CCs, looking only into the financial 
aspects of  the alternatives, not the effectiveness[38-50]. 
The majority of  articles compared different radiotherapy techniques or fractionation 
schedules (n=19), being normo- versus hypofractionation and/or intra-operative tech-
niques, or the cost implication of  IMRT. Eleven articles evaluated the effect of  additional 
radiotherapy (adjuvant radiotherapy or not (n= 8), boost or no boost (n=2), complemen-
tary internal mammary field (n=1)) and two compared photon- with proton-therapy. A 
final article compared the cost of  breast conserving therapy, including radiotherapy, over 
three different reimbursement systems.
Qualitative evaluation 
A visual representation of  the fulfilment of  the CHEERS criteria and a ranking of  com-
pleteness of  the items can be found in figure 2a-b for CEAs, in figure 3a-b for CCs.
Treatment comparators were always described. However, the number of  fractions, rele-
vant information in the context of  radiotherapy costs, was unclear in three papers[25, 26, 
29]. In four papers, all based on SEER data, a combination of  various schedules resulted 
in the reported costs[37, 38, 40, 50]. For accelerated partial breast irradiation (APBI), 
covering multiple techniques, in three out of  nine papers it was unclear whether single- or 
multi-lumen balloon brachytherapy was used[25, 26, 39].
Only in five CEAs, measurement and valuation of  preference-based outcomes was either 
reported directly, based on a systematic review or a motivated selection[18, 22, 24, 35, 
36]. The other CEAs referred to the source of  utilities used, without justifying the selec-
tion. An almost similar observation was made for the clinical outcomes, where 11/20 
CEAs based outcomes on specific studies, without conducting a systematic review or jus-
tifying the choice made[19, 21, 25-31, 34, 37].
Regarding the cost inputs, currency was always mentioned, but in one article the reference 
year could not be found[47] and in one only after thorough searching[36]. In the CEAs, 
discounting percentages were usually mentioned (17/20), but only 2 articles justified the 
chosen percentages[24, 36].
Except for 3 publications[27, 29, 34], all CEAs included one-way and/or probabilistic 
sensitivity analysis. Heterogeneity however, a potential source of  uncertainty, was de-
scribed in only half  of  CEAs[18, 21-24, 28, 31, 33, 36, 37].
Three elements of  discussion (study findings, fit in with literature and limitations) were 
present in most publications. Generalizability however, was discussed in only 6/20 
CEAs[25, 31, 32, 35-37] and 4/13 CCs[43, 47-49].
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 Quantitative evaluation
Tufts scores were available for 14 CEAs and resulted in an average score of  72.4% (CI 
64.1-80.8%). Average QHESmidrange score was 75.2% (CI 67.8-82.6%), with 57.3% (CI 
46.8-67.9%) for QHESmin and 93% (CI 87.6-98.4%) for QHESmax. CHEERS quanti-
fication resulted in an average of  74.0% (CI 66.4-81.6%) for CEA and 75.6% (CI 70.7-
80.5%) for CC. Statistical pairwise comparison between CHEERS, QHESmidrange and 
Tufts scores did not result in significant differences (figure 4), whereas QHESmin and 
QHESmax did differ significantly (p-values <0.05).
Discussion
In order to support decision-making in healthcare, evidence on cost and cost-effectiveness 
of  new interventions and technologies needs to be reliable and of  good quality, in other 
words, based on a transparent methodology, traceable sources and a justifiable selection 
of  data inputs. Different instruments evaluating the quality of  HEEs have been devel-
oped, evolving in the CHEERS Consort statement, a comprehensive checklist incorporat-
ing the most essential elements required for transparent reporting. Since its publication in 
2013, over 34 review articles in different medical domains evaluated adherence of  HEEs 
to the CHEERS checklist.
A quality review may serve two objectives: it may be intended to select publications that 
meet a minimal standard before being accepted for publication or before including results 
in a review. In addition, it may be intended for signalling shortcomings, indicating what 
elements are underreported and where and how to improve quality. 
In radiotherapy, such a qualitative review of  CEAs has previously been performed by Bar-
bieri et al. in different tumour types (breast, prostate, colorectal and head & neck cancer), 
evaluating compliance to the NICE reference case and UK-specific criteria[51]. They sig-
nalled absence of  a systematic review for data selection, of  a methodology for preferences 
of  outcomes and of  probabilistic sensitivity analyses as important obstacles for quality. 
A similar exercise has been done by Nguyen et al., who reviewed the quality of  CEAs in 
radiotherapy for a variety of  tumours[52]. Evaluation was limited to a selection of  data 
abstraction variables, based on the CHEERS guideline, while the Tufts’ score was used for 
qualitative benchmarking. Although reporting improved with time, they concluded that 
even in more recent years there was still room for awareness, especially concerning the re-
porting of  funding or conflict of  interest (COI), discounting, the choice of  a time horizon 
and the application of  multivariate and probabilistic sensitivity analysis. 
Quality review of  the selected publications in our study revealed some recurrent short-
comings. 
As already signalled by Nguyen et al.[52], a declaration of  COI and funding sources in the 
domain of  HEE is important to avoid all doubt on bias. Although journals have become 
stricter on the subject, a declaration on funding is often lacking, whereas declarations on 
COI are more often present. This discrepancy may be explained by the presumption that 
a negative declaration on COI encompasses both topics. However, explicit statements 
would avoid all doubt.
Similar to the findings of  Barbieri et al.[51], definition of  the origin of  data, including 
clinical outcome, costs and especially preferences of  outcome, needs far more attention. 
Selective data input and analysis may bias outcomes, potentially resulting in misleading 
information and jeopardizing valid decision-making on the allocation of  limited health 
care resources. Hence, in the absence of  a systematic review, the choices made should at 
least be clearly motivated. 
Most articles contained a sensitivity analysis, at least to some extent. The topic of  het-
erogeneity however, analysing the impact of  the population chosen on the final results, is 
rarely discussed. This seems connected to the recurrent neglect of  generalizability in the 
discussion. CEA-results are at risk to be considered as ‘evidence of  cost-effectiveness’ of  a 
specific intervention, although a different indication or modified base case may complete-
ly change the picture.
A surprising finding was the lack of  clarity on the radiotherapy fractionation schedules. 
If  analysis is based on large-scale data such as registries or claim-based data sets, the 
advantage of  these real-world data may come at the cost of  loss of  specificity regarding 
118 119Accelerating Adjuvant Breast Radiotherapy Accelerating Adjuvant Breast Radiotherapy
indications and acts performed[53]. Most articles however compare specific strategies. 
In those cases, a clear description of  fractionation as well as radiotherapy technique is 
strongly advisable because both influence costs, as well in a reimbursement[39] as in real 
cost-based setting[49, 54].
To avoid arbitrariness, a quantitative evaluation with acceptable thresholds may be superior 
to a purely qualitative approach. Policy makers sometimes adopt such a strategy, frequently 
extended with country-specific requirements, as listed on the ISPOR website (https://www.
ispor.org/PEguidelines/index.asp). Quantitative benchmarking is often extracted from the 
Tufts Medical Centre CEA registry. These Tufts scores are based on a subjective apprecia-
tion, and no information is provided on how scores are precisely obtained. 
A second tool, the QHES checklist, is a validated quantitative instrument. This checklist 
does not permit intermediate scores although several items consist of  various sub-items 
and combine transparency evaluation (formal presence of  data) with quality appreciation 
(appropriateness of  choices made). As a consequence, QHES-results are observer-depen-
dent[17]. Averaging out interpretative differences by increasing the number of  observers 
may remediate this problem, but such a solution results in a high workload. As an alter-
native, we applied a least and a most strict interpretation of  ‘fulfilment’ of  the items, and 
used the midrange of  the respective results for comparison with the other instruments.
The CHEERS checklist was not intended for quantitative benchmarking. However, its 
structure predisposes to quantification, as has been confirmed repeatedly after the first 
exercise by Mangham-Jefferies et al.[13, 55-69]. Most of  these CHEERS-based quality 
reviews of  HEEs implemented a score for ‘partially respected’ to overcome the problem 
of  incompleteness and accorded an equal weight to each item. Regarding weights, one 
may question if  every item is of  a similar importance, from completeness of  title over 
reporting of  data sources to uncertainty analysis. 
Another question regarding CHEERS is whether its use can be extended to the evalu-
ation of  CCs. For the moment, no checklists dedicated to CC evaluation exist. For our 
evaluation, it seemed reasonable to adopt the CHEERS for quantification of  CC quality, 
excluding 11 items related to effectiveness outcome or modelling.
A last unsolved question is the threshold. Ofman et al. proposed three categories for QHES 
evaluation, with high quality for scores over 75%, medium quality between 50 and 75% 
and low quality below 50%[15]. The same threshold has been adopted for quantitative 
CHEERS evaluations[58, 60, 61, 63-65, 67]. Plumpton et al. even applied a threshold of  
85% for high quality[69]. Although practicable, such thresholds remain arbitrary. 
In the present study focusing on adjuvant breast radiotherapy, quantification of  quality 
with CHEERS resulted in an average score of  74% for CEAs and 75.6% for CCs. If  a 
threshold of  75% would be applied, only 6 out of  13 CCs and 13 out of  20 CEAs would 
be considered reliable and of  good quality. A minimal threshold of  50% (medium quality) 
was met by all CCs and almost all CEAs whereas the stricter ‘Plumpton’ threshold (85%) 
was attained by only 4 CCs and 4 CEAs. Similar numbers would be obtained with both 
validated quantitative instruments.
Possible limitations of  our study are related to the unsolved questions raised above and to 
the limited number of  observers performing the evaluation. Consequently, this exercise 
cannot be interpreted as a validation of  CHEERS for quantitative benchmarking, nei-
ther as a confirmation of  the use of  this instrument for CCs. Nevertheless, the extension 
of  CHEERS guidelines to quantitative benchmarking of  CEAs as well as CCs seems 
feasible. Moreover, comparison to other validated quantitative instruments did not re-
sult in significant differences. A critique may be that transparency is a prerequisite, not 
a substitute for model validity[70]. Therefore, it remains advisable to evaluate HEE not 
only on transparency, but to also critically appraise the quality of  the sources and models 
used. More particularly, the validity of  the model itself  as well as the appropriateness of  
the results in the own health economic environment should be considered, to ascertain 
reliability and generalizability of  the results.
In conclusion, quantitative CHEERS evaluation is feasible and yields comparable results 
to validated instruments. For HEE in adjuvant breast radiotherapy, the quantitative eval-
uation of  reporting transparency typically reached an acceptable threshold of  medium 
to high quality. Thresholds are however arbitrary and may result in loss of  granularity. 
This was illustrated by the qualitative evaluation, which showed that some items like data 
sources, population heterogeneity and sensitivity analysis, essential for reliable cost-effec-
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tiveness results, could benefit from more transparent reporting and justification of  choic-
es. A combination of  quantitative and qualitative evaluation of  HEE is indispensable for 
assessing relevance, reliability and generalizability of  the results, hence to support valid 
decision-making on the allocation of  the scarce health care resources.
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2a (left) : Visual representation of the 24-item CHEERS evaluation applied on the 20 selected CEAs.
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2b (right) : Ranking of completeness of sub-items. Same code was applied as in figure 2a. 
High percentages of ‘partially respected’ indicate either presence of requested elements without justification (items 9, 15, 12, 11, 13…) or presence of some elements, but not 
all (items 22, 2, 14…). The items ‘funding’ and ‘conflict of interest’ are either ‘complete’ or ‘not mentioned’, with a worse score for funding as this is probably not always 
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Figure 2: Overview of  qualitative evaluation of  cost-effectiveness analyses using 
CHEERS checklist, per article (left) and per item (right).
resulted in the reported costs [37,38,40,50]. For accelerated partial
breast irradiation (APBI), covering multiple techniques, in three out
of nine papers it was unclear whether single- or multi-lumen bal-
loon brachytherapy was used [25,26,39].
Only in five CEAs, measurement and valuation of preference-
based outcomes was either reported directly, based on a system-
atic review or on a motivated selection [18,22,24,35,36]. The other
CEAs referred to the source of utilities used, without justifying the
selection. An almost similar observation was made for the clinical
outcomes, where 11/20 CEAs based outcomes on specific studies,
without conducting a systematic review or justifying the choice
made [19,21,25–31,34,37].
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Study included: 1 
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Figure 2a (left): Visual representation of  the 24-item CHEERS evaluation applied on 
the 20 selected CEAs.
Completely fulfilled Partially respected Applicable but not mentioned
 
Fig 2b (right): Ranking of  completeness of  sub-items. Same code was applied as in fig 
2a. High percentages of  ‘partially respected’ indicate either presence of  requested elements 
without justification (items 9, 15, 12, 11, 13…) or presence of  some elements, but not all 
(items 22, 2, 14…). The items ‘funding’ and ‘conflict of  interest’ are either ‘complete’ or ‘not 
mentioned’, with a worse score for funding as this is probably not always explicitly separated 
from the conflict of  interest declaration
 representation of  the 24-item CHEERS evaluation applied on the 20 selected CEAs.
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Figure 3: Overview of  qualitative evaluation of  cost comparisons using CHEERS check-
list, per article (left) and per item (right)
Regarding the cost inputs, currency was always mentioned, but
in one article the reference year could not be found [47] and in one
only after thorough searching [36]. In the CEAs, discounting per-
centages were usually mentioned (17/20), but only 2 articles justi-
fied the chosen percentages [24,36].
Except for 3 publications [27,29,34], all CEAs included one-way
and/or probabilistic sensitivity analysis. Heterogeneity however, a
potential source of uncertainty, was described in only half of CEAs
[18,21–24,28,31,33,36,37].
Three elements of discussion (study findings, fit in with litera-
ture and limitations) were present in most publications. Generaliz-
ability however, was discussed in only 6/20 CEAs [25,31,32,35–37]
and 4/13 CCs [43,47–49].
Quantitative evaluation
Tufts scores were available for 14 CEAs and resulted in an aver-
age score of 72.4% (CI 64.1–80.8%). Average QHESmidrange score
was 75.2% (CI 67.8–82.6%), with 57.3% (CI 46.8–67.9%) for QHES-
min and 93% (CI 87.6–98.4%) for QHESmax. CHEERS quantification
resulted in an average of 74.0% (CI 66.4–81.6%) for CEA and 75.6%
(CI 70.7–80.5%) for CC. Statistical pairwise comparison between
CHEERS, QHESmidrange and Tufts scores did not result in signifi-
cant differences (Fig. 4), whereas QHESmin and QHESmax did dif-
fer significantly (p-values < 0.05).
Discussion
In order to support decision-making in healthcare, evidence on
cost and cost-effectiveness of new interventions and technologies
needs to be reliable and of good quality, in other words, based on
a transparent methodology, traceable sources and a justifiable
selection of data inputs. Different instruments evaluating the qual-
ity of HEEs have been developed, evolving in the CHEERS Consort
statement, a comprehensive checklist incorporating the most
essential elements required for transparent reporting. Since its
publication in 2013, over 34 review articles in different medical
domains evaluated adherence of HEEs to the CHEERS checklist.
A quality review may serve two objectives: it may be intended
to select publications that meet a minimal standard before being
accepted for publication or before including results in a review.
In addition, it may be intended for signalling shortcomings, indi-
cating what elements are underreported and where and how to
improve quality.
In radiotherapy, such a qualitative review of CEAs has previ-
ously been performed by Barbieri et al. in different tumor types
(breast, prostate, colorectal and head & neck cancer), evaluating
compliance to the NICE reference case and UK-specific criteria
[51]. They signalled absence of a systematic review for data selec-
tion, of a methodology for preferences of outcomes and of proba-
bilistic sensitivity analyses as important obstacles for quality. A
similar exercise has been done by Nguyen et al., who reviewed
the quality of CEAs in radiotherapy for a variety of tumors [52].
Evaluation was limited to a selection of data abstraction variables,
based on the CHEERS guideline, while the Tufts’ score was used for
qualitative benchmarking. Although reporting improved with time,
they concluded that even in more recent years there was still room
for awareness, especially concerning the reporting of funding or
conflict of interest (COI), discounting, the choice of a time horizon
and the application of multivariate and probabilistic sensitivity
analysis.
Quality review of the selected publications in our study
revealed some recurrent shortcomings.
As already signalled by Nguyen et al. [52], a declaration of COI
and funding sources in the domain of HEE is important to avoid
all doubt on bias. Although journals have become stricter on the
subject, a declaration on funding is often lacking, whereas declara-
tions on COI are more often present. This discrepancy may be
explained by the presumption that a negative declaration on COI
encompasses both topics. However, explicit statements would
avoid all doubt.
Similar to the findings of Barbieri et al. [51], definition of the
origin of data, including clinical outcome, costs and especially pref-
erences of outcome, needs far more attention. Selective data input
and analysis may bias outcomes, potentially resulting in mislead-
ing information and jeopardizing valid decision-making on the
allocation of limited health care resources. Hence, in the absence
3a (left) : Visual representation of the CHEERS, applied on the 13 selected CCs and limited to the items relevant for cost comparison. 
Completely fulfilled Partially respected Applicable but not mentioned
3b (right) : Ranking of completeness of items for CC. Same color codes were applied as in figure 3a. The items ‘perspective’ and ‘funding’ were 
missing most frequently. Item 2 ‘abstract’ and 22 ‘discussion’ consist of several sub-items. As a result, these items are often only partially respected.
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Regarding the cost inputs, currency was always mentioned, but
in one article the reference year could not be found [47] and in one
only after thorough searching [36]. In the CEAs, discounting per-
centages were usually mentioned (17/20), but only 2 articles justi-
fied the chosen percentages [24,36].
Except for 3 publications [27,29,34], all CEAs included one-way
and/or probabilistic sensitivity analysis. Heterogeneity however, a
potential source of uncertainty, was described in only half of CEAs
[18,21–24,28,31,33,36,37].
Three elements of discussion (study findings, fit in with litera-
ture and limitations) were present in most publications. Generaliz-
ability however, was discussed in only 6/20 CEAs [25,31,32,35–37]
and 4/13 CCs [43,47–49].
Quantitative evaluation
Tufts scores were available for 14 CEAs and resulted in an aver-
age score of 72.4% (CI 64.1–80.8%). Average QHESmidrange score
was 75.2% (CI 67.8–82.6%), with 57.3% (CI 46.8–67.9%) for QHES-
min and 93% (CI 87.6–98.4%) for QHESmax. CHEERS quantification
resulted in an average of 74.0% (CI 66.4–81.6%) for CEA and 75.6%
(CI 70.7–80.5%) for CC. Statistical pairwise comparison between
CHEERS, QHESmidrange and Tufts scores did not result in signifi-
cant differences (Fig. 4), whereas QHESmin and QHESmax did dif-
fer significantly (p-values < 0.05).
Discussion
In order to support decision-making in healthcare, evidence on
cost and cost-effectiveness of new interventions and technologies
needs to be reliable and of g od quality, in other words, based on
a transparent methodology, traceable sources and a justifiable
selection of data inputs. Different instruments evaluating the qual-
ity of HEEs have been developed, evolving in the CHEERS Consort
statement, a comprehensive checklist incorporating the most
essential elements required for transparent reporting. Since its
publication in 2013, over 34 review articles in different medical
domains evaluated adherence of HEEs to the CHEERS checklist.
A quality review may serve two objectives: it may be intended
to select publications that meet a minimal standard before being
accepted for publication or before including results in a review.
In addition, it may be intended for signalling shortcomings, indi-
cating what elements are underreported and where and how to
improve quality.
In radiotherapy, such a qualitative review of CEAs has previ-
ously been performed by Barbieri et al. in different tumor types
(breast, prostate, colorectal and head & neck cancer), evaluating
compliance to the NICE reference case and UK-specific criteria
[51]. They signalled absence of a systematic review for data selec-
tion, of a methodology for preferences of outcomes and of proba-
bilistic sensitivity analyses as important obstacles for quality. A
similar exercise has been done by Nguyen et al., who reviewed
the quality of CEAs in radiotherapy for a variety of tumors [52].
Evaluation was limited to a selection of data abstraction variables,
based on the CHEERS guideline, while the Tufts’ score was used for
qualitative benchmarking. Although reporting improved with time,
they concluded that even in more recent years there was still room
for awareness, especially concerning the reporting of funding or
conflict of interest (COI), discounting, the choice of a time horizon
and the application of multivariate and probabilistic sensitivity
analysis.
Quality review of the selected publications in our study
revealed some recurrent shortcomings.
As already signalled by Nguyen et al. [52], a declaration of COI
and funding sources in the domain of HEE is important to avoid
all doubt on bias. Although journals have become stricter on the
subject, a declaration on funding is often lacking, whereas declara-
tions on COI are more often present. This discrepancy may be
explained by the presumption that a negative declaration on COI
encompasses both topics. However, explicit statements would
avoid all doubt.
Similar to the findings of Barbieri et al. [51], definition of the
origin of data, including clinical outcome, costs and especially pref-
erences of outcome, needs far more attention. Selective data input
and analysis may bias outcomes, potentially resulting in mislead-
ing information and jeopardizing valid decision-making on the
allocation of limited health care resources. Hence, in the absence
3a (left) : Visual representation of the CHEERS, applied on the 13 selected CCs and limited to the items relevant for cost comparison. 
Completely fulfilled Partially respected Applicable but not mentioned
3b (right) : Ranking of completeness of items for CC. Same color codes were applied as in figure 3a. The items ‘perspective’ and ‘funding’ were 
missing most frequently. Item 2 ‘abstract’ and 22 ‘discussion’ consist of several sub-items. As a result, these items are often only partially respected.
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Figure 3a (left): Visual representation of  the CHEERS, applied on the 13 selected CCs 
and limited to the items relevant for cost comparison. 
Completely fulfilled Partially respected Applicable but not mentioned
Figure 3b (right): Ranking of  completeness of  items for CC. Same color codes were ap-
plied as in figure 3a. The items ‘perspective’ and ‘funding’ were missing most frequently. 
Item 2 ‘abstract’ and 22 ‘discussion’ consist of  several sub-items. As a result, these items 
are often only partially respected.
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of a systematic review, the choices made should at least be clearly
motivated.
Most articles contained a sensitivity analysis, at least to some
extent. The topic of heterogeneity however, analysing the impact
of the population chosen on the final results, is rarely discussed.
This seems connected to the recurrent neglect of generalizability
in the discussion. CEA-results are at risk to be considered as ‘evi-
dence of cost-effectiveness’ of a specific intervention, although a
different indication or modified base case may completely change
the picture.
A surprising finding was the lack of clarity on the radiotherapy
fractionation schedules. If analysis is based on large-scale data
such as registries or claim-based data sets, the advantage of these
real-world data may come at the cost of loss of specificity regard-
ing indications and acts performed [53]. Most articles however
compare specific strategies. In those cases, a clear description of
fractionation as well as radiotherapy technique is strongly advis-
able because both influence costs, as well in a reimbursement
[39] as in real cost-based setting [49,54].
To avoid arbitrariness, a quantitative evaluation with accept-
able thresholds may be superior to a purely qualitative approach.
Policy makers sometimes adopt such a strategy, frequently
extended with country-specific requirements, as listed on the
ISPOR website (https://www.ispor.org/PEguidelines/index.asp).
Quantitative benchmarki is often extracted from the Tufts Med-
ical Centre CEA registry. These Tufts scores are based on a subjec-
tive appreciation, and no information is provided on how scores
are precisely obtained.
A second tool, the QHES checklist, is a validated quantitative
instrument. This checklist does not permit intermediate scores
although several items consist of various sub-items and combine
transparency evaluation (formal presence of data) with quality
appreciation (appropriateness of choices made). As a consequence,
QHES-results are observer-dependent [17]. Averaging out interpre-
tative differences by increasing the number of observers may
remediate this problem, but such a solution results in a high work-
load. As an alternative, we applied a least and a most strict inter-
pretation of ‘fulfilment’ of the items, and used the midrange of
the respective results for comparison with the other instruments.
The CHEERS checklist was not intended for quantitative bench-
marking. However, its structure predisposes to quantification, as
has been confirmed repeatedly after the first exercise by
Mangham-Jefferies et al. [13,55–69]. Most of these CHEERS-based
quality reviews of HEEs implemented a score for ‘partially
respected’ to overcome the problem of incompleteness and
accorded an equal weight to each item. Regarding weights, one
may question if every item is of a similar importance, from com-
pleteness of title over reporting of data sources to uncertainty
analysis.
Another question regarding CHEERS is whether its use can be
extended to the evaluation of CCs. For the moment, no checklists
dedicated to CC evaluation exist. For our evaluation, it seemed rea-
sonable to adopt the CHEERS for quantification of CC quality,
excluding 11 items related to effectiveness outcome or modelling.
A last unsolved question is the threshold. Ofman et al. proposed
three categories for QHES evaluation, with high quality for scores
over 75%, medium quality between 50 and 75% and low quality
below 50% [15]. The same threshold has been adopted for quanti-
tative CHEERS evaluations [58,60,61,63–65,67]. Plumpton et al.
even applied a threshold of 85% for high quality [69]. Although
practicable, such thresholds remain arbitrary.
In the present study focusing on adjuvant breast radiotherapy,
quantification of quality with CHEERS resulted in an average score
of 74% for CEAs and 75.6% for CCs. If a threshold of 75% would be
applied, only 6 out of 13 CCs and 13 out of 20 CEAs would be con-
sidered reliable and of good quality. A minimal threshold of 50%
(medium quality) was met by all CCs and almost all CEAs whereas
the stricter ‘Plumpton’ threshold (85%) was attained by only 4 CCs
and 4 CEAs. Similar numbers would be obtained with both vali-
dated quantitative instruments.
Possible limitations of our study are related to the unsolved
questions raised above and to the limited number of observers per-
forming the evaluation. Consequently, this exercise cannot be
interpreted as a validation of CHEERS for quantitative benchmark-
ing, neither as a confirmation of the use of this instrument for CCs.
Nevertheless, the extension of CHEERS guidelines to quantitative
benchmarking of CEAs as well as CCs seems feasible. Moreover,
comparison to other validated quantitative instruments did not
Fig. 4. Comparison of CEA-scores for CHEERS, QHESmidrange and Tufts. Statistical comparison (paired Wilcoxon rank test) of CHEERS with Tufts and QHESmidrange scores
did not result in a significant difference between instruments (QHESmidrange vs. Tufts: p = 0.7; QHESmidrange vs. CHEERS: p = 0.3; CHEERS vs. Tufts: p = 0.8). Scores per
article are illustrated in percentages to allow comparison. Tufts scores were available for 14 out of 20 CEA. Dark grey = QHESmidrange, medium grey = CHEERS, light
grey = Tufts.
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Figure 4: Comparison of  CEA-scores for CHEERS, QHESmidrange and Tufts
Statistical comparison (paired Wilcoxon rank test) of  CHEERS with Tufts and QHE-
Smidrange scores did not result in a significant difference between instruments (QHE-
Smidrange vs. Tufts: p=0.7; QHESmidrange vs. CHEERS: p=0.3; CHEERS vs. Tufts: 
p=0.8). Scores per article are illustrated in percentages to allow comparison. Tufts scores 
were available for 14 out of  20 CEA. Dark grey = QHESmidrange, medium grey = 
CHEERS, light grey = Tufts.
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APPENDICES
Appendix 1: Search strategy according to PRISMA guidelines
PICOS
 
Participant: Breast cancer 
Intervention: radiotherapy (adjuvant) 
Comparator: radiotherapy or no radiotherapy 
Outcome: cost or effectiveness 
Study design: economic analysis (cost comparison, cost effectiveness, cost utility) 
Embase
 
‘radiotherapy’/exp OR radiotherapy OR ‘radiation’/exp OR radiation OR ‘irradiation’/exp OR irradiation AND (‘cost’/exp 
OR cost OR costs OR economic OR economical OR effectiveness OR benefit) AND (‘breast’/exp OR breast) AND ([article]/
lim OR [article in press]/lim OR [review]/lim OR [short survey]/lim) AND ([dutch]/lim OR [english]/lim OR [french]/lim) 
AND [humans]/lim 




(“radiotherapy”[MeSH Terms] AND “Costs and Cost Analysis”[Mesh]) AND “Breast Neoplasms”[Mesh]) OR (((radiothera-
py[Ti le/Abstract] OR radiation[Title/Abstract] OR irradiation[Title/Abstract]) AND (Cost[Title/Abstract] OR costs[Title/
Abstract] OR economic[Title/Abstract] OR economical[Title/Abstract] OR effectiveness[Title/Abstract] OR benefit[Title/
Abstract])) AND breast[Title/Abstract]) AND (“2000/01/01”[PDAT] : “3000/12/31”[PDAT]) 
Cochrane
 
Search Name: Cochrane_CEA_word and MeSH combined 
Description:   
ID Search Hits 
#1 radiotherapy:ti,ab,kw or radiation:ti,ab,kw or irradiation:ti,ab,kw   
                (Word variations have been searched) 25548 
 
#2 benefit:ti,ab,kw or cost:ti,ab,kw or economic:ti,ab,kw or economical:ti,ab,kw or effectiveness:ti,ab,kw     
                (Word variations have been searched) 167655
#3 Breast:ti,ab,kw  (Word variations have been searched) 28316
#4 #1 and #2 and #3  722
#5 MeSH descriptor: [Costs and Cost Analysis] explode all trees 24985
#6 MeSH descriptor: [Breast Neoplasms] explode all trees 9949
#7 MeSH descriptor: [Radiotherapy, Adjuvant] explode all trees 993
#8 #5 and #6 and #7  9
#9 #4 or #8  722 
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Appendix 3: Overview of  CHEERS and QHES questionnaires. 
CHEERS         Weight QHES Weight
1. Identify the study as an economic evaluation, or use more specific terms 
such as “cost-effectiveness analysis” and describe the interventions compared
1 Was the study objective presented in a clear, specific, and measurable manner? 7
2. Provide a structured summary of  objectives, perspective, setting, meth-
ods (including study design and inputs), results (including base-case and un-
certainty analyses) and conclusions
1 Were the perspective of  the analysis (societal, third-party payer, etc.) and reasons for its 
selection stated?
4
3. Provide an explicit statement of  the broader context for the study. Present 
the study question and its relevance for health policy or practice decision
1 were variable estimates used in the analysis from the best available source (ie. RCT - best, 
Expert opinion-worst)?
8
4. Describe characteristics of  the base-case population and subgroups ana-
lyzed including why they were chosen
1 If  estimates came from a subgroup analysis, were the groups pre-specified at the beginning 
of  the study?
1
5. State relevant aspects of  the system(s) in which the decision(s) need(s) to be made 1 Was uncertainty handled by: 1) statistical analysis to address random events; 2) sensitivity 
analysis to cover a range of  assumptions?
9
6. Describe the perspective of  the study and relate this to the costs being evaluated 1 Was incremental analysis performed between alternatives for resources and costs? 6
7. Describe the interventions or strategies being compared and state why 
they were chosen
1 Was the methodology for data abstraction (including value health states and other benefits) 
stated?
5
8. State the time horizon(s) over which costs and consequences are being evaluated and 
say why appropriate
1 Did the analytic horizon allow time for all relevant and important outcomes? Were benefits 
and costs that went beyond 1 year discounted 3-5%) and justification given for the discount 
rate?
7
9. Report the choice of  discount rate(s) used for costs and outcomes and say why appropriate 1 Was the measurement of  costs appropriate and the methodology for the estimation of  quan-
tities and unit costs clearly described?
8
10. Describe what outcomes were used as the measure(s) of  benefit in the evaluation and 
their relevance for the type of  analysis performed
1 Were the primary outcome measures for the economic evaluation clearly stated and were the 
major short term, long term and negative outcomes included?
6
11a. Single study-based estimates: Describe fully the design features of  the single effec-
tiveness study and why the single study was a sufficient source of  clinical effectiveness data
1 Were the health outcomes measures/scales valid and reliable? If  previously tested valid and 
reliable measures were not available, was justification given for the measures/scales used?
7
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11b. Synthesis-based estimates: Describe fully the methods used for the identification of  
included studies and synthesis of  clinical effectiveness data
1 Were the economic model (including structure), study methods and analysis, and the compo-
nents of  the numerator and denominator displayed in a clear transparent manner?
8
12. If  applicable, describe the population and methods used to elicit preferences for outcomes 1 Were the choice of  economic model, main assumptions and limitations of  the study stated 
and justified?
7
13a. Single study-based economic evaluation: Describe approaches used 
to estimate resource use associated with the alternative interventions. De-
scribe primary or secondary research methods for valuing each resource 
item in terms of  its unit cost. Describe any adjustments made to approxi-
mate to opportunity costs
1 Did the author(s) explicitly discuss direction and magnitude of  potential biases? 6
13b. Model-based economic evaluation: Describe approaches and data 
sources used to estimate resource use associated with model health states. 
Describe primary or secondary research methods for valuing each resource 
item in terms of  its unit cost. Describe any adjustments made to approxi-
mate to opportunity costs
1 Were the conclusions/recommendations of  the study justified and based on the study results? 8
14. Report the dates of  the estimated resource quantities and unit costs. 
Describe methods for adjusting estimated unit costs to the year of  reported 
costs if  necessary. Describe methods for converting costs into a common 
currency base and the exchange rate
1 Was there a statement disclosing the source of  funding for the study? 3
15. Describe and give reasons for the specific type of  decision-analytic model used. Pro-
viding a figure to show model structure is strongly recommended
1
16. Describe all structural or other assumptions underpinning the decision-analytic model 1
17. Describe all analytic methods supporting the evaluation. This could include methods 
for dealing with skewed, missing, or censored data; extrapolation methods; methods for 
pooling data; approaches to validate or make adjustments (eg half  cycle corrections) to a 
model; and methods for handling population heterogeneity and uncertainty
1
18. Report the values, ranges, references and if  used, probability distribution for all pa-
rameters. Report reasons or sources for distributions used to represent uncertainty where 
appropriate. Providing a table to show the input values is strongly recommended
1
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19. For each intervention, report mean values for the main categories of  esti-
mated costs and outcomes of  interest, as well as mean differences between the 
comparator groups. If  applicable, report incremental cost-effectiveness ratios
1
20a. Single study-based economic evaluation: Describe the effects of  sampling uncertainty for 
estimated incremental cost, incremental effectiveness and incremental cost-effectiveness, together 
with the impact of  methodological assumptions (such as discount rate, study perspective)
1
20b. Model-based economic evaluation: Describe the effects on the results of  uncertainty for 
all input parameters, and uncertainty related to the structure of  the model and assumptions.
1
21. If  applicable, report differences in costs, outcomes or cost-effectiveness that can be ex-
plained by variations between subgroups of  patients with different baseline characteristics 
or other observed variability in effects that are not reducible by more information.
1
22. Summarize key study findings and describe how they support the conclu-
sions reached. Discuss limitations and the generalizability of  the findings 
and how the findings fit with current knowledge.
1
23. Describe how the study was funded and the role of  the funder in the 
identification, design, conduct and reporting of  the analysis. Describe other 
nonmonetary sources of  support.
1
24. Describe any potential for conflict of  interest among study contributors 
in accordance with journal policy. In the absence of  a journal policy, we rec-
ommend authors comply with International Committee of  Medical Journal 
Editors’ recommendations.
1
Items in bold were only used for cost comparison evaluation. Weights per item to obtain a total 
score are indicated.
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Appendix 3: Overview of  the characteristics, comparators and scores of  the 20  
publications on cost-effectiveness analysis.
Publication Comparison HEE characteristics Scores
Year Author Title Country Type Specific comparators Perspec-
tive
Type of  costing CHEERS QHES Tufts
2000 Hayman Cost-effectiveness of  adding an electron-beam 
boost to tangential radiation therapy in pa-
tients with negative margins after conservative 
surgery for early-stage breast cancer 
USA Additional RT BCT +/- boost  
(8 fractions)
Societal Reimbursement 80,7% 91,0% 78,6%
2000 Dunscombe A cost-outcome analysis of  adjuvant postmas-
tectomy locoregional radiotherapy in premeno-
pausal node-positive breast cancer patients 
Canada Additional RT Lymph node irradiation Institutional Real cost 69,8% 68,0% 35,7%
2002 Lee Decision-Analytic model and cost-effec-
tiveness evaluation of  postmastectomy ra-
diation therapy in high-risk premenopausal 
breast cancer patients 
USA Additional RT Lymph node irradiation Payers Reimbursement 78,2% 85,0% 78,6%
2005 Lundkvist Economic evaluation of  proton radiation 
therapy in the treatment of  breast cancer 
Sweden Proton vs. photon BCS + EBRT  
(25 fractions)
Societal Real cost 77,5% 59,5% 64,3%
2005 Suh Cost-effectiveness of  radiation therapy 
following conservative surgery for ductal 
carcinoma in situ of  the breast 
USA Additional RT BCS +/- EBRT 
(30 fractions)
Societal Reimbursement 83,8% 94,5% 78,6%
2005 Lievens Economic consequence of  local control 
with radiotherapy: cost analysis of  inter-
nal mammary and medial supraclavicular 
lymph node radiotherapy in breast cancer 
Belgium Additional RT Lymph node irradiation Institutional - 
including  
patient cost
Real cost 82,2% 88,0% 57,1%
2007 Prescott A randomised controlled trial of  postop-
erative radiotherapy following breast-con-
serving surgery in a minimum-risk older 
population. The PRIME trial. 
UK Additional RT BCS +/- EBRT 
(15 fractions)
Payers Reimbursement 83,9% 84,5% N/A
2008 Sher Partial breast irradiation versus whole 
breast irradiation for early-stage breast  
cancer:  a cost-effectiveness analysis 
USA Technique/ fractionation EBRT (10 or 15 fractions) vs. 
APBI-ML (10 fractions)
Payers Reimbursement 74,3% 74,0% 78,6%
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2012 Shah Cost-effectiveness of  3-Dimensional con-
formal radiotherapy and applicator-based 
brachytherapy in the delivery of  accelerat-
ed partial breast irradiation 
USA Technique/ fractionation EBRT vs. IMRT vs. APBI-SL 
vs. APBI-ML  
(10 fractions)
Payers  Reimbursement 38,0% 34,0% N/A
2012 Gold Cost effectiveness of  new breast cancer radio-
therapy technologies in diverse populations 
USA Technique/ fractionation EBRT (10 or 25 fractions) vs. 
APBI-Mammosite (10 frac-
tions)
Societal Reimbursement 69,6% 77,5% 85,7%
2012 Bai Economic evaluation of  radiotherapy for 
early breast cancer after breast-conserving 
surgery in a health resource limited setting 
China Additional RT EBRT (25 or 30 fractions) Societal Reimbursement 87,0% 85,0% 85,7%
2013 Shah Evaluating radiotherapy options in breast 
cancer: does intra-operative radiotherapy 
represent the most cost-efficacious option?
USA Technique/ fractionation IORT (1 fraction) vs. EBRT 
(10 or 25 fractions) vs. IMRT 
(10 fractions) vs. APBI-SL or 
APBI-ML or APBI-IS (10 frac-
tions) 
Societal Reimbursement 35,9% 45,0% 57,1%
2013 Shah Cost-efficacy of  acceleration partial-breast 
irradiation compared with whole breast 
irradiation
USA Technique/ fractionation EBRT (10 or 28 fractions) vs. 
IMRT (10 or 28fractions) vs. 
APBI-SL or APBI-ML or AP-
BI-IS (10 fractions) 
Societal Reimbursement 44,3% 45,0% 71,4%
2013 Alvarado Cost-effectiveness analysis of  intraoperative 
radiation therapy for early stage breast cancer
USA Technique/ fractionation IORT (1 fraction) vs.  
EBRT (15 or 33 fractions)
Payers  Reimbursement 69,2% 71,5% 71,4%
2014 Sen Examining the cost-effectiveness of  radi-
ation therapy among older women with 
favorable-risk breast cancer
USA Additional RT BCS only vs. BCS + EBRT or 
IMRT (mix of  fractions) or  
APBI-IS (10 fractions) 
Payers  Reimbursement 85,4% 87,0% 85,7%
2015 Picot The intrabeam photon radiotherapy sys-
tem of  the adjuvant treatment of  early 
breast cancer: a systematic review and eco-
nomic evaluation 
UK Technique/ fractionation IORT (1 fraction) vs.  
EBRT (15 fractions)
Payers Real cost 93,8% 98,0% N/A
2015 Wan Subgroup economic evaluation of  radio-
therapy for breast cancer after mastectomy. 
China Additional RT Lymph node irradiation Societal Reimbursement 79,2% 83,0% 85,7%
2016 Vaidya An international randomised controled 
trial to compare TARGeted Intraoperative 
radioTherapy (TARGIT) with conventional 
postoperative radiotherapy after breast-con-
serving sugery for women with early-stage 
breast cancer (the TARGIT-A trial)
UK Technique/ fractionation IORT (1 fraction) vs.  
EBRT (15 fractions)
Payers Reimbursement 88,1% 83,5% N/A
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2016 Lester-Coll Cost-effectiveness assessment of  lumpec-
tomy cavity boost in elderly women with 
early stage estrogen receptor positive breast 
cancer receiving adjuvant radiotherapy 
USA Additional RT BCT +/- boost 
(8 fractions)
Payers Reimbursement 80,8% 76,0% N/A
2016 Mailhot Establishing cost-effective alllocation of  
proton therapy for breast irradiation
USA Proton vs. photon Cardiac toxicity with  
photon vs. proton therapy  
(28 fractions)
Societal Real cost 78,0% 73,5% N/A
Abbreviations: RT: radiotherapy; BCS: breast conserving surgery; BCT: breast con-
serving therapy (BCS + RT); EBRT: external beam radiotherapy; IMRT: intensity modu-
lated radiotherapy; IORT: intra-operative radiotherapy; APBI: accelerated partial breast 
irradiation; SL: single-lumen; ML: multi-lumen; IS: interstitial; N/A: if  Tufts score not 
available
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Appendix 4: Overview of  the characteristics, comparators and scores of  the 13  
publications on cost comparison. 
Publication Comparison HEE characteristics
Score
Year Author Title Coun-
try
Type Specific comparators Perspective Type of  costing
2002 Warren Costs of  Treatment for elderly women with 
early-stage breast cancer in Fee-for-Service 
settings 
USA Additional RT ME vs. BCS + RT (type and number of  fractions 
not specified)
Societal Reimbursement 66,6%
2005 Suh A cost comparison analysis of  partial 
versus whole-breast irradiation after 
breast-conserving surgery for early-stage 
breast cancer 
USA Technique/ fractionation EBRT (10 or 16 or 25 or 30 fractions) vs. IMRT 
(10 or 30 fractions) vs. APBI-Mammosite or AP-
BI-IS (10 fractions)
Societal Reimbursement 73,3%
2010 Lievens Hypofractionated radiotherapy: Financial 
and economic consequences 
Belgium Technique/ fractionation EBRT (5 vs. 13 vs. 15 vs. 16 vs. 25 vs. 30 fractions) Institutional Real cost 77,8%
2011 Smith Adoption of  intensity-modulated radiation 
therapy for breast cancer in the united 
states 
USA Technique/ fractionation EBRT vs. IMRT (number of  fractions not speci-
fied)
Payers Reimbursement 89,1%
2012 Greenup Cost comparison of  radiation treatment 
options after lumpectomy for breast cancer 
USA Technique/ fractionation EBRT (9 vs. 20 vs. 30 fractions) Payers Reimbursement 67,8%
2013 Hamada Cross-national comparison of  medical 
costs shared by payers and patients: a study 
of  postmenopausal women with early-stage 
breast cancer based on assumption case 
scenarios and reimbursement fees. 
Japan Different reimbursement  
systems
EBRT 25 fractions - patient and payers’ cost in 
Germany, UK vs. Japan
Societal Reimbursement 93,9%
2013 Lanni A cost comparison analysis of  adju-
vant radiation therapy techniques after 
breast-conserving surgery 
USA Technique/ fractionation EBRT vs. IMRT (10 or 16 or 28 or 33 fractions) 
vs. APBI-SL or APBI-ML (10 fractions)
Payers  Reimbursement 65,2%
2014 Min Hypofractionated radiation therapy for 
early stage breast cancer: outcomes, toxici-
ty and cost analysis 
USA Technique/ fractionation EBRT (4 vs. 16 vs. 25 fractions) Payers  Reimbursement 57,4%
2014 Bekelman Uptake and costs of  hypofractionated vs 
conventional whole breast irradiation after 
breast conserving surgery in the United 
States, 2008-2013
USA Technique/ fractionation EBRT (15 vs. 25 fractions in endorsed vs. permit-
ted population)
Payers Reimbursement 89,2%
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2016 Smith Cost and complications of  local therapies 
for early-stage breast cancer 
USA Technique/ fractionation ME +/- reconstruction vs. BCS +/- RT (type and 
number of  fractions not specified)
Payers Reimbursement 94,3%
2016 Dupin Evolution des pratiques médicales d’hypof-
ractionnement en radiothérapie pour can-
cer du sein et impact économique 
France Technique/ fractionation EBRT (5 vs. 15 vs. 16 vs. 25 fractions) Payers Reimbursement 60,4%
2016 Mortimer Use of  hypofractionated post-mastectomy 
radiotherapy reduces health costs by over 
$2000 per patient: An Australian perspective 
Austra-
lia
Technique/ fractionation EBRT (15 vs. 25 fractions) Payers Reimbursement 79,4%
2016 Schutzer Time-driven activity-based costing: a 
comparative cost analysis of  whole-
breast radiotherapy versus balloon-based 
brachytherapy in the management of  ear-
ly-stage breast cancer
USA Technique/ fractionation EBRT (20 or 30 fractions) vs.  
APBI-ML (10 fractions)
Institutional Real cost 67,9%
 
Abbreviations: RT: radiotherapy; BCS: breast conserving surgery; ME: mastectomy; 
EBRT: external beam radiotherapy; IMRT: intensity modulated radiotherapy; APBI: 
accelerated partial breast irradiation; SL: single-lumen; ML: multi-lumen; IS: interstitial
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1. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie 
R, Parpia S, et al. Long-term results of  hypofractionat-
ed radiation therapy for breast cancer. N Engl J Med. 
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Abstract
Introduction: The introduction of  new fractionation schedules and techniques for 
adjuvant breast radiotherapy has been followed by health economic evaluations (HEE) 
comparing the efficiency of  these new strategies. This overview assembles the available 
evidence and evaluates to what extent HEE-results can be compared.
Methods: Based on a systematic literature review of  HEEs from 1/1/2000 to 
30/10/2016, all cost comparison and cost-effectiveness analyses comparing different ad-
juvant breast radiotherapy approaches were analyzed. Costs were extracted and convert-
ed to Euro 2016 and costs per QALY were summarized in cost-effectiveness planes.
Results: Twenty-four publications are withheld, comparing different fractionation 
schedules and/or irradiation techniques or evaluating the value of  adding radiotherapy. 
Normofractionation, IMRT and interstitial as well as intraluminal techniques are import-
ant cost-drivers. Highest reimbursement costs come from the US, but may overestimate 
the real-cost. Whereas cost-effectiveness of  hypofractionation seems evident, the results of  
APBI are less unequivocal. Intra-operative radiotherapy and external beam APBI seem 
the most cost-effective APBI techniques for favourable risk groups, but WBI is superior in 
terms of  health effect and omission of  radiotherapy in terms of  costs.
Discussion: In conclusion, although comparison of  CC and CEA is inherently based on 
many uncertainties and assumptions, HEE-based evidence can guide decision-making to 
tailor-made strategies, allocating the optimal treatment in terms of  effectiveness as well as 
efficiency to the right indication.
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Introduction
Excellent survival results in early and locally advanced breast cancer allowed to change 
the treatment paradigm in breast cancer therapy from maximizing cure to awareness for 
long-term toxicity, quality of  life and treatment burden[1]. 
An evolution from normofractionation to shorter, hypofractionated schedules was made 
possible through growing evidence on the radio-biologic aspects of  breast cancer, indi-
cating a higher sensitivity to fraction dose than originally assumed[2-5]. These schedules 
have further evolved into extremely accelerated schedules[6, 7]), and in combination with 
knowledge on the recurrence patterns of  breast cancer and new technological capabili-
ties, have paved the way for accelerated partial breast irradiation (APBI)[8-17].
In health care, the development of  evidence is built on three core questions, evaluating 
efficacy, effectivity and efficiency of  new approaches[18, 19]. 
Efficacy research – can it work? – is confined to the rules of  a trial, with strict intake crite-
ria, follow up of  compliance and complications and quality check of  the providers’ inter-
ventions. This question has been answered for most of  the above-mentioned approaches, 
although for APBI, be it with post-operative external, intra-operative of  peri-operative 
dose delivery, longer follow up is still awaited[13-15, 17, 20]. 
The question on effectivity – does it work? – evaluates if  results can be repeated in a 
real-world setting, under less ideal circumstances. This can be provided by observational 
research, based on large-scale databases[21]. As an example, a Medicare-based analysis 
compared brachytherapy-based APBI with standard whole breast irradiation (WBI) for 
overall survival, complications and mastectomy rates. It found equivalence for survival, 
but an increase in complications and subsequent mastectomies[22].
But even if  a new approach proves effective, additional expenses in health care must be 
worthwhile, most certainly from the perspective of  health-care payers. This evaluation 
of  efficiency is explored in health economic evaluations (HEE), with cost comparisons 
(CC) inventorying the cost difference of  new strategies versus the gold standard, whereas 
cost-effectiveness evaluations (CEA) compare this incremental cost to incremental health 
effects. In HEE, health effects are expressed in natural units, ideally in ‘life years gained’ 
(LYG) or in quality adjusted life years gained (QALY), factoring in the importance that 
individuals assign to purely clinical gains. Whereas CCs give a mere representation of  the 
cost, be it resource costs, reimbursement figures or charges, CEAs provide a more com-
plete analysis with the ultimate aim to define whether its implementation is financially 
acceptable from a societal perspective. Such societal acceptance can be translated in a 
‘willingness-to-pay’ (WTP), indicating how much a society is prepared to pay per LYG or 
per QALY. This can be a fixed amount, depending on the economic status of  a country, 
or variable, depending on factors such as the societal impact, the illness burden or the 
innovative nature of  the technology[23].  
Even with reassuring and robust evidence, implementation of  new approaches can be 
slow, as is observed for hypofractionation[24-29] or on the contrary, can anticipate the 
evidence, as for APBI, where the need for reassuring long-term results on intra-operative 
and balloon-based APBI has not impeded its wide-spread application, within but also 
outside of  clinical trials[30, 31]. The answer to this paradox may at least to some extent 
be ascribed to the conflicting economic impact of  these techniques between different 
stakeholders.
This paper aims at providing a comprehensive overview of  the published literature on 
costs and cost-effectiveness of  hypofractionated and accelerated breast radiotherapy, 
based on a systematic review of  the literature. Comparability of  data is ascertained by 
applying monetary conversions, categorization is performed for different radiation tech-
niques and fractionation schedules.
Materials and methods
Publications on HEE of  adjuvant breast radiotherapy, published between 1/1/2000 and 
31/10/2016, were retrieved through systematic literature review in Medline, Embase and 
Cochrane databases. The methods are described in a previous publication[32]. From this 
series, only publications focusing on the cost and cost-effectiveness of  adjuvant whole 
breast irradiation (WBI), post-mastectomy radiotherapy (PMRT) or partial breast irradi-
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ation (PBI) were withheld for comparison. Publications were excluded if  results could not 
be related to the specific radiotherapy cost (e.g. if  including surgery or systemic therapy 
cost) or to specific techniques or fractionation schedules (e.g. in large database evaluations, 
as in SEER analyses, based on global charges over different techniques and fractionation 
schedules).
Comparison of  treatment cost
Cost data were extracted from both CCs and CEAs. Direct radiotherapy costs per tech-
nique and fractionation schedule are presented, excluding non-medical and indirect costs. 
The published costs are inflated to the year 2016 (for one article that did not mention a 
reference year, 2015 was assumed, based on publication date), according to the coun-
try-specific Consumer Price Indices (http://fxtop.com/en/inflation-calculator.php) and 
then converted to Euro, using available conversion factors (www.xe.com/currencytables). 
Because monetary values are subject to fluctuations, the 31st January of  2016 was chosen 
as reference date. 
Comparison of  cost-effectiveness
Data were derived from the CEA publications. Incremental cost-effectiveness is defined 
as the incremental cost of  a new intervention compared to the standard, and divided by 
the incremental health effect  between both interventions, also referred to as incremental 
cost-effectiveness ratio (ICER)[33]. If  incremental health effect is based on LYG, it results 
in a cost-effectiveness analysis (CEA). A cost-utility analysis (CUA) is based on QALY, with 
health effects weighted by the utilities adhered to each possible health state. The term 
CEA often covers both definitions. For reasons of  readability, we further use the more 
common term of  cost-effectiveness, even if  QALYs are applied.
For the incremental costs, the same technique of  inflation and conversion to Euro-2016 
was applied as described above. Only ICERs based on QALYs are presented in this 
publication.
Results
Comparison of  treatment cost
Twenty-four publications are withheld, 4 based on real-cost exercises [34-37] and 20 on 
reimbursement[26, 38-56] (table 1). 
WBI or PMRT are delivered with external beam radiotherapy (EBRT) or more specifical-
ly, intensity-modulated radiotherapy (IMRT) and costs are available for normofraction-
ated schedules, with or without a boost (25-35 fractions for EBRT; 28-33 for IMRT) and 
hypofractionated schedules (EBRT 11-20 fractions; IMRT 16 fractions). 
APBI is delivered with EBRT (APBI-EBRT 4-10 fractions) or IMRT (APBI-IMRT 10 
fractions), with single-fraction intra-operative radiotherapy (IORT), with post-operative 
interstitial brachytherapy (APBI-IS) or with balloon-based brachytherapy, applying a sin-
gle- or a multi-lumen balloon-technique (APBI-balloon, further subdivided in either AP-
BI-SL or APBI-ML). Postoperative intraluminal partial-breast techniques all apply 10 
fractions. Two articles, included in the APBI-EBRT group, report the cost of  EBRT in 5 
fractions for WBI[35, 55].
Overall, 81 radiotherapy costs are extracted from these publications, of  which 69 are 
based on reimbursement and 12 on real costs. An overview of  the published costs, ex-
pressed in € for 2016, can be found in table 1; aggregated data per treatment category 
(technique and fractionation schedule) and per cost type are presented in figure 1. Unsur-
prisingly, costs increase with the number of  fractions, especially when IMRT is applied. 
Post-operative intraluminal strategies also lead to higher costs. In contrast, the cost of  
IORT remains low over different reimbursement systems (UK and US-data available), 
comparable to the cost of  APBI-EBRT. 
Regional and time-bound factors influence costs. On average, hypofractionated and nor-
mofractionated EBRT cost almost twice as much in the US than elsewhere (respectively 
7,609€ and 11,316€ versus 3,649€ and 6,670€). Large variability is also observed within 
the US healthcare system itself: the reimbursement of  APBI-IS ranges from 11,709€ to 
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20,276€; the same goes for balloon-based brachytherapy, with APBI-ML ranging from 
13,453€ to 24,141€. From 2011 on, reimbursements drop with almost 25%.
The number of  real-cost calculations per radiotherapy technique is too low to draw firm 
conclusions. Overall, real-life costs seem lower than reimbursement, except for IORT, 
where reimbursement seems to align with real-cost (figure 1). However, when costs and re-
imbursement are compared within the European setting, the opposite goes, with real-life 
costs exceeding the reimbursement in several countries (table 1).
Comparison of  cost-effectiveness  
Fourteen publications were analysed on cost-effectiveness results (table 2). A fifteenth 
CEA was not withheld, because aesthetic outcome was used as health effect, hampering 
comparison with the recommended effects of  LYGs and QALYs[53]. Cost-effectiveness 
results are illustrated in figure 2, comparing the cost-effectiveness of  radiotherapy versus 
no radiotherapy in different age- and risk-groups[34, 38, 40, 41, 43, 52, 54] and figure 
3, comparing different fractionation schedules and radiotherapy techniques (either APBI 
compared to WBI or inter-comparison of  different APBI-techniques)[36, 42, 44, 47, 49, 
50, 56] on cost-effectiveness planes[57].
When comparing radiotherapy with no radiotherapy in different age- and risk-groups 
(presence or not of  lymph nodes in earlier stages breast cancer) (figure 2), the addition 
of  radiotherapy after breast-conserving surgery or mastectomy always results in an in-
crease in health effect, but at a higher cost, most explicit for IMRT and normofractionat-
ed schedules. One study evaluated the effect of  PMRT in older women, and calculated a 
decreasing effect for equal costs with increasing age, hence a higher ICER for older age 
groups[52]. A similar observation is made in the CEA of  the PRIME-trial, evaluating the 
effect of  WBI in older women with favourable breast cancer. These results demonstrate a 
minor improvement of  health effect at a non-negligible cost, questioning the efficiency of  
radiotherapy in this target population[41].
Two studies evaluated the addition of  radiotherapy in lymph node positive indications. 
Bai et al. calculated an acceptable ICER for WBI in lymph-node negative as well as 
positive patients, with the higher incremental cost for pN0 versus pN+ outweighted by 
an even higher incremental effectiveness for pN0, resulting in a superior ICER for this 
subgroup. Wan et al. analysed the pN+ group and found a significantly lower ICER for 
PMRT when the number of  lymph nodes involved was limited to maximally three. This 
was based on a lower cost for the pN1-3 subgroup together with improved effectiveness 
compared to 4 or more lymph nodes[43, 54].
The cost-effectiveness of  APBI versus WBI is spread over the four quadrants of  the dia-
gram, with a concentration of  results in the left-lower quadrant, indicating reduced ex-
penses at the cost of  a lower benefit (figure 3). Expensive techniques as balloon-based 
brachytherapy are dominated by WBI, even if  compared to normofractionation. The re-
sults of  IORT are scattered over 3 quadrants, with disagreement in utility (Picot and Shah 
calculate reduced QALYs for IORT compared to WBI, whereas Alvarado and Vaidya 
report better QALYs) and disagreement in cost (Picot refers to the CEA by the manufac-
turer Zeiss, indicating a higher cost for IORT whereas he himself  calculates almost no 
cost difference; in contrast, Shah, Alvarado and Vaidya report lower costs with IORT)[36, 
47, 49, 56].
Discussion
HEE on the cost and cost-effectiveness of  adjuvant breast radiotherapy covers a vast 
landscape of  fractionation schedules and techniques. Evidence is available from sever-
al geographic regions (US, Europe, Canada, Australia and Asia). The reviewed publi-
cations either evaluate the effect of  additional radiotherapy versus no radiotherapy or 
compare different fractionation schedules and/or techniques, varying from single-fraction 
intra-operative APBI to 35-fraction WBI or PMRT. Although most cost data are reim-
bursement-tariffs, some are based on real-cost calculations.
All evaluations on the cost-effectiveness of  additional radiotherapy in specific age and 
risk groups result in an increased health effect for radiotherapy, be it at an additional 
cost. Apart from the IMRT-arm in Sen’s publication[52], incremental costs, even with 
normofractionation in the investigational schedule, systematically remain below 10,000€. 
However, in combination with varying QALYs gained, these relatively acceptable incre-
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mental costs result in a wide range of  ICERs. The ICERs calculated by Wan, Bai, Lee 
and Dunscombe remain between 1,000€ to 30,000€/QALY, with incremental costs out-
weighed by relatively high incremental outcome. However, the CEA of  protracted frac-
tionation schedules in elderly women by Sen et al. combines high incremental costs with 
limited gains in health effects, resulting in ICERs between 37,188€/QALY to 232,479€/
QALY when IMRT is applied. A similar conclusion can be drawn for the ICER of  ad-
juvant EBRT-30 for DCIS[39]. The PRIME-study, evaluating hypofractionated WBI in 
the breast-conserving setting, is an extreme example: although the incremental costs are 
a mere 2,800€, combined with the very limited gain in health effect of  0.0075 QALYs, 
results in an ICER of  370,445€/QALY[41]. 
This result invites to debate. Clearly, an ICER of  over 370,000€/QALY is not acceptable, 
even if  the sensitivity analysis, excluding 4 outliers, resulted in significantly different costs 
and effects and reduced the ICER by a factor of  three. The outcomes, however, remain 
the main issue. Although in the CEA effects were based on a median follow-up of  15 
months, which is very short in favourable breast cancer treated with adjuvant Tamoxi-
fen, outcomes remained excellent in both arms. As even the five-year outcomes of  the 
PRIME-trial revealed no differences in overall survival or loco-regional control, this anal-
ysis approaches a cost-minimisation study, where in the absence of  incremental effects, 
the lowest cost (no treatment) should be favoured[58]. In addition, seeing the good results 
of  omission of  radiotherapy in favourable risk groups, this ‘no-treatment-arm’ may be a 
relevant comparator for future APBI trials.
Other trials, however, do not support this: the comparable CALGB 9343-trial, evaluating 
omission of  radiotherapy in a seemingly more favourable risk group (women over 70 years 
with T1N0 breast cancer), reported an 8% increase in loco-regional relapse at 10 years 
[59]. If  a similar long-term effect would have been observed in the PRIME trial, different 
costs and QALYs would probably have impacted the ICER. 
The results for APBI-techniques are widely spread-out over the cost-effectiveness plane. 
Some techniques come at increased costs, even when compared to normofractionation 
(balloon-based APBI and interstitial APBI). Other techniques are less costly (IORT, AP-
BI-EBRT, APBI-IMRT). Most publications compare these new strategies with normof-
ractionation. However, in line with growing evidence on hypofractionated and even ac-
celerated WBI and its lower costs, shorter fractionation schedules may again be a more 
valuable comparator. Effectively, Picot and Vaidya only report a marginally lower cost 
when IORT is compared to hypofractionation.
Except for two publications (Vaidya and Alvarado assume an increased QALY with 
IORT), QALYs slightly decrease with APBI. If  such a loss in health effect – however lim-
ited – is esteemed acceptable in return for lower costs or patient burden, the rationale to 
preferentially compare APBI to no radiotherapy for prognostic favourable indications, is 
further substantiated.
The ICERs in the upper-right quadrant of  the cost-effectiveness plane require a trade-off 
in acceptable supplementary expenses per QALY, decisions that are typically made on the 
basis of  willingness-to-pay thresholds, varying from country to country and being all or 
not explicit[60]. In contrast, ICERs located in the lower-left quadrant represent possible 
budgetary savings by sacrificing QALYs. As a result, higher ICERs are more favourable 
in this quadrant, as they indicate either higher gains in costs or lower loss in health. In 
contrast to the willingness-to-pay thresholds for the upper-right quadrant, no thresholds 
are available to support decision-making in lower-left situations.
When looking at these results, and considering whether they are applicable in the own 
health care environment, several caveats must be kept in mind. 
First it should be acknowledged that a large discrepancy is observed for real-cost estima-
tions versus reimbursement data. However easy to use, reimbursement is only a surrogate 
for costs[61]. Based on the available data, for IORT, real-life costs and reimbursement 
seem well-aligned. In contrast, the cost calculation by Schutzer et al. results in a much 
lower cost for EBRT and balloon-based brachytherapy than the US reimbursement tar-
iffs[37] whereas the activity-based-costing exercise by Lievens et al. suggests that reim-
bursement in most European countries underestimates the real-life cost of  EBRT[35]
Secondly, although real-life costs may seem more relevant than reimbursement, heteroge-
neity of  costing exercises makes results difficult to compare: different models for real-cost 
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calculation are used with a variety of  cost inputs and computing various cost outputs[62]. 
The large differences in incremental costs for IORT between Picot et al. and the manu-
facturer Zeiss, illustrate this heterogeneity[36]. In addition, even if  a uniform template is 
used for cost calculation, heterogeneity of  personnel salaries and time investment, infra-
structure cost, equipment use and overhead cost will lead to a range of  results, as demon-
strated in a Belgian multi-centre time-driven activity-based-costing exercise[63].
Thirdly, costs - and more importantly - reimbursements, are strongly influenced by re-
gion and time. The large differences between US reimbursement versus other countries 
support this regional effect. And although inflation may to some extent correct for time-
bound differences, it does not neutralize the effect of  reimbursement renegotiations.
In addition, not only costs but also health effects may be subject to selection bias. The con-
troversies in the literature on the results of  the TARGIT-trial demonstrate how arguable 
clinical outcomes can be. When using QALYs, this heterogeneity is further magnified by 
an even larger uncertainty regarding utilities[64, 65].
A last remark concerns the perspective used. All articles adopt a payers’ perspective, ex-
tended to a societal perspective when non-medical costs are included. However, other 
stakeholders, like patients and caregivers, play a role in the choice of  treatment strate-
gies[29, 66]. Different perspectives may lead to very different results. For example, if  a 
radiation department would consider adopting hypofractionation as standard therapy, 
they would compare the reimbursement received with the departmental costs of  normo- 
versus hypofractionation. If  reimbursement of  hypofractionation would be lower than its 
cost and thus jeopardize income, hard evidence may not overcome this financial hurdle 
related to the need of  radiotherapy departments to function within an economic reality. 
This virtual example may at least partially explain the slow implementation of  hypofrac-
tionation world-wide.
In conclusion, although comparison of  CC and CEA is inherently based on many uncer-
tainties and assumptions, some conclusions can be drawn. Substituting normo- by hypof-
ractionation reduces healthcare costs for a comparable health-effect. Addition of  radio-
therapy, even in favourable risk groups, improves QALY, but comes at a cost. ICERs may 
become acceptable if  shorter fractionation schedules are adopted. The results for APBI 
are more controversial, especially for IORT, where longer follow-up and relevant compar-
ators may eventually settle its place within the landscape of  adjuvant breast radiotherapy.
All in all, the one-disease-one-treatment paradigm no longer prevails: whereas different 
strategies have proven effectiveness, an evolution to tailor-made allocation of  the most 
efficient radiotherapy option could be facilitated if  evidence from cost-effectiveness re-
search where more systematically implemented.   
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Table 1: Overview of  costs converted to €, 2016, per publication. 
 
































Decision-Analytic model and cost-effec-
tiveness evaluation of  postmastectomy 
radiation therapy in high-risk premeno-








Cost-effectiveness of  radiation therapy 
following conservative surgery for duc-







A cost comparison analysis of  partial 
versus whole-breast irradiation after 
breast-conserving surgery for ear-









 8,690 (10)  11,104 
(10) 




A randomised controlled trial of  
postoperative radiotherapy follow-
ing breast-conserving surgery in a 










Partial breast irradiation versus whole 
breast irradiation for early-stage breast 










Economic evaluation of  radiotherapy 
for early breast cancer after breast-con-










Cost effectiveness of  new breast cancer 











Cost comparison of  radiation treat-









 5,321 (9) 
162 163Accelerating Adjuvant Breast Radiotherapy Accelerating Adjuvant Breast Radiotherapy
Hamada 
2013
Cross-national comparison of  medical 
costs shared by payers and patients: a 
study of  postmenopausal women with 
early-stage breast cancer based on as-



















Cost-effectiveness analysis of  intraop-










 6,695 (1) 
Lanni 
2013
A cost comparison analysis of  adju-













 13,602 (16)  6,552 (10)  10,505 
(10) 




Evaluating radiotherapy options in 
breast cancer: does intra-operative ra-







 6,552 (10)  10,505 
(10) 




Cost-efficacy of  acceleration par-
tial-breast irradiation compared with 






 20,555 (25)  6,552 (10)  10,505 
(10) 




Hypofractionated radiation therapy for 
early stage breast cancer: Outcomes, 








 4,642 (4) 
Shah 
2014
Cost-effectiveness of  3-Dimensional 
conformal radiotherapy and applica-
tor-based brachytherapy in the delivery 
of  accelerated partial breast irradiation 
USA USD 
2011
 6,575 (10)  10,543 
(10) 




Subgroup economic evaluation of  








Evolution des pratiques médicales 
d’hypofractionnement en radiothéra-









 923 (5)* 
164 165Accelerating Adjuvant Breast Radiotherapy Accelerating Adjuvant Breast Radiotherapy
Mortimer 
2016
Use of  hypofractionated post-mastec-
tomy radiotherapy reduces health costs 










An international randomised controlled 
trial to compare TARGeted Intraop-
erative radioTherapy (TARGIT) with 
conventional postoperative radiother-
apy after breast-conserving sugery for 











A cost-outcome analysis of  adjuvant 
postmastectomy locoregional radiother-
apy in premenopausal node-positive 







Hypofractionated breast radiotherapy: 













The intrabeam photon radiotherapy 
system of  the adjuvant treatment of  
early breast cancer: a systematic review 









ing: a comparative cost analysis of  
whole-breast radiotherapy versus bal-
loon-based brachytherapy in the man-










Incremental costs are inflated to 2016 (Consumer price index of  respective country) and con-
verted to euro and grouped per publication and per category of  fractionation and/or technique. 
* Costs of  a 5-fraction EBRT-schedule for whole breast irradiation (Lievens et al. and Dupin 
et al.). Upper panel for reimbursement-based costs, costs in lower panel are real-cost based. 
** No mentioning of  reference year (Ref  year) in publication – assumption based on pub-
lication date.
 
Abbreviations: EBRT = External beam radiotherapy with number indicating number of  
fractions; IMRT = Intensity-modulated radiotherapy; APBI = Accelerated partial breast 
irradiation; IORT = Intraoperative radiotherapy; APBI-IS = Interstitial brachytherapy; 
APBI-SL = Intraluminal brachytherapy with single-lumen balloon technique; APBI-ML 
= Intraluminal brachytherapy with multi-lumen balloon technique; APBI-IS = Interstitial 
brachytherapy.
166 167Accelerating Adjuvant Breast Radiotherapy Accelerating Adjuvant Breast Radiotherapy
Table 2: Overview of  incremental cost (€, 2016), incremental outcome and ICER  
(€, 2016/QALY) per publication. 
Publication Setting Health Economic Evaluation 
Author 
Year







Radiotherapy vs no radiotherapy 
Dunscombe 
2000
A cost-outcome analysis of  adju-
vant post-mastectomy loco-regional 
radiotherapy in premenopausal 
node-positive breast cancer patients 
Canada CDN$, 1997 EBRT-25  
vs no PMRT




Decision-Analytic model and 
cost-effectiveness evaluation of  
post-mastectomy radiation therapy 
in high-risk premenopausal breast 
cancer patients 
USA USD, 2000 EBRT-25  
vs no PMRT




Cost-effectiveness of  radiation thera-
py following conservative surgery for 
ductal carcinoma in situ of  the breast 
USA USD, 2002 DCIS, EBRT-30  
vs no RT




A randomized controlled trial of  
postoperative radiotherapy follow-
ing breast-conserving surgery in a 
minimum-risk older population. 
The PRIME-trial. 
UK £, 2004 65y ESBC, EBRT-20  
vs no RT




Economic evaluation of  radiother-
apy for early breast cancer after 
breast-conserving surgery in a 
health resource limited setting
China USD, 2012
ESBC pN0, EBRT-30  
vs no RT
ESBC pN+, EBRT-30  
vs no RT
ESBC all, EBRT-30  
vs no RT
 621 € 1.5  410 € Increased effectiveness,  
increased cost
 914 € 1.6  570 € Increased effec-
tiveness,  
increased cost
 426 € 1.31  330 € Increased effec-
tiveness,  
increased cost
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Sen 
2014
Examining the cost-effectiveness 
of  radiation therapy among older 
women with favorable-risk breast 
cancer
USA USD, 2012
75-79y, EBRT  
vs no RT
80-94y, EBRT  
vs no RT




80-94y, IMRT  
vs no RT
70-74y, EBRT  
vs no RT
 9,148 € 0.246  37,188 € Increased effectiveness,  
increased cost
 9,171 € 0.218  42,067 € Increased  
effectiveness,  
increased cost
 9,234 € 0.17  54,316 € Increased  
effectiveness,  
increased cost
 17,119 € 0.106  161,500 € Increased  
effectiveness,  
increased cost
 17,140 € 0.095  180,425 € Increased  
effectiveness,  
increased cost





Subgroup economic evaluation of  
radiotherapy for breast cancer after 
mastectomy.
China USD, 2014
pN1-3, EBRT - 35  
vs no PMRT
pN1-3, chemo, EBRT-35  
vs no PMRT
pN4+, EBRT-35  
vs no PMRT
pN+, EBRT - 35  
vs no PMRT
 3,714 € 0.49  7,579 € Increased effectiveness,  
increased cost
 2,732 € 0.71  3,847 € Increased  
effectiveness,  
increased cost
 2,573 € 0.76  3,386 € Increased  
effectiveness,  
increased cost
 4,637 € 0.26  17,834 € Increased  
effectiveness,  
increased cost
Different fractionation schedules and techniques 
Sher 
2009
Partial breast irradiation versus 
whole breast irradiation for ear-
ly-stage breast cancer:  






-3,911 € -0.0052  752,181 €  Decreased effectiveness, decreased 
cost 
 9,047 € -0.0052  -1,739,847 Dominated
Gold 
2012
Cost effectiveness of  new breast 







-739 € -0.001  738,529 €  Decreased effectiveness, decreased 
cost 





Cost-effectiveness analysis of   
intraoperative radiation therapy  






-910 € 0.014 -64,880 € Dominant
-5,189 € 0.00026 -19,957,157 
€
Dominant
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Shah 
2013
Evaluating radiotherapy options in 
breast cancer: does intra-operative 
radiotherapy represent the most 
cost-efficacious option?
USA USD, 2011
IORT (T, 15%)  
vs EBRT-25


























-8,628 € -0.04  215,711 € Decreased effectiveness,  
decreased cost 
-3,721 € -0.04  93,037 € Decreased  
effectiveness,  
decreased cost 
-3,019 € -0.04  75,469 € Decreased  
effectiveness,  
decreased cost 
-3,483 € -0.04  87,064 € Decreased  
effectiveness,  
decreased cost 
-7,450 € -0.04  186,248 € Decreased  
effectiveness,  
decreased cost 
-9,504 € -0.04  237,602 € Decreased  
effectiveness,  
decreased cost 
-13,340 € -0.04  333,488 € Decreased  
effectiveness,  
decreased cost 
-8,667 € -0.04  216,686 € Decreased  
effectiveness,  
decreased cost 
-8,628 € -0.06  143,807 € Decreased  
effectiveness,  
decreased cost 
-3,483 € -0.06  58,042 € Decreased  
effectiveness,  
decreased cost 
-7,450 € -0.06  124,165 € Decreased  
effectiveness,  
decreased cost 
-9,504 € -0.06  158,401 € Decreased  
effectiveness,  
decreased cost 
-13,340 € -0.06  222,325 € Decreased  
effectiveness,  
decreased cost 
-8,667 € -0.06  144,457 € Decreased  
effectiveness,  
decreased cost 
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Shah 
2013
Cost-efficacy of  acceleration par-
tial-breast irradiation compared 




















-5,146 € -0.07  73,512 €  Decreased effectiveness,  
decreased cost 
-1,179 € -0.07  16,836 € Decreased  
effectiveness,  
decreased cost 
 876 € -0.07 -12,509 € Dominated
 4,711 € -0.07 -67,301 € Dominated
 31 € -0.07 -443 € Dominated
-14,053 € -0.07  200,760 € Decreased  
effectiveness,  
decreased cost 
-10,086 € -0.07  144,083 € Decreased  
effectiveness,  
decreased cost 
-8,032 € -0.07  114,738 € Decreased  
effectiveness,  
decreased cost 





The intrabeam photon radiothera-
py system of  the adjuvant treatment 
of  early breast cancer: a systematic 
review and economic evaluation 
UK £, 2013 IORT  
vs EBRT-15




An international randomized con-
trolled trial to compare TARGeted In-
traoperative radioTherapy (TARGIT) 
with conventional postoperative radio-
therapy after breast-conserving sur-
gery for women with early-stage breast 
cancer (the TARGIT-A trial)
UK £, 2013 IORT 
vs EBRT-15
-923 € 0.034 -27,143 € Dominant
Incremental costs are inflated to 2016 (Consumer price index of  respective country) and 
converted to euro. In italic, the situations where a lower cost comes with a loss in QALYs.
Abbreviations: ICER = Incremental cost effectiveness ratio; QALY = Quality adjusted life 
years gained; RT = radiotherapy; PMRT = Post-mastectomy RT; WBI = Whole breast 
irradiation; EBRT = External beam radiotherapy with number indicating number of  
fractions; IMRT = Intensity-modulated radiotherapy; APBI = Accelerated partial breast 
irradiation; APBI-IS = Interstitial brachytherapy; APBI-SL = Intraluminal brachyther-
apy with single-lumen balloon technique; APBI-ML = Intraluminal brachytherapy with 
multi-lumen balloon technique; APBI-IS = Interstitial brachytherapy; IORT = Intraop-
erative radiotherapy with E indicating outcome data based on ELIOT-trial results, T on 
Targit-trial results and percentage indicating percentage of  patients receiving additional 
WBI; ESBC = Early-stage breast cancer; y = years old; pN = pathological lymph node 
stage with pN0 for non-involved, pN+ for involved, pN1-3 for 1-3 lymph nodes involved 
and pN4+ for four or more lymph nodes involved; DCIS = Ductal carcinoma in situ.
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Figure 1: Cost results per category of  fractionation and technique (€, 2016).
Results are grouped per category of  fractionation schedule and technique, inflated to 
2016 (Consumer price index of  respective country) and converted to euro. Grey shades 
evolve from low cost (light grey) to high cost (dark grey). 
Abbreviations: NA = Not applicable; EBRT = External beam radiotherapy; IMRT = 
Intensity-modulated radiotherapy; APBI = Accelerated partial breast irradiation; IORT 
= Intraoperative radiotherapy; APBI-IS = Interstitial brachytherapy; APBI-balloon = In-
traluminal brachytherapy with single- or multi-lumen balloon technique; n = number of  
cost data, SD = standard deviation of  the means.
Figure 2: Cost-effectiveness plane representing incremental cost and health effect for 
radiotherapy versus no radiotherapy (€, 2016).
 
Location of  the results on the X-axis indicates the incremental health effect and on the 
Y-axis, the incremental cost for the investigational strategy compared to the standard.
The dashed lines indicate willingness-to-pay thresholds of  30,000€/QALY and 50,000€/QALY.
Circles have WBI as comparator, squares indicate PMRT as comparator. Open markers 
are US-based, light-grey markers represent Canada, dark-grey Europe and black rep-
resents Asia.
Abbreviations: QALY = Quality adjusted life years gained; RT = radiotherapy; PMRT = 
Post-mastectomy RT; EBRT = External beam radiotherapy with number indicating num-
ber of  fractions; IMRT = Intensity-modulated radiotherapy; ESBC = Early-stage breast 
cancer; y = years old; pN = pathological lymph node stage with pN0 for non-involved, 
pN+ for involved, pN1-3 for 1-3 lymph nodes involved and pN4+ for four or more lymph 
nodes involved.
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Figure 3: Cost-effectiveness plane representing incremental cost and health effect for 
different fractionation schedules and techniques (€, 2016).
vLocation of  the results on the X-axis indicates the incremental health effect and on the 
Y-axis, the incremental cost for the investigational strategy compared to the standard.
Results located in the lower right quadrant are dominant strategies, combining a lower 
cost with improved health effect. Results in the upper left quadrant are dominated situa-
tions, with the investigational strategy being more expensive for less health effect than the 
comparator. In the upper right quadrant, increased health effect comes at a higher cost. 
Strategies that are less costly but come with a loss in health effect, are found in the lower 
left quadrant. The dashed lines indicate willingness-to-pay thresholds of  30,000€/QALY 
and 50,000€/QALY.Triangles represent IORT, circles compare fractionated schedules. 
Open markers are US-based, dark-grey filled markers are European.
Abbreviations: QALY = Quality-adjusted life years gained; EBRT = External beam ra-
diotherapy with number indicating number of  fractions; IMRT = Intensity-modulat-
ed radiotherapy; APBI = Accelerated partial breast irradiation; APBI-IS = Interstitial 
brachytherapy; APBI-balloon = Intraluminal brachytherapy with single (SL)- or multi-lu-
men (ML) balloon technique; IORT = Intraoperative radiotherapy with E indicating out-
come data based on ELIOT-trial results, T on Targit-trial results and percentage indicat-
ing percentage of  patients receiving additional WBI.
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GENERAL  
DISCUSSION AND CRITICAL  
INTERPRETATION
Objective 1: Partial breast irradiation: is it feasible in prone position? 
Evaluation of  a practical approach to obtain precise and accurate target vol-
ume delineation for accelerated partial breast irradiation in prone position.
In search of  a balance between small target volumes and accurate and precise tumourbed delineation 
for partial breast irradiation
Several trials have explored the safety and feasibility of  APBI. Intra-operative techniques 
limit dose to the tissue adjacent to the excision cavity only. The 5-year results of  random-
ized trials on these intra-operative techniques revealed increased local relapse rates[1, 
2]. In contrast, local control remained equivalent to WBI in the GEC-ESTRO trial on 
interstitial brachytherapy[3]. The GEC-ESTRO did not provide information on the tar-
get volumes, but an expansion of  at least 2cm from the tumourbed does suggest larger 
volumes. Five-year evidence on partial breast irradiation came with the IMPORT LOW 
trial. In this trial, a hypofractionated schedule in 15 fractions was delivered in all three 
arms, targeting either the whole breast or the tumourbed only (40Gy) and in the third arm 
delivering two doses, with the tumourbed receiving 40Gy and the remaining breast 36Gy. 
Local control was excellent. However, these good results may be partially related to the 
large fields receiving high-dose, also in the partial breast arm. To facilitate feasibility, su-
pine position in combination with an easy tangential field set-up with field-in-field IMRT 
was applied. This led to large volumes receiving high doses, including one-third up to half  
of  the breast and, for locations in the upper half, even part of  the axilla. 
It is an important merit of  the IMPORT LOW trial to have compared volume as a 
single variable. Although impact on aesthetic outcome was altogether limited, they did 
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observe a significant increase in ‘marked breast change’, mainly due to breast shrink-
age, in the WBI-arm. The relation between volume and breast appearance emphasizes 
the role that APBI could play in further improving aesthetic outcome for favourable 
ESBC, however at the condition of  accurate delivery of  the dose to the tumourbed to 
avoid relapses. This requires correct reconstruction of  the preoperative tumour loca-
tion in an operated, often deformed breast. The difficulty of  reproducible tumourbed 
delineation can be deducted from the low inter-observer conformity rates in the litera-
ture, on boost as well as partial breast target volumes. Inter-observer delineation exer-
cises report conformity rates between 0.35 and 0.54 despite optimal circumstances. To 
improve inter-observer conformity, delineation guidelines have been published, based 
on general information (preoperative imaging, surgical report, pathology, scar) com-
plemented with planning-CT based landmarks (tissue distortion, seroma, clips). How-
ever, in our centre full thickness closure and prone position are applied. Full-thickness 
closure reduces the infection risk, thus improving aesthetic outcome[134]. The advan-
tages of  prone position have been explained in chapter 2.6.b. Prone positioning also 
helps in avoiding the axillary region.
What is needed to combine prone position and full-thickness closure  
with accurate and precise tumourbed delineation?
Prone positioning comes with some drawbacks, rendering existing guidelines insuffi-
cient and thus impacting accuracy and precision in tumourbed volume delineation:
– a larger anterior-posterior diameter amplifies the risk to miss the target along this 
axis. More than for supine position, the depth of  the primary tumour location must 
be clearly defined.
– to distinguish tissue distortion from glandular tissue in prone position, one cannot 
rely on comparison with the contralateral breast as it lies compressed on the breast 
board
– relevant clips along the surgical trajectory are difficult to distinguish from irrelevant hae-
mostatic clips, or from deep clips placed on the thoracic wall. Blind inclusion of  all clips 
would lead to long, protracted target volumes unto the thoracic wall, thus foregoing the 
advantages of  prone and partial breast irradiation, as demonstrated by Lakosi et al. [135].
We tested the added value on precision and accuracy of  tumour bed delineation of  
an indicator-clip as indirect depth-marker and of  a preoperative CT in treatment po-
sition. A target volume delineation exercise demonstrated an improved inter-observ-
er conformity or precision for delineation based on the indicator-clip (0.75 vs 0.38). 
More importantly, even simple expansion based on this clip proved more accurate to 
cover the preoperative GTV with the CTV than standard delineation (overlap rate of  
0.67 for clip-based CTV versus 0.48 for standard delineation). As could be expected, 
fusion with the preoperative CT in treatment position further improved the overlap 
rate to 0.88. Improved overlap resulted in higher mean dose to GTV and in less fails 
(underdosing of  the GTV).
Conclusions from the inter-observer target volume exercise
Preoperative CT in treatment position may thus be regarded as the most accurate aid 
for target localization. Our results indicate that if  postoperative APBI is aimed for, in-
direct tumourbed localization based on an indicator-clip improves inter-observer con-
formity but is not accurate enough if  small volumes are aimed for. However, for boost 
delineation (with WBI compensating for the risk of  missing the target) an indicator-clip 
may be sufficient to add information on depth of  the tumour, especially if  prone posi-
tioning is intended. The added value of  such larger ‘indicator-clip’ over the ‘ad random 
clips’ in the cavity walls, is the additional information it brings on the anterior-posterior 
depth of  the tumour in the preoperative breast. But although it takes only a short extra 
surgical handling to be inserted during the tumourectomy, agreement on the protocol, 
inclusion of  the operation nurses in this strategy and regular feedback on the dosimetric 
impact of  this clip, all may be required to ascertain understanding and collaboration of  
the surgical team in maximising the impact of  such markers.
An indicator-clip clearly intended to mark the depth of  the tumour increases the prob-
ability of  covering the primary tumour location, but cannot entirely replace the addi-
tional value of  a preoperative CT in treatment position. Avoiding the cost and effort 
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of  such a preoperative CT, implies accepting a risk of  missing the target, especially 
when small volumes are aimed for. Increasing target volumes may reduce this risk, but 
questions the concept of  APBI. With shorter treatment schedules and lower costs of  
EB-APBI compared to WBI (publication 4), adding a preoperative CT may be consid-
ered as a marginal expenditure for improving accuracy.
Preoperative APBI as an alternative for volume shrinkage
Although an indicator-clip in combination with a preoperative CT in treatment position 
leads to acceptable results in inter-observer conformity and overlap with the preopera-
tive GTV, APBI still balances between the challenge to reduce volume and the risk of  
missing the target. A solution to this problem may be found in preoperative APBI: with 
the tumour present, delineation conformity further improves, as has been tested by Van 
der Leij et al.[136, 137]. However, preoperative radiotherapy holds several drawbacks: 
– Treatment cannot be based on definite pathology, and if  high radiation doses are 
delivered, this precludes subsequent WBI in case pathology reveals unfavourable prog-
nostic features. In the ELIOT trial, pathology revealed upstaging of  clinical evalua-
tion in up to 25% of  cases. This problem is partially resolved if  a sentinel lymph node 
procedure is performed before radiotherapy, however at the cost of  two separate sur-
gical interventions for ESBC.
– Tumours are irregular in shape and medical imaging may underestimate the actual tu-
mour size, a problem especially encountered with lobular carcinoma. Tackling this prob-
lem by substituting large margins for location uncertainty with large margins for unknown 
tumour diameter, would undo the advantage of  smaller preoperative target volumes.
– If  post-operative pathology warrants mastectomy, patients may have been needlessly 
exposed to potential radiation-induced toxicity. 
- CT-based tumour location is not always clear-cut, especially for non-palpable small 
tumours, which are the primary indication for preoperative radiotherapy. This has al-
ready been confirmed in surgical studies, struggling with complete excision of  non-pal-
pable breast lesions, with over 20% of  patients needing re-excision for involved exci-
sion margin despite wire-guided tumour-localization and wide resections[4]. The Milan 
group even developed a technique of  Radio-guided Occult Lesion Localization (ROLL) 
with injection of  technetium-labelled albumin particles in the centre of  the tumour to 
improve the probability of  complete excision[5, 6]. These surgical studies coincide with 
our experience in localizing the preoperative non-palpable tumour on CT, even in the 
presence of  pre- and postoperative mammography, and are confirmed by the difficulties 
to identify the GTV for small tumours in the setting of  preoperative radiotherapy[7]. 
Despite the radiologist accurately describing the tumour localization compared to the 
harpoon-tip on mammography, translating mammographic information to CT may 
remain difficult. During the interobserver exercise, uncertainty was larger for GTV-de-
lineation in case of  harpoon-localization compared to contrast-enhanced lesions.
MRI may solve this problem[7], but needs to be performed in treatment position and 
without deforming the pendant breast. In combination with breast coils and a strict 
contra-indication for metallic support as in breast boards, this is a difficult hurdle to 
take. From a more practical perspective, the unavailability of  scanning slots and the 
long waiting-lists may not permit timely MRI in a preoperative setting.
Restrictive breast delineation as an alternative for volume shrinkage
A second alternative may be the combining of  the advantages of  WBI with lessons 
learned from APBI experiments. Why sacrificing OARs to cover each inch of  the 
breast tissue if  even half  breast irradiation may be sufficient? In view of  the good 
results for APBI, with dose mainly delivered in the region of  the primary tumour loca-
tion, one could argue that all other breast tissue is considered target, but not at the cost 
of  nearby OARs. This seems in line with evidence from Holland et al. and Vicini et 
al., who demonstrated that the spread of  microsatellites knows a geographic pattern, 
diluting when further away from the initial tumour[8, 9]. Knowledge on the primary 
tumour location is useful, even if  no boost is intended, to cover the breast tissue most 
at risk. No compromises should be allowed in this region. However, at the medial and 
lateral side of  the breast, no clear ‘demarcation’ line indicates where the breast stops 
and fatty tissue starts. With the breast being a large volume (+/-250cc to +/- 3000cc) 
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between indisputable anterior and posterior borders (skin and thoracic wall), inter-ob-
server delineation differences in these directions are altogether limited. However, if  we 
focus in on the medial and lateral borders, these appear the main source of  delineation 
uncertainty[138, 139]. ESTRO guidelines suggest the mid-axillary line or the arteria 
thoracica lateralis as lateral border and the rami mammarii from the arteria thoracica 
interna as medial border[140]. But not only can these arteries be difficult to recognize, 
fatty tissue is interposed between the fascia surrounding the breast tissue and these 
vascular structures. The price of  strictly respecting borders is paid in dose to lungs, 
heart and the contralateral breast, or, if  large breast volumes are included, even in 
dose to the axilla. In prone, breast tissue falls forward, and so far, no evidence on the 
true borders of  the pendant breast is available. Blind transposition of  supine borders 
to the prone position leads to breast delineation high up along the thoracic wall and 
compromises the advantages of  the breast hanging down. A more restrictive delinea-
tion, based on visible glandular tissue, judicious use of  wires indicating the breast folds 
and for cranio-caudal borders, the second and sixth rib, may be more in line with the 
effect of  gravity while prone is applied.
Patient- and tumour-tailored underdosage as an alternative for vol-
ume-shrinkage
Even if  accurate delineation guidelines will become available, uncompromised dose 
coverage of  the entire breast may still come at the cost of  increased dose to OARs. 
In such situations, tailoring the dose to the risk profile of  patient and tumour would 
consider the primary tumour location as a region of  no compromise, whereas accep-
tance of  under-dosage of  regions, distant to the tumourbed, may well be justified as a 
less radical alternative for APBI to reduce dose to OAR, especially in case of  ESBC. 
Factors to take into account in such trade-off between dose to PTV and OAR may be 
tumour-based, including tumour location, type and stage as well as lympho-vascular 
invasion or multi-focality. Relevant patient-related risk factors for radiation-induced 
morbidity are age, cardiac co-morbidity and smoking status, as discussed in chapter 1.2.
In this perspective, it is interesting to look once again into the results of  the IMPORT 
LOW trial. Although statistical testing only compared experimental arms with WBI 
(40.05Gy), differences in aesthetic outcome between WBI-SIB (36Gy with SIB 40.05Gy) 
and PBI (40.05Gy PBI) remained low and suggest equivalence. This coincides with the 
improvement in acute toxicity when SIB was compared to a sequential boost[141].
Conclusion
In conclusion, results of  our inter-observer exercise demonstrated the need for a pre-
operative CT in treatment position if  small volume APBI is aimed for. The results also 
show that even if  high inter-observer conformity is reached, this cannot substitute for 
accuracy, the main issue of  target delineation. Increasing delineated volumes improves 
both, but comes at the cost of  higher dose to OARs and disfavours the ratio between 
target and off-target breast tissue. In view of  these findings and the small window of  
opportunity for APBI, we decided to abandon this strategy and to explore feasibility 
of  accelerated radiotherapy beyond partial breast irradiation.
Research on the true borders of  a breast in prone position is needed to further ex-
plore the impact of  this position on avoiding toxicity. Depending on the risk profile, 
compromises between dose-coverage of  the ipsilateral breast and dose to OARs seem 
acceptable. In our centre, the boost region is systematically delineated, even if  no 
boost dose is given, to define the high-risk region where underdosage is not accepted. 
In this regard, a protocol on an indicator-clip in addition to the usual ‘Solin’ clips in 
the cavity wall[45] improves knowledge on the depth of  the primary tumour location 
without additional imaging.
In selected cases, EB-APBI may remain interesting, but if  true APBI with small vol-
umes confined to the high-risk region are aimed for, preparation should include preop-
erative imaging in treatment position to permit maximal avoidance of  off-target breast 
tissue without missing the target.
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Objective 2: Accelerated radiotherapy: can it be extended beyond partial 
breast irradiation, without increasing acute toxicity?
Evaluation if  accelerated breast irradiation may be safely be expanded to 
a broader population of  elderly patients with early as well as locally-ad-
vanced stage breast cancer
Acceleration beyond partial breast irradiation
Based on the reassuring 3-year results of  tumour control and toxicity of  the FAST 
trial, as well as publications reporting longer follow-up from Ortholan, Kirova and 
Rovea[25, 142-144], acceleration of  EBRT to 5 fractions was estimated a safe alter-
native for EB-APBI. However, these trials are limited to WBI with, only for Ortholan, 
TWI. No information was available thus far on acceleration in combination with a 
SIB or LNI.
As our centre has a long-standing experience with IMRT and simultaneous delivery 
of  different dose levels, we decided to test the feasibility and efficacy of  bringing the 
advantages of  acceleration to a larger range of  indications, including ESBC as well 
as LABC. All potential adjuvant target volumes were included: WBI, TWI, WBI with 
SIB if  needed and LNI. Only TWI requiring a boost was excluded in this phase 1-2 
trial. Because long-term data on the risk of  acceleration in terms of  aesthetic outcome 
or radiation-induced brachial plexopathy (RIBP) are not yet available, an age limit of  
at least 65 years was chosen for inclusion. In the higher age group, the highest rates 
of  underutilization of  radiotherapy are found, probably due to an underestimation of  
the impact on outcome, local control as well as survival, in combination with logistical 
obstacles. Finally, the long-term results of  the boost-no boost trial confirmed age as an 
adverse factor for radiotherapy-related fibrosis. As such, this may be the most sensitive 
age group for detecting adverse effects of  high-fraction doses on aesthetic outcome, 
together with less impact on body-image as compared to younger patients. The initial 
objective to implement EB-APBI was thus changed into a project on accelerated irra-
diation in 5 fractions, the HAI-5 trial, testing accelerated adjuvant breast radiotherapy 
in the elderly population, as described in publication 2.
Doses were 28.5Gy/5.7Gy for the breast or the thoracic wall after mastectomy, and 
27Gy/5.4Gy for the lymph node regions. As discussed before, our SIB trial found 
less acute toxicity with SIB compared to a sequential boost[141]. In line with this 
finding and to respect treatment delivery within 5 fractions, SIB was applied in case a 
boost was needed, delivering 32.5Gy/6.5Gy for negative margins or 34.5Gy/6.9Gy 
if  margins were involved. Fractions were delivered every other day to guarantee an 
inter-fraction repair-time of  at least 24h. 
Calculation of  dose conversion was based on the linear quadratic model, with an α/β 
ranging between 2.8Gy and 4.6Gy for tumour control and for breast toxicity and an 
α/β of  1.5Gy for plexopathy. Conversion resulted in EQD2 ranging between 44.5-
50.5Gy for WBI and 54.7-63Gy for the tumourbed or, in case of  involved margins, 
60.1-69.7Gy. For the brachial plexus, an EQD2 of  53.2Gy was calculated.
Multi-beam IMRT delivery was chosen to avoid all risk for overlap incidents, especial-
ly cumbersome in the region of  the brachial plexus[22, 145, 146]. For complex fields, 
VMAT with concatenated arcs helped in accelerating delivery. Maximal tolerated dos-
es were based on the AAPM-guidelines by Benedict et al. on SBRT[147]. 
Results from the HAI-5 trial
Feasibility and acute toxicity results of  this first cohort of  95 patients are reported in 
publication 2. Despite older age and longer machine-time per fraction, delivery was 
feasible, including prone position where indicated. Doses were well tolerated, with low 
overall toxicity. Grade 2-3 toxicity was only observed in the SIB group. 
We concluded that acceleration to 5 fractions is feasible. However, an equivalent 
EQD2, as for the boost, may underestimate the effect of  higher doses per fraction and 
shortening of  the overall treatment time on the repair mechanisms in between frac-
tions. The same assumption has instigated the FAST trialists’ group to compensate for 
shorter overall treatment time, by lowering the breast dose to even 26Gy/5.2Gy and 
27Gy/5.4Gy in the FAST Forward schedule (5 consecutive days), resulting in EQD2 
ranges of  38.6-43.3Gy and 40.9-46.9Gy[10].
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As soon as 1- and 2-year follow-up data become available for our HAI-5 trial pop-
ulation, the results of  tumour control and aesthetic outcome will be evaluated in a 
matched-pair analysis, comparing acceleration with hypofractionation. 
The good results of  the HAI-5 feasibility trial will be further explored in subsequent 
trials randomizing between hypofractionation or acceleration in WBI +/- SIB (YO-
HAI-5 RCT), WBI and SIB with LNI adding randomization between prone versus 
supine position (PRO-SURF RCT) and in a patient preference trial comparing hy-
pofractionation with acceleration for TWI+/- SIB with or without LNI (HAI-5-III 
patient preference trial, including only women of  65 years or over). We decided to 
maintain the convenience of  dose-delivery every other day, partly because it guaran-
tees a minimum of  24h repair time in between fractions but also because it is consid-
ered a convenient rhythm by patients and family. Because grade 2-3 dermatitis was 
only found in the group with boost, the SIB-dose is lowered to 31Gy/6.2Gy (EQD2 
range 50.7-58.1Gy) and in case of  involved margins, 32.5Gy/6.5Gy. 
As explained in chapter 2.7.b, the LQ model is intended for doses up to 5Gy per frac-
tion. With the LQmodel, EQD2s comparable to normofractionation were calculated 
and comparable toxicity was expected. However, acute toxicity seemed even lower 
than expected with standard hypofractionation, although this observation needs to 
be confirmed in an ongoing matched-case control study. This may signify that the 
LQ-model potentially overestimates toxicity or underestimates the effect of  a lower 
total dose, whereas the effect of  higher fraction doses on tumour control may be un-
derestimated. This hypothesis has so far been confirmed in reports on 5-8-years fol-
low-up after once weekly acceleration, displaying excellent tumour control and overall 
survival, even if  WBI-only was applied for patients presenting with involved lymph 
nodes[25, 142-144]. 
The effects of  high fraction doses on the brachial plexus remain closely monitored: 
effects of  radiotherapy on this late reacting tissue may only become apparent many 
years after radiotherapy[22, 146]. Concern for cardiac injury should primarily lead to 
methods for shielding the heart, as no threshold dose for major cardiac events has been 
withheld[47]. With an α/β between 1.5 and 3Gy for cardiac toxicity, the EQD2 of  an 
accelerated regimen is situated between 49.6 and 58.6Gy for a 28.5Gy/5fr regimen (to 
compare with 50Gy if  normofractionation) and 57-68.2Gy for a 31Gy/5fr regimen if  
a SIB is added (compared with 66Gy if  normofractionation)[106]. With acceleration 
permitting lower total doses, the LQ model may again overestimate the effect on the 
heart. Regarding the lungs, SBRT has shown a relation between pneumonitis and 
mean lung dose or irradiated volume. Lungs are a parallel organ, and therefor benefit 
from keeping the irradiated volumes as low as possible. With IMRT for accelerated 
breast radiotherapy including LNI, the ipsilateral lung V13 was in most patients be-
low 20% (mean V13 was 15%), and mean ipsilateral lung dose was kept low (Dmean 
5.3Gy). Doses became negligible with WBI in prone position.
The major advantage of  the HAI-5 regimen is the inclusion of  all curative indications 
for adjuvant breast radiotherapy, thus expanding the advantage of  a short fraction-
ation schedule from the limited indication of  APBI to the entire breast cancer popu-
lation. In our feasibility trial, age was limited to 65 years and over. In the subsequent 
RCTs, inclusion is accepted as of  18 years of  age, as well for the cohort with WBI and 
LNI (PRO-SURF RCT) as for the WBI only group (YO-HAI-5 RCT).
Future perspectives of  accelerated breast irradiation
A potential advantage of  short schedules is the role that accelerated radiotherapy may 
play in a neo-adjuvant setting. With an overall treatment time of  10 days, radiothera-
py becomes an interesting alternative for chemotherapy in LABC. The advantage of  
such approach is the possibility to explore the pathological effect of  radiotherapy on 
tumour biology. 
First attempts for neo-adjuvant radiotherapy go back to the seventies[148], but de-
spite promising results, were abandoned with the uprising of  chemotherapy. At this 
moment, large or inoperable LABC is treated with chemotherapy in a neo-adjuvant 
setting, resulting in variable tumour responses. However, since the past two decades, 
new studies on preoperative radiotherapy appeared and confirmed feasibility, either 
or not with concomitant chemotherapy. An interesting pathological analysis of  15 pa-
tients with large tumours, treated by radiotherapy alone in the neo-adjuvant setting, 
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showed good response in 60% of  patients; a remarkable finding in this cohort is that 
although the invasive tumour decreased in size, tumour cells remained present in the 
peripheral zone of  the initial primary tumour[149]. Riet et al. reported on 32 years 
of  follow-up after preoperative hypofractionation (18-22x2,5Gy) to breast and lymph 
nodes, followed by ME and ALND. OS and DFS at 25 years were 30%, with 89% 
loco-regional control. Pathological revision of  the specimen showed triple-negative 
(TN) phenotype in 22% of  tumours. Complete response had been achieved in 10% 
of  patients, but in 26% of  TN tumours. On multivariate analysis, TN status was the 
only predictive factor for response, and together with pN status, for OS. Postoperative 
complication rate was high (>19% grade 3 or higher complications), but it should be 
kept in mind that this patient cohort had been treated between 1970 and 1984. 
Within the group of  patients requiring neo-adjuvant therapy, women under the age 
of  40 are particularly interesting. In these young women, age was found an indepen-
dent adverse prognostic factor for loco-regional control (38% 10-year LRR in women 
younger then 40 years, diagnosed with ESBC), with a relative risk increase of  7% for 
every decreasing year of  age[9]. Bringing radiotherapy to the neo-adjuvant setting 
may give insight into the question if  this different tumour behaviour also translates in 
different radio-sensitivity. 
To explore these questions, a study on the effect of  accelerated radiotherapy in the 
neo-adjuvant setting is planned. Neo-adjuvant treatment cannot only evaluate the 
effect of  radiotherapy on different tumour types, but also the effect of  acceleration to 
even shorter schedules. Another issue would be the search for the ideal delay between 
radiotherapy and surgery, permitting maximal tumour shrinkage without compro-
mising operability. Lastly, the combination of  radiotherapy with chemotherapy in a 
neo-adjuvant setting has shown interesting results and deserves further research[150, 
151]. 
From a global perspective, safe delivery of  WBI or TWI in 5 fractions may be an at-
tainable option for adjuvant breast cancer radiotherapy in low- and middle-income 
countries. Although awareness, diagnostic means and availability of  treatment (sur-
gery, systemic therapy as well as radiotherapy) are a first concern in these countries, 
easy access acceleration may help in reducing logistical obstacles such as waiting lists, 
costs of  sessions, transport and lodging and socio-economic impact of  absence during 
protracted treatment courses. The higher incidence of  LABC with higher need for 
LNI requires technical experience that is seldom available in these countries. However, 
even if  only the breast or thoracic wall are included, lowering the threshold for adju-
vant radiotherapy may at least to some extent improve overall outcome[11, 12]. Lower 
acute toxicity because of  decreased total dose adds to the list of  advantages.
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Objective 3: Health economic evidence of  post-operative breast  
radiotherapy: is it valid?
Evaluation of  the quality of  the available health economic evidence on 
post-operative breast radiotherapy, and its validity to guide health care 
decision-making 
Clinical trials mainly focus on efficacy (can it work?) and effectiveness (can we do it?) 
of  new strategies[13, 14]. Whereas efficacy research is confined to strict recruitment 
and quality rules, effectiveness research will evaluate if  these outcomes can be repro-
duced in a non-ideal but realistic every day clinical world. One step further is to anal-
yse whether such effective strategies are worthwhile from an economic point of  view, 
adding costs to the picture. This brings health research to the domain of  HEE.
As extensively explained in publication 3, the results of  a HEE strongly depend on 
the quality of  the analysis performed. Before results can be interpreted or generalized 
to the own situation, the reader must have insight into what models were applied, 
which data sources where used and to what extent uncertainty and heterogeneity were 
explored. This can only be achieved with transparent reporting of  each step taken. 
To homogenize reporting quality in HEE, guidelines have been published, listing the 
items needed to appreciate the validity of  HEE[15-17]. The most recent publica-
tion comes from the ISPOR group, who published the CHEERS’ guidelines with 24 
items representing the most essential elements required for transparent reporting in 
cost-effectiveness analysis[18]. Although this checklist is not primarily conceived for 
quantification, its structure predisposes to a straightforward scoring system, as each of  
the items is limited to one single aspect. Such quantification facilitates benchmarking 
between publications and comparison with predefined thresholds. However, the scor-
ing system accords equal weights to each item, regardless of  its importance, varying 
from completeness of  title over reporting of  data sources unto presence of  uncertain-
ty analysis. For further nuancing, qualitative evaluation is also required. Moreover, 
transparency is not a substitute for validity: a transparently reported wrong method 
remains wrong. Nevertheless, as transparency of  reporting is the first step in quality 
analysis of  HEE, quantitative and qualitative evaluation of  reporting quality, based on 
the CHEERS’ checklist, allows to separate the chaff from the grain, for researcher, for 
journal editors and for policy makers.
We performed a systematic literature review on HEE of  adjuvant breast radiotherapy 
and applied the CHEERS’ criteria for qualitative evaluation of  these publications. 
Results were also quantified, in line with similar examples in other healthcare do-
mains[19]. As quantification of  the CHEERS’ checklist is not yet validated, scores 
were compared with two validated methods, the QHES and the Tufts’ scores. The 24 
items CHEERS’ items were applied on the cost-effectiveness analyses (CEA) and a 
selection of  13 relevant items was applied on the cost comparison analyses (CC).
As explained in publication 3, qualitative analysis revealed that several items, includ-
ing data sources, population heterogeneity and sensitivity analysis, essential for reli-
able cost-effectiveness results, could benefit from more transparent reporting and jus-
tification of  choices made. Selective data input may bias results, potentially resulting 
in misleading information and jeopardizing valid decision-making on the allocation 
of  limited health-care resources. Hence, in the absence of  a systematic review, choic-
es made should at least be clearly motivated. Where most publications contained a 
sensitivity analysis, the topic of  heterogeneity, analysing the impact of  the population 
chosen on the final results, was rarely discussed. This seems connected to the recurrent 
neglect of  generalizability in the discussion. Without heterogeneity analysis, evidence 
of  cost-effectiveness risks to be transferred erronously to different indications or mod-
ified base cases.
Quantification of  scores resulted in an acceptable high to intermediate level for most 
publications, with an overall score of  75.6% for CCs and 74% for CEAs. These re-
sults did not significantly differ from QHES’ or Tufts’ scores. If  a threshold of  75% 
would have been applied, only 6 out of  13 CCs and 13 out of  20 CEAs would have 
been considered valid, whereas a medium quality threshold (50% score) was reached 
by all CCs and almost all CEAs. Although practicable, it must be kept in mind that 
such thresholds remain altogether arbitrary. Firstly, quantitative benchmarking may 
forego important items like reporting of  data sources, population heterogeneity and 
sensitivity analysis, especially when all items are attributed an equal weight. Secondly, 
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transparent reporting may be a prerequisite, but not a substitute for model validity. A 
wrong model remains wrong, even if  transparently reported[20].
Overall, quantitative CHEERS’ evaluation was found feasible and reliable compared 
to validated instruments. HEE evaluation for adjuvant breast radiotherapy is of  an ac-
ceptable quality, but further efforts are needed to improve comprehensive reporting of  
all data, indispensable for assessing relevance, reliability and generalizability of  results.
Objective 4: Post-operative breast radiotherapy: what are its cost and 
cost-effectiveness?
Evaluation of  the available health economic evidence on post-operative 
breast radiotherapy regarding the balance between costs and effective-
ness of  different techniques and fractionation schedules
A next step was taken in publication 4, where costs and cost-effectiveness were com-
pared for a subset of  the HEEs on adjuvant breast radiotherapy, more specifically HEEs 
that compared different fractionation schedules and/or techniques or evaluated the 
cost of  adding radiotherapy for specific risk populations. Costs were converted to euro, 
2016, and were brought together in cost-effectiveness planes to permit comparison of  
outcomes and cost-effectiveness results. 
Although many caveats must be taken into account, as extensively explained in the 
discussion of  this publication, some conclusions can be drawn: substituting normo- by 
hypofractionation reduces healthcare costs for an at least equivalent health-effect and 
should be considered the new gold standard for comparison. In very favourable sub-
groups, omission of  radiotherapy is a valuable option as comparator for APBI. 
Results of  HEEs on APBI are controversial: interstitial and balloon-based techniques 
prove too expensive to compete with less costly WBI EBRT techniques, especially when 
normofractionation is replaced by hypofractionation or acceleration. However, caution is 
needed as data mainly come from the US, are reimbursement-based and potentially over-
estimate the costs. Results on IORT are diverging, mainly due to discrepancy in estimated 
QALYs. Two authors righteously compared IORT with hypofractionation. Whereas the 
ICER, calculated by Vaidya et al., led to a dominant situation, combining a gain in QALY 
with a lower cost, Picot found a comparable lower cost to come with a loss in QALY, thus 
situating the result in the “lower-benefit-for-lower-cost” trade-off quadrant. Publications 
on IORT are all based on the premature data of  the TARGIT trial, with a median fol-
low-up of  less than 3 years for a very favourable subset of  ESBC. It seems advisable to 
await long-term data, preferentially beyond 5 years, and to add omission of  radiotherapy 
as comparator, before settling the place of  IORT in the spectrum of  adjuvant treatments. 
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With several ICERS located in the “lower-benefit-for-lower-cost” trade-off quadrant, com-
bining a financial benefit with a loss in QALY, the question rises how much loss in QALY 
is acceptable in return for budgetary savings. If  an alternative treatment is less expensive but comes 
with a loss in effectiveness, would this be acceptable for society? And if  so, what is the willingness-to-accept 
threshold of  society? The authors of  the PRIME trial, which includes a piggyback analysis on omission of  
radiotherapy for low risk breast cancer in the elderly, state that omission of  radiotherapy comes at a saving of  
over 200.000£ for one QALY lost, which is well above the UK threshold of  30.000£ acceptable as extra 
expenditure per QALY gained. Such reasoning foregoes the difference between a willingness-to-accept versus 
a willingness-to-pay threshold. In fact, the acceptable selling-price has been found systematically larger than 
the buying price, resulting in a ‘kink’ in the accept-reject threshold of  a cost-effectiveness plane, with a larg-
er rejection area in the lower-benefit-for-lower-cost quadrant compared to the ‘higher-benefit-for-higher-cost’ 
quadrant[21]. One of  possible explanations may be the ‘endowment effect’, which implies the psychological 
reflex of  considering the utility of  a loss greater than the utility of  an equivalent gain.
In view of  the results of  the Canadian and the START trials, proving equivalence in terms 
of  tumour control and overall survival, HEEs comparing hypo- with normofractionation 
are expected to approach cost minimization strategies, with shorter schedules winning the 
game. However, for partial breast strategies, stating budgetary savings together with other 
advantages, several publications reported not only a loss in QALY, but also a higher socie-
tal cost. Such findings seem to contradict the wide-spread implementation of  intraluminal 
balloon-techniques, especially in the US. At least part of  the explanation for such paradox 
may be found in an exercise by Schutzer et al., who calculated the real cost for balloon-based 
brachytherapy within the US and reported a cost less than half  the reimbursement advocat-
ed in other publications[22]. From an institutional perspective, such profitable balance may 
become an attractive source of  income, justifying a slight loss in QALY, especially because 
the patient shares in the benefits from a shorter treatment course.
Economic issues may also explain to some extent the implementation pattern of  hypofrac-
tionation. A review on publications exploring the uptake of  hypofractionation revealed this 
to be slow, despite robust evidence on the clinical safety and the evidently lower societal cost 
(figure 13). This may become more comprehensible, when changing again the perspective 
from payer to institutional: in fraction-based reimbursement systems, loss in reimbursement 
may not be compensated for by lower treatment costs. Radiotherapy costs indeed do not 
scale linearly with fraction number: the cost of  treatment preparation (simulation, planning, 
dosimetry check…) is independent from the number of  fractions, implying a higher relative 
preparation cost per fraction for accelerated schedules. Moreover, the cost of  quality assur-
ance may rise, as the relative contribution of  each fraction to the entire treatment increases, 
leaving little room for error. Hence, in case of  a negative cost balance, robust clinical evi-
dence may not be sufficient to overcome the financial hurdle of  radiotherapy departments 
who need to function within an economic reality.
Fig 13 - Timeline indicating the milestones on hypofractonation in relation to the progressive uptake of  hypofractionation in  
different countries[23-29]
Consequently, it seems overhasty to conclude that the ultimate societal saving will be found 
in acceleration to 5 fractions or even less, since higher doses imply more complex planning 
and intensified quality assessment. Delivery of  multiple high dose levels over large fields 
requires multibeam-IMRT or VMAT to avoid the risk of  accidental or systematic over-
lap with adjacent field set-up. Shorter high-dose treatment schedules are less tolerant in 
terms of  random errors, hence require more intense quality assessment, including IGRT: 
each fraction of  a HAI-5 regimen contributes 20% of  the radiotherapeutic treatment. 
Judicious policy making should therefore not blindly focus on potential budgetary savings 
and reallocate budgets, but use liberated means to improve quality and reduce long-term 
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General considerations
Objective 1
An indicator-clip improves inter-observer delineation conformity for tumourbed delin-
eation in prone position and after full thickness closure, with results comparable to more 
favourable delineation circumstances as supine positioning and visible seroma. This is an 
easy solution to improve precision for boost indications. 
However, in APBI, delineation errors are not compensated for by the WBI component. 
Even if  conformity is acceptable, accuracy without preoperative CT in treatment position 
was in our opinion too low to proceed to EB-APBI. Therefore, also in view of  our expe-
rience with complex planning techniques, it was decided not to proceed with the devel-
opment of  prone IMRT-APBI, but to extend the advantages of  accelerated fractionation 
beyond partial breast indications.
Objective 2
Accelerated radiotherapy of  the whole breast or thoracic wall, including a simultaneously 
integrated boost and/or lymph node irradiation is feasible and well tolerated in terms of  
acute toxicity. Longer follow-up data are needed before implementing such high doses 
outside of  clinical trials. 
Acceleration to five fractions expands the small window of  opportunity for APBI to the 
wide range of  adjuvant indications in ESBC as well as LABC. Bringing accelerated radio-
therapy to the neo-adjuvant setting will help in understanding the tumour-biologic impact 
of  high-dose fractions.
Objective 3
Quantification of  CHEERS’ evaluation on reporting transparency in HEE is feasible and 
results in comparable results compared to validated instruments.
Quality of  reporting in HEE on adjuvant breast radiotherapy is of  an acceptable inter-
mediate to high level. However, there is still room for improvement, especially regarding 
the use of  valid and reliable data sources and more elaborate handling of  uncertainty, 
through sensitivity analysis including population heterogeneity, to provide data for sound 
health-care decision-making.
In general, the systematic use of  quality checklists, both for reporting and methodologic 
evaluation, would help policy-makers in assessing the validity of  HEE when reimburse-
ment for new technologies is discussed. In line with the ACCP guidelines on quality of  
clinical evidence, categorizing HEE according to methodologic quality and robustness of  
input data would provide a simple and transparent means for comparing decisions regard-
ing acceptance and level of  reimbursement policy across nations[30].
Objective 4
Based on the available evidence, HEE indicate hypofractionation and acceleration are less 
costly and appear cost-effective strategies compared to normofractionated WBI. Acceler-
ated partial breast techniques, as intraluminal balloon-based and interstitial APBI, have 
not yet established cost-effectiveness when compared to WBI. Stronger evidence, with 
longer effectiveness data and the use of  relevant comparators is needed before the role 
of  IORT within the spectrum of  breast radiotherapy can be defined, with personalised 
approaches for the individual patient going from accelerated WBI schedules over APBI 
up to omission of  radiotherapy. 
For favourable ESBC, choosing hypofractionated WBI as gold standard and comparing 
this with the omission of  radiotherapy, intra-operative and external-beam APBI, would 
clarify which strategies are the most efficient in a population where the benefit of  adju-
vant breast radiotherapy is limited. A heterogeneity analysis based on different age groups 
would help further refine outcomes. Health-effect should be based on long-term follow-up 
of  at least 5 to 10 years to avoid underestimation of  the loco-regional relapse risk. Re-
al-costing exercises are less likely to overestimate the budgetary weight of  the different 
strategies. With avoidance of  toxicity as the main driver in the search for alternative strat-
egies, a scenario-analysis could explore the impact on cost-effectiveness of  adding techni-
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cal solutions to further reduce toxicity, such as IMRT, prone positioning and breath-hold 
techniques.
Whereas accelerated schedules may liberate both financial means and machine time, it 
also requires more complex planning and increases the need for quality assessment. This 
comes with a redistribution of  personnel and infrastructural resources and costs. Judicious 
policy making should therefore not simply translate shorter fractionation schedules to 
budgetary savings, but reallocate at least part of  such savings to investments required for 
safe delivery of  high fractional doses and for further reducing long-term toxicity in this 
large cohort of  patients.
Summary
My thesis was initially intended for introducing accelerated partial breast irradiation 
in very early stage breast cancer. The first hurdle to take in this process, was getting 
the target right, so we started with exploring how precise the tumourbed could be de-
lineated, without giving up assets as full-thickness closure and prone positioning. An 
inter-observer exercise demonstrated the need for additional preoperative preparation 
to permit a reproducible as well as accurate delineation of  the tumourbed. Preopera-
tive contrast-enhanced imaging in treatment position was deemed necessary, besides 
the usual cavity wall clips, to clearly indicate the depth of  the tumour in the breast. 
A purposely inserted indicator-clip, marking the depth of  the primary tumour in the 
breast, was found an acceptable compromise for boost delineation, but not accurate 
enough for partial breast irradiation.
The two main advantages of  partial breast irradiation are reduction of  overall treatment 
time together with reduced toxicity of  the surrounding tissue. However, without abandon-
ing whole breast irradiation, improved radiation techniques, including prone positioning, 
intensity-modulated radiotherapy and deep inspirational breath-hold, significantly reduce 
doses to heart, lungs, contralateral breast and axilla. The original protracted treatment 
schedules of  25 to 33 fractions were already addressed by the introduction of  hypofrac-
tionation to 15 fractions[31, 32] and by the promising results of  our simultaneously inte-
grated boost trial that led to further shortening of  the overall treatment time[33]. 
With the promising results of  accelerated whole breast irradiation in mind[10-12, 34, 
35], we decided to take acceleration one step further and implement it for all indi-
cations, including whole breast, thoracic wall and lymph node irradiation as well as 
simultaneous boost delivery if  needed. We hypothesized that by integrating our tech-
nical abilities to simultaneously deliver different dose levels without overlap risk, accel-
eration could safely offer the advantages of  a shorter treatment schedule to the entire 
group of  patients needing adjuvant breast radiotherapy. Because long-term data on 
such a schedule are not yet available and because undertreatment – partly due to the 
burden of  protracted radiotherapy schedules – is mainly a problem in elderly women, 
inclusion was in this first phase limited to women over 65 years[36, 37]. 
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Delivery of  high doses was found feasible, even in prone position, and results on acute 
toxicity were more than reassuring, with occurrence of  grade 2 dermatitis limited to 
the group including a boost. Only one patient developed a grade 3 dermatitis. These 
first experiences are now further explored in a patient-preference trial for mastecto-
mized patients over 65 years and two randomized trials for whole breast and whole 
breast with lymph node irradiation, applying the same strategy, yet with a lower boost 
dose and extending inclusion to younger patients as well.
To answer the question if  accelerated and partial breast techniques are worthwhile from 
an economic perspective, we performed a systematic literature review on health economic 
evaluations in this domain. In a first phase, the validity of  HEE in adjuvant breast radiother-
apy was evaluated through a qualitative analysis, based on the Consolidated Health Eco-
nomic Evaluation Reporting Standards’ guideline, and publications were benchmarked by 
translating the results to percentages. Because quantification is not yet a validated method, 
scores were compared with the Quality in Health Economic Studies’ and the Tufts’ scores, 
two validated scoring instruments. Results did not differ significantly and indicated an ac-
ceptable quality for most publications, although some caveats must be kept in mind, most 
importantly concerning validity of  source data and handling of  uncertainty, which may ob-
viate applying the results in a broader context than the one described in the actual analyses.
Then, costs or cost-effectiveness for different fractionation schedules and/or techniques or 
for adding radiotherapy were analysed. To allow comparison, costs were converted to euro, 
2016 and brought together in cost-effectiveness planes. Hypofractionation and accelerat-
ed external beam radiotherapy were found less costly and more cost-effective strategies. 
Accelerated partial breast techniques, as intraluminal balloon-based and interstitial APBI, 
have not yet established cost-effectiveness when compared to WBI. Stronger evidence, with 
longer effectiveness data and the use of  relevant comparators is needed before the role of  
IORT for early stage breast cancer can be defined. In this subgroup of  patients, a person-
alised choice will have to be made, ranging from hypofractionated or accelerated whole 
breast irradiation over partial breast irradiation up to omission of  radiotherapy.
In conclusion, robust long-term evidence on the effectiveness and cost-effectiveness for 
accelerated radiotherapy, is not yet available. So far, it appears both feasible and safe 
to reduce the number of  fractions from 15 to 5 within the confines of  a trial. Although 
accelerated schedules may lower machine time and thus reduce resource needs and 
treatment cost, it should be kept in mind that higher fraction doses require more com-
plex planning and increased quality assessment. 
All in all, the one-disease-one-treatment paradigm no longer prevails: whereas dif-
ferent strategies have proven benefit, an evolution to tailor-made allocation of  the 
most efficient radiotherapy option, including the equilibrium between patient- and 
tumour-related risk factors, could be facilitated if  besides sufficiently long-term clin-
ical evidence also evidence from cost-effectiveness research were more systematically 
implemented.
Samenvatting
Initieel beoogde mijn thesis de implementatie van versnelde partiële borstbestraling bij 
vroegtijdige borstkanker. De eerste stap in dit proces was het accuraat definiëren van het 
doelvolume, zonder de voordelen van diepe wondsluiting en buikligging op te geven. Een 
oefening die de intekening van meerdere radiotherapeuten vergeleek, toonde aan dat bij-
komende preoperatieve voorbereiding noodzakelijk was, zowel om reproduceerbaarheid 
als accuraatheid van de intekening van het tumorbed te verbeteren. De oefening toonde 
de noodzaak van preoperatieve beeldvorming met contrast in bestralingshouding om de 
locatie van de tumor in de borst zo nauwkeurig mogelijk te reproduceren. Een indica-
tor-clip, tijdens de operatie ingebracht en bedoeld om de diepte van de tumor in de borst 
aan te geven, bleek een aanvaardbaar compromis, bruikbaar voor intekening van het 
boost-volume, maar onvoldoende accuraat voor partiële borstbestraling.
De twee belangrijkste voordelen van partiële borstbestraling zijn het inkorten van de to-
tale behandelingsduur en het verminderen van de dosis op de omliggende organen. Maar 
met verbeterde bestralingstechnieken, waaronder buikligging, intensiteits-gemoduleerde 
radiotherapie en diepe ademhalingsstop kunnen dosis op hart, longen, contralaterale 
borst en okselregio ook bij volledige borstbestraling laag gehouden worden. De vroegere 
langdurige schema’s van 25-33 fracties werden inmiddels reeds vervangen door hypofrac-
tionatie in 15 fracties, en sedert de gunstige resultaten van de SIB-trial werd de sequentiële 
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boost vervangen door een simultaan geïntegreerde boost, met verder verkorten van de 
totale behandelingsduur als resultaat.
In navolging van de geruststellende resultaten met versnelde borstbestraling in meerdere 
publicaties, beslisten we om versnelde borstbestraling ter beschikking te stellen voor een 
bredere waaier aan indicaties, inclusief  bestraling van borst, thoraxwand, lymfeklierre-
gio’s en/of  geïntegreerde boost. Onze hypothese was dat we op basis van onze technische 
ervaring om simultaan meerdere dosisniveaus te bereiken binnen één bestralingsveld en 
–sessie, alle overlaprisico konden vermijden en zo de voordelen van versnelde bestraling 
veilig konden aanbieden aan de hele groep van patiënten verwezen voor adjuvante borst-
bestraling. Vermits er nog geen lange-termijn data beschikbaar zijn over de neveneffecten 
van dit schema en ook omdat onderbehandeling vooral een probleem is in de oudere po-
pulatie, werd de inclusie in deze eerste fase beperkt tot vrouwen vanaf  65 jaar.
De studie toonde dat bestraling met hoge dosis per fractie niet alleen haalbaar was, zelfs 
met toepassing van buikligging, maar dat de eerste gegevens over acute toxiciteit gerust-
stellend bleken, met het optreden van graad 2 roodheid en irritatie van de borst enkel 
in de groep mét geïntegreerde boost. Graad 3 huidschade (vochtige desquamatie) trad 
slechts op in één patiënte. Deze eerste ervaringen worden inmiddels verder geëvalueerd in 
een studie met versnelde bestraling na mastectomie, waarbij de patiënte zelf  mag kiezen 
tussen het 15- of  5-fractie schema (HAI-5-III studie), en in twee gerandomiseerde studies 
die beide schema’s vergelijken voor borst-bestraling (YO-HAI5 studie) en voor borst mét 
lymfeklierbestraling (PRO-SURF studie). In deze vervolgstudies werd de boost-dosis wel 
lichtjes gereduceerd en werd de intrede-leeftijd verlaagd tot 18 jaar.
Alvorens een antwoord te kunnen geven op de vraag of  versnelde en partiële borstbe-
stralingstechnieken ook interessant kunnen zijn vanuit een economisch oogpunt, startten 
we met een systematische literatuurstudie van gezondheids-economische evaluaties in dit 
domein. In een eerste stap evalueerden we de betrouwbaarheid van gezondheids-eco-
nomische evaluaties in adjuvante borstbestraling middels een gevalideerde kwalitatieve 
checklist, de CHEERS’ checklist, en zetten we deze kwalitatieve evaluatie om in scores 
om vergelijking oftewel benchmarking van de kwaliteit van de publicaties mogelijk te 
maken. Gezien deze omzetting tot nog toe nog niet gevalideerd werd, vergeleken we onze 
resultaten met de scores van twee gevalideerde checklists. Deze bleken gelijklopend en 
bevestigden een aanvaardbare kwaliteit voor de meeste studies, al moet opgemerkt wor-
den dat bepaalde items zoals rapportering en motivatie van de gekozen brondata evenals 
probabiliteits-analyse zeker meer aandacht verdienen.
In een volgende stap werden de kost en kosteneffectiviteit van de verschillende bestralings-
schema’s en –technieken vergeleken, evenals de impact van het weglaten van bestraling. 
Om de gegevens van de publicaties te kunnen vergelijken, werden kosten geconverteerd 
naar euro (2016) en samengebracht in kosteneffectiviteitsdiagrammen. De oefening toon-
de dat hypofractionatie en versnelde externe bestraling de laagste kost genereren en het 
meest kosteneffectief  zijn. Technisch geavanceerde technieken zoals interstitiële en bal-
lon-brachytherapie konden dusver geen kosteneffectiviteit aantonen. De resultaten voor 
de intraoperatieve Intrabeam toepassing (IORT) zijn eerder controversieel: sterkere evi-
dentie, met langere-termijn data over de effectiviteit van deze techniek en vergelijking 
van de resultaten met relevante bestralingsschemata (hypofractionatie en/of  weglaten van 
radiotherapie) zijn nodig alvorens de rol van IORT voor vroegtijdige borstkanker finaal 
bezegeld kan worden. In deze doelgroep van laag-risico patiënten zal op basis van pati-
ent- en tumorkarakteristieken een gepersonaliseerde aanpak mogelijk zijn, met keuzemo-
gelijkheden gaande van gehypofractioneerde of  versnelde borstbestraling over partiële 
borstbestraling tot weglaten van radiotherapie.
Tot besluit moet gesteld dat robuuste, lange termijn evidentie over effectiviteit en kosteneffec-
tiviteit van versnelde borstbestraling voorlopig nog niet beschikbaar is. Tot nog toe lijken de 
resultaten erop te wijzen dat het haalbaar zowel als veilig is om het aantal fracties verder te 
reduceren van 15 naar 5 fracties, maar bij voorkeur binnen een klinische studie. Alhoewel ver-
snelde borstbestraling minder ‘machinetijd’ vereist en dus de behandelingskost kan verlagen, 
vereist deze techniek complexere bestralingsplannen en intensievere kwaliteitsbewaking.
Als finale conclusie willen we stellen dat het ‘één-ziekte-één-behandeling’ paradigma ook 
voor borstbestraling niet langer kan weerhouden worden: verschillende strategieën heb-
ben inmiddels voordeel aangetoond. De ideale strategie neemt zowel patiënt- als tumor-
gerelateerde factoren mee in rekening, en is gebaseerd op zowel klinische lange-termijn-
data als de resultaten van kosteneffectiviteitsonderzoek.
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DANKWOORD
Mei 2011.
Na maanden broeden op welke richting uit te gaan, uiteindelijk toch een telefoon aan 
Wilfried De Neve.
Zou ik als 40-jarige alsnog het roer omgooien en vanuit mijn comfortabele positie binnen 
de ziekenfondswereld durven terugkeren naar het assistentschap, om zo mijn droom om 
radiotherapeut-oncoloog te worden alsnog te realiseren?
Eén telefoon heeft het gekost.  
Met één cruciale vraag terug: ben je wetenschappelijk nieuwsgierig? 
Een dag later al zijn antwoord: ‘Wanneer kan je beginnen?’.
Die ene telefoon heeft veel veranderd. Heel veel. Op zowat alle vlakken. Met vandaag de 
grande finale van dat keerpunt – een doctoraat afleveren. 
Mijn pad was een slingerpad, dat geef  ik grif  toe, maar juist die kronkelingen maakten het 
bijzonder boeiend. Want onderweg ben ik vele mensen en werelden tegengekomen. En 
die neem ik mee, in mijn ervaringen en in mijn hart. 
De lijst is eindeloos: van mijn proffen en mede-studenten aan de KULeuven en na-
dien de mensen van de dienst radiotherapie aldaar, inclusief  mijn huidige promotor en 
diensthoofd Yolande Lievens (toen nog piepjong) tot de orthopedisten in het AZ 
Sint-Lucas tijdens een 2-jaar durend Brugs intermezzo als vrij assistent. Later ontmoette 
ik de collega’s in de ziekenfondswereld, zowel artsen en management als administrati-
eve medewerkers. Na enkele jaren als adviserend geneesheer, werd ik lid van de directie en 
nam ik deel aan de onderhandelingen met ‘de andere banken’. Ik leerde er tegengestelde 
visies waarderen: akademisch en syndicaal, maar ook vanuit de ziekenfondswereld en het 
RIZIV. Een wereld die ik recent opnieuw binnentrad, via de CTIIMH, waar ik samen 
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met Marleen Louagie en haar team de wonderlijke wereld van de implantaten in 
goede banen tracht te leiden.
2011 voerde me dus naar Ugent en UZ Gent: hier dank ik in de eerste plaats mijn 
opleiders: sommige waren vooral inspirerend, andere eerder uitdagend, maar elk bracht 
me vanuit zijn eigen perspectief  waardevolle inzichten. Yolande, Wilfried, Marcus, 
Sabine, Frederik, Piet, Marc, Tom en natuurlijk mijn buro-maatje Pieter. 
En vooral mijn vrouwelijke collega’s, met wie ik zalig kon en kan herbronnen tijdens het 
middaguur: Katrien, Liv en Valerie. Ik dank de wizards van de fysicagroep, mijn bak-
ens voor lastige vraagstukken: Werner, Tom, Luiza, Leen, Evelien, Frederik, Tes-
sa, Geert, Carlos… En natuurlijk, het bijzondere ‘borstenteam’: Annick, Giselle, 
Bruno, Raf  en Philippe, onze studie-verpleegkundigen en planners. Met sedert kort 
‘den Hans’ en ‘den Michael’, twee doctoraatsstudenten onderweg.
Ik heb gezweet en genoten van de lange avonden en zware discussies met mijn promotor 
Yolande Lievens. Het moet voor haar een ware uitdaging geweest zijn mijn verha-
lenvertellende natuur in te tomen om telkens weer tot de zuivere essentie te geraken. 
Yolande, die tussen haar onmogelijk drukke agenda door toch telkens weer tijd vond om 
me te ondersteunen. Ik genoot van de vriendschap en wijze raad van Liv Veldeman, 
mijn lieve co-promotor en collega van het borsttraject, mijn klankbord voor als ik even 
de weg kwijt was. En Rudy Van Den Broecke, die andere co-promotor, die ik tot in de 
operatiezaal toe mocht komen lastig vallen met vragen en inzichten.
Niet dat het leerproces zich daartoe beperkte: ik leerde van onze poli- en toestelver-
pleegkundigen, van de psychologen, sociaal-assistenten, diëtisten… Via het 
lymfetraject ontmoette ik vele kinesisten, waaronder Vickie, Annelies en Nele, ev-
enals de mensen die zorgen voor compressief  materiaal, waarbij ik vooral terugdenk aan 
de zoektochten naar onmogelijk geachte oplossingen met Thérèse Hoste. Ook in UZ 
Gent bonden we immers de strijd aan tegen lymfoedeem, samen met mijn kompanen 
Koen Van Landuyt, Caren Randon en Rita Hietbrink. 
Ik bracht fijne uren door met mijn collega’s arts-specialisten-in-opleiding (ASO), 
binnen en ook buiten de groep radiotherapie-oncologie. Want vanuit de ASO-verenigin-
gen leerde ik zowel op Gents (de GVGA) als op nationaal nivo (de VASO) geëngageerde 
jonge collega’s kennen: de spreekwoordelijke luizen in de pels: Krishna, Wouter, Bas, 
de beide Frederiks… De lijst is gelukkig heel erg lang. Stuk voor stuk jonge beloftes, 
niet alleen binnen maar ook buiten de micro-wereld van de eigen discipline. 
Met hen nam ik deel aan het overleg op de commissie MSG, waar het er soms hard aan 
toe ging, maar waar ieder slechts één doel voor ogen had: de ASO-opleiding verbeteren, 
zowel kwalitatief  als op menselijk vlak. 
Een aparte plek reserveer ik voor mijn patiënten. Het blijft telkens weer een eer het 
vertrouwen te mogen ontvangen van vrouwen en mannen, die in kwetsbaarheid naar 
onze dienst komen en hun leven in handen leggen van de kennis en kunde van het team 
radiotherapie UZ Gent. Ik voel in het bijzonder een dankbaarheid voor onze studie-pa-
tiënten die bereid waren de schijnbare zekerheid van  standaardschema’s te verlaten om 
samen met ons te zoeken hoe het voor de toekomstige generaties toch weer beter kan.
Ook buiten mijn medische traject bewoog er veel. Zeker sedert mijn ontmoeting met 
Patricia Van Lingen en haar ‘School voor relaties’, waar ik ontdekte hoezeer elke 
irritatie, frustratie of  boosheid een waardevolle spiegel is van de eigen innerlijke wereld, 
een spiegel die mits wat moed, elke trigger transformeert in een boeiend ont-wikkelings-
moment onderweg naar jezelf. En waar ik leerde hoe fijn het is nooit meer alleen te staan, 
hoe we als vrouwen gedragen worden door de vrouwen rond ons. Mijn sisterhood.
Ik dank mijn ouders, die me van jongs af  aan zagen worstelen met de wereld, een wereld 
in Lommel die te klein, te nauw, te braaf  aanvoelde voor de vrije vogel die zich al heel 
vroeg in me nestelde. Mijn ouders die me uiteindelijk moesten loslaten en hopen dat het 
goed kwam. Het is goed gekomen, al kan ik me voorstellen dat ze het af  en toe benauwd 
hebben gehad. 
Mijn broer Stephan en mijn zus Kathleen, met wie ik een verbondenheid deel die ik ie-
dereen toewens. Hun namen staan op die kleine vierkante centimeter papier van mensen die 
je blindelings vertrouwt, omdat ze je niet alleen voor je positieve kanten, en zelfs niet alleen 
‘ondanks’ je duistere kanten waarderen, maar juist ‘omwille’ van je rauwe en oprechte ik.
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Mijn gezin, niet meer ongeschonden, maar wel nog steeds een warme nest, nu met twee 
adressen. Drie zoons zijn er uit die nest opgegroeid: Jonathan alias Oprechte Bij, Zeno 
alias Overpeinzende Jako en David, immer de jongste. Ze hebben afwezigheden 
gedragen, buien geïncasseerd, stormen doorstaan. En ze zijn gegroeid, tot wijze gasten die 
nu langzaamaan elk hun eigen pad inslaan, terwijl ik aan de zijlijn in stille verwondering 
geniet, in de gerustheid dat het goed is, waarheen hun pad hen ook voeren mag.
En Dan. Op mijn beurt moest ik loslaten. Nu kan ik terugkijken op het moois dat we 
samen realiseerden. En zien dat ons beider pad misschien wel splitste, maar ons elk dich-
ter bij onszelf  bracht. Want het moet niet meer.
En uiteindelijk ook mijn dieren: Betty & Qamille, ontwapenend blij, gewoon omdat ik 
het ben. Trouwe gezellen op mijn wandelingen telkens een nieuwe writers’ block zich aan-
diende. En Loes & Charlie, urenlang in onverstoorbare rust aan mijn PC, zoals enkel 
poezen dat kunnen.
***
In retrospect zie ik één rode lijn doorheen mijn traject: alles durven in vraag stellen: ‘Zijn 
we wel zo goed bezig als we denken?’ Verandering als enige constante van het leven. Met 
vallen en opstaan. Telkens weer opstaan, want daarin schuilt ware kracht.
Ik meen dus het juiste antwoord gegeven te hebben op die simpele vraag van Wilfried 
De Neve in 2011: Ben je wetenschappelijk nieuwsgierig?
Ja, ik ben nieuwsgierig, op wetenschappelijk vlak, en ver daarbuiten. En hoop dat mijn 
nieuwsgierigheid een heel klein beetje mag bijdragen aan een betere wereld.
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